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ABSTRACT 
 
Methods for redesigning the specificity of secreted proteases 
by 
Jennifer Lauren Guerrero 
 
     Proteases regulate many biological processes through their ability to activate or 
inactivate their target substrates and therefore present unique opportunities for therapeutic 
application. Because proteases catalytically turnover proteins, they could potentially be 
used at lower doses in therapy, reducing the cost of treatment. However, many proteases 
are capable of cleaving multiple physiological substrates. Therefore their activity, 
expression, and localization are tightly controlled to prevent unwanted proteolysis that 
could lead to side effects. Currently approved protease therapeutics rely on naturally 
evolved specificities and are often used for protease replacement therapy in genetically 
deficient patients. The clinical use of proteases in replacement therapy has been successful 
due to the narrow substrate specificity of these enzymes, which limits their toxicity. 
However, the application of proteases in therapy could be extended beyond their native 
biological functions. The emergence of methods for engineering proteases with new 
activities and narrow specificities toward substrates relevant in disease could greatly 
expand their therapeutic potential. 
     Here we have developed a novel intracellular screen in yeast for redesigning the 
specificity of human secreted proteases which we have termed protease evolution via 
cleavage of an intracellular substrate (PrECISE). Using PrECISE, a protease library and a 
x 
target substrate flanked by fluorescent proteins CyPet and YPet, capable of Fӧrster 
resonance energy transfer (FRET), are co-expressed in the endoplasmic reticulum (ER) of 
yeast. The ER provides an oxidizing environment for the formation of disulfide bonds 
common to human secreted proteases and the co-localization of the protease and substrate 
promotes cleavage. Protease activity on the selection substrate leads to loss of intracellular 
FRET and increases cyan fluorescence enabling screening of large protease libraries using 
fluorescence activated cell sorting (FACS). As a model system, we screened randomly 
mutated and rationally designed libraries of the secreted protease human kallikrein 7 (hK7) 
using PrECISE to isolate variants with improved selectivity toward the hydrophobic core 
of the amyloid beta peptide (Aβ8: KLVF↓F↓AED).  
     Sequential rounds of low error rate random mutagenesis were found to be most 
effective in altering protease selectivity by incrementally introducing and screening for 
beneficial substitutions. Findings from our work emphasize the importance of screening 
large libraries during protease evolution since multiple substitutions were required to alter 
hK7 selectivity for Aβ. The substitutions found to improve hK7 selectivity would be 
impossible to predict since the majority were located far from the hK7 active site. 
Interestingly, improvements in selectivity were accompanied by a reduction in toxicity of 
the protease variant toward mammalian cells and improved resistance to wild-type 
inhibitors. Analysis of the crystal structures of improved variants provided insights to the 
potential mechanisms that affected hK7 activity and selectivity. The PrECISE method and 
techniques developed here can be broadly applied to evolve human proteases for specific 
degradation of toxic proteins involved in disease to enable their greater use in therapy.  
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1. Introduction 
1.1. Motivation 
     Proteases represent a class of enzymatic proteins that regulate many biological 
processes through their ability to irreversibly activate or inactivate their target substrates 
through peptide bond hydrolysis. Since most proteases have on the order of 10 to 100 
physiological substrates, they often participate in multiple and sometimes opposing 
pathways in the body. For example, thrombin dually functions as a procoagulant by 
cleaving fibrinogen to fibrin to form blood clots and also elicits anticoagulant effects by 
activating protein C
1
. A generally applicable, high-throughput strategy to engineer 
proteases to cleave a target substrate with high specificity and high catalytic efficiency, 
while minimizing off-target activity, would greatly expand the use of proteases for 
analytical, biotechnological, and therapeutic applications.   
     Deficiencies or abnormalities in protease activity are common to many diseases, 
therefore proteases present attractive targets for use as therapeutics. Due to their catalytic 
properties, proteases provide a significant advantage over antibodies, since they need not 
be present at stoichiometric ratios to a given target, which could reduce the dosage and cost 
of treatment. Currently approved protease therapeutics rely on naturally evolved narrow 
specificities, which limits their toxicity. Anticoagulants such as t-PA and u-PA break down 
clots for the treatment of heart attacks and stroke, while procoagulants, such as Factor IX 
and Factor VIIa, are approved to treat haemophilia
2,3
. Currently, the use of proteases as 
therapeutics is limited in part by their specificity for a given target substrate, since off-
target recognition would lead to unwanted side-effects
4
. And methods for engineering 
human secreted proteases, candidates for therapy, are lacking. Therefore a high-throughput 
2 
screen to engineer human proteases with novel and narrow specificities could greatly 
expand their use in therapy. 
 
1.2. Organization of the dissertation 
     This dissertation describes the development of a screening system in yeast for 
engineering the specificity of human secreted proteases by assaying the activity of large 
protease variant libraries against a fluorogenic target substrate. This general cell-based 
assay can be applied toward multiple protease targets that are actively expressed in yeast, 
to increase their activity and selectivity toward an arbitrary peptide target. Additionally, 
through application of this screen, a deeper understanding of the molecular mechanisms by 
which proteases achieve a high level of substrate selectivity can be gained. As a model 
system for developing highly specific proteases that could be applied in therapy, we chose 
to engineer the protease human kallikrein 7 (hK7) to selectively cleave the hydrophobic 
core of the amyloid beta (Aβ) peptide, which aggregates in the brains of patients with 
Alzheimer’s disease (AD) and is widely considered to be the key pathological event in 
AD
5
.  
     The dissertation is composed of six chapters where Chapter 1 describes the mechanisms 
by which proteases recognize their targets and past work in engineering proteases 
specificity. In Chapter 2, we describe the development of a novel cell-based method for 
engineering proteases which belong to the family of human secreted proteases that contain 
multiple disulfide bonds required for proper folding and activity. In Chapter 3, this cell-
based assay is applied to hK7 to screen large randomly mutated libraries for selectivity 
toward the amyloid beta (Aβ) peptide. Chapter 4 describes the extension of this approach 
3 
to a site-saturation mutagenesis library of the hK7 S1 pocket to determine the amino acids 
in the S1 subsite that contribute to activity and selectivity. In Chapter 5, opportunities to 
improve the screen by the addition of a counterselection substrate are explored. Chapter 6 
discusses current challenges in the field of protease engineering and potential for future 
advancements. Collectively, our studies demonstrate the benefit of developing high-
throughput screens for protease engineering, since multiple substitutions were required to 
alter the selectivity of hK7 for Aβ. Additionally, our work uses key information obtained 
from analysis of the crystal structures of improved variants to postulate mechanisms 
responsible for substrate specificity within hK7.  
      
1.3. Proteases and their role in therapy 
     Proteases constitute 2% of the human genome and are key players in diverse biological 
pathways including digestion
6
, inflammation
7
, coagulation
8
, and apoptosis
9
 through 
proteolytic processing of their substrates. Their mechanism of action allows organization 
of proteases into classes based on the residues responsible for catalysis. These residues and 
surrounding amino acids that contact the substrate during catalysis make up the active site 
of the protease. The most abundant human protease class are the metalloproteases followed 
by serine, cysteine, threonine and aspartyl family members
10
. Additionally, the position of 
the cleaved peptide bond within a substrate, either internal or terminal, is further used to 
classify a protease as an endopeptidase or exopeptidase, respectively. 
     The protease class dictates whether covalent or non-covalent hydrolysis is used to 
cleave the peptide bond
11
. Serine, threonine, and cysteine proteases participate in covalent 
catalysis through the utilization of amino acids within their active sites which serve as 
4 
nucleophiles. The hydroxyl and thiol groups of serine, threonine, and cysteine effectively 
attack the substrate peptide backbone resulting in hydrolysis. In non-covalent catalysis, the 
nucleophile is an activated water molecule and this mechanism is used by the 
metalloproteases and aspartic proteases. During catalysis, histidines function as bases in 
covalent catalysis, whereas either aspartic acid, glutamic acid or zinc serve as acids and 
bases in non-covalent catalysis
11
. The rate at which a substrate is cleaved depends largely 
on the interactions it forms when docked into the protease active site. These interactions 
form the basis for protease substrate recognition, also known as the specificity of a 
protease. 
 
1.3.1. Protease substrate recognition 
     In order for hydrolysis of a substrate to occur, the substrate must first dock into the 
active site of the protease in the correct orientation that permits catalysis. Protease 
substrate recognition was first described by Schechter and Berger in 1967
12
. Using the 
Schechter and Berger nomenclature, the substrate residues are labeled H2N-PX…P4-P3-
P2-P1 ↓ P1’-P2’-P3’-P4’…PX’-COO-, where P1 is the new C-terminal residue and P1’ is 
the new N-terminal residue following catalysis (Figure 1.1). The substrate residues dock 
into the corresponding subsites that run along the surface of the protease, that are labeled 
SX-S1 and S1’-SX’, respectively. Therefore, the P1 residue of the substrate interacts with 
the S1 subsite of the protease and so forth. Crystal structure analysis of a substrate docked 
within a protease can elucidate which amino acids compromise the various subsites. 
However, the importance of specific residues within a given subsite is often difficult to 
predict from structural information alone. 
5 
 
Figure 1.1. Protease specificity nomenclature.  
 
The protease active site (grey) is composed of subsites (SX…S1-S1’…SX’) that each 
interact with the corresponding residue in the substrate. Proteolysis occurs between 
substrate residues P1 and P1’. 
 
     A protease’s increased activity and preference for certain residues at a subsite is known 
as the specificity of a protease. Some subsites within a protease may be restricted to one or 
two amino acids and are therefore significant in defining the protease’s specificity. While 
other subsites display no discrimination between different amino acids and contribute less 
to the overall binding energy of the protease-substrate interaction. Because cleavage occurs 
after the P1 residue, the S1 subsite is considered the primary binding site and critical 
determinant of protease specificity since it correctly orients the substrate for catalysis. 
Within the serine protease class, trypsin-like proteases favor cleavage after basic residues 
arginine and lysine. The preference for arginine and lysine has been attributed in part to the 
aspartic acid (Asp189) at the bottom of the S1 binding pocket in trypsin
13
.  
     The subsites which affect protease specificity can be highly variable and can both 
positively and negatively affect binding of the P1 residue into the S1 pocket. The favorable 
or deleterious interactions that occur between substrate residues at distinct subsites is 
known as subsite cooperativity. Studies on the protease subtilisin discovered that favorable 
amino acids at the P1 or, more significantly, the P4 position in the substrate could 
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overcome the adverse effects of less favorable residues at other positions
14
. Many 
proteases of viral origin, such as the tobacco etch virus protease (TEVp), have evolved 
extended subsite recognition to facilitate efficient viral protein processing and assembly 
within host cells
15
. TEVp displays very narrow selectivity for the sequence ENLYFQ↓S/G 
within the TEV polyprotein
16
. Additionally, mammalian proteases involved in cellular 
pathways have evolved to recognize a limited set of peptide sequences. For example, 
proteases responsible for the formation and breakdown of blood clots have evolved 
exquisite substrate specificity
17
. While proteases involved in processes such as digestion 
and in the recycling of proteins display relaxed specificity.  
     To determine a protease’s substrate specificity, typically kinetic assays are run with 
synthetic substrates that lead to a fluorescent output upon cleavage. Measuring the change 
in fluorescence over time allows calculation of the specificity constant or kcat/KM. To 
increase the throughput of mapping protease specificity, combinatorial fluorogenic peptide 
libraries can be assayed in microtiter plates with the protease of interest. However, 
manually synthesized libraries are limited in their size, generally containing 10
5
 to 10
6
 
members, and can be expensive to make
18
. Substrate phage display and bacterial peptide 
display profile protease specificity on much large libraries containing 10
7
 to 10
8
 members 
and are cost effective, since phage and bacteria produce the peptides. In these methods, 
phage or bacteria encoding protease-sensitive peptides are collected and the optimal 
cleavage motif is determined by DNA sequencing
19–21
. The preferred substrate motif can 
then be searched against the human proteome to determine candidate proteins that may 
serve as physiological substrates. One drawback to phage and bacterial display of 
substrates is that the P1-P1’ cleavage site cannot be directly determined. Further studies 
7 
using mass spectrometry to analyze cleaved fragments of synthetic substrates are needed to 
determine the scissile bond. Once the preferred substrate residues are identified, analysis of 
the crystal structure can help explain what mechanisms, such as hydrogen bonding, 
electrostatics, steric hindrance, and hydrophobicity, govern the preference of an amino acid 
at a subsite. 
     Protease specificity characterization has mainly focused on residues in the substrate that 
preferentially dock into the active site. However, proteases can additionally use surfaces 
distant from the active site called exosites to influence substrate selectivity and increase or 
decrease the rate of catalysis. The influence of exosites is evident in studies describing the 
enhanced cleavage of large physiological substrates compared to short peptide sequences 
that bind solely to the active site
22,23
. The most widely recognized example of exosite 
utilization is in the serine protease thrombin. Thrombin has a strong preference for arginine 
at P1, which is found in its three primary physiological targets, fibrinogen, activated 
protein C, and protease-activated receptor 1 (PAR1)
24
. In addition to its active site, the 
presence of two positively charged surface patches termed exosite I and exosite II on 
thrombin interact with extended substrate sequences and kinetically control docking of the 
substrates
23
. An extended exosite binding motif in PAR1 (LRNPNDKYEPFWEDEEK) 
aids in forming the initial protease substrate complex and increases thrombin catalysis by 
325-fold over a substrate containing only the residues which interact with the active site 
alone
25
.  
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1.3.2. Regulation of protease activity  
     Most proteases are predicted to cut ~10-100 physiological substrates through their 
involvement in various pathways. Therefore protease activity must be tightly regulated to 
promote activity when needed and also prevent improper processing of substrates. 
Misregulated proteolysis is lethal and has been linked to a diverse set of pathologies such 
as cardiovascular
26
 and inflammatory disease
27
, cancer
28,29
, and neurodegenerative 
disorders
30
. Therefore, protease activity is tightly controlled in the body through a 
protease’s substrate specificity, as well as through temporal and spatial regulation of 
protease activity. To minimize unregulated proteolysis, nearly all proteases are produced as 
zymogens which have undetectable activity until activated through proteolytic processing. 
Proteases are further regulated through the action of inhibitors, which bind the active 
enzyme effectively reducing its concentration
31
. 
     To reduce off-target proteolysis, proteases are localized to specific tissues and 
compartments of the cell through protein-protein interactions. Proteases may also be 
secreted and circulate in the blood stream or lymphatic system. Additionally, nearly all 
proteases are inactive after translation due to the presence of a short N-terminal propeptide 
that blocks or alters activity of the active site
32
. These inactive versions termed zymogens 
become activated after proteolytic processing of the propeptide, which often leads to a 
conformational change and correct rearrangement of the active site for catalysis. For 
example, cleavage of the propeptide in many serine proteases produces an N-terminal 
isoleucine, which inserts itself into the protease and forms an internal salt bridge with 
Asp194
33
. Formation of the internal salt bridge is critical for stabilizing the active site and 
producing a functional S1 pocket
13
. Interestingly, synthetic peptides which mimic the 
9 
activated N-terminus of the serine proteases trypsin and hepatocyte growth factor have 
been shown to bypass proteolytic processing and reversibly stimulate the functional forms 
of the proteases
34,35
. Protease zymogens which participate in catalytic cascades, such as 
apoptosis, are activated in a hierarchical fashion with the first proteases in the pathway 
activating proteases below them
36
. Often the first proteases in the pathway have been 
shown to self-activate, cleaving and releasing their own propeptides, initiating the catalytic 
cascade
37
. 
     Protease activity is further regulated by the action of inhibitors which bind to the active 
site or allosteric sites preventing substrate docking and reducing the concentration of active 
protease
31
. Inhibitors are generally non-specific and can effectively bind to multiple 
proteases with similar folds
38
. The mechanism of inhibition may be reversible or 
irreversible and the strength of inhibition is characterized by the binding constant Ki and 
association rate constant kass to describe the binding speed. The largest class of inhibitors 
are the serine protease inhibitors or serpins, which employ an irreversible mechanism of 
inhibition by trapping the active site of the protease in a covalent complex with the reactive 
site of the inhibitor
39
. In humans, serpins are localized to the bloodstream and regulate the 
activity of serine proteases responsible for inflammation and blood clotting/fibrinolysis
40
. 
Because protease activity is necessary for viral replication in diseases such as acquired 
immunodeficiency syndrome (AIDS), synthetic inhibitors that bind to the active site of the 
human immunodeficiency virus (HIV) protease have been developed
41
. These inhibitors 
have dramatically increased the life expectancy of those living with AIDS
42
. However in 
many cases, HIV protease has evolved resistance to inhibitor drugs rendering treatment 
ineffective
43
.  
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1.3.3. Proteases as therapeutics 
     Because proteases have the unique ability to catalytically turnover their target 
substrates, they have been commercially used as reagents for research, detergent additives, 
and increasingly looked to as therapeutics. Currently, around 17 proteases have been 
clinically approved with the majority of these proteases being used for enzyme 
replacement therapy in genetically deficient patients. For example, the proteases Factor 
VIII, Factor IX, and Factor FVII are essential for the formation of blood clots and have 
been approved to treat patients with hemophilia A, B, and C, respectively, who lack 
production of these proteins
44–46
. In patients with cystic fibrosis, a deficiency in pancreatic 
proteases causes severe intestinal malabsorption. Therefore, replacement therapy with 
digestive proteases has been used to improve fat and nitrogen uptake
47
.  
     Proteases used in replacement therapy generally have narrow substrate specificities 
which has enabled their success in the clinic while limiting their toxicity. However, the 
application of proteases in therapy does not need to solely arise from their biological 
functions. The emergence of new tools for protease engineering will allow the design of 
proteases with novel activities and specificities for therapeutic targets. Proteases can be 
engineered to neutralize toxic proteins such as the amyloid beta protein or mutant 
huntingtin protein, which aggregate in neurological disorders. Additionally, the proteolytic 
inactivation of acute phase response proteins can help treat inflammation observed in 
asthma and rheumatoid arthritis. Due to their catalytic properties, proteases provide a 
significant advantage over antibodies, since their therapeutic application does not depend 
on stoichiometric addition to a given target, which could reduce the dosage and cost of 
treatment. 
11 
     The lack of substrate specificity has limited the use of proteases in therapy, since off-
target activity would lead to unwanted side-effects. For example, the approved protease 
therapy activated protein C (APC) participates in both inflammation and blood coagulation 
and its anti-inflammatory properties provide cytoprotective effects against serious infection 
in patients with sepsis
48,49
. However, the excessive anticoagulant properties of APC often 
lead to serious bleeding in patients, which has complicated its use
50,51
. Protein engineering 
studies to reduce APC’s inactivation of targets involved in coagulation while maintaining 
its anti-inflammatory properties would greatly minimize these side effects. Therefore high-
throughput methods for engineering target-specific proteolytic enzymes of human origin 
with high activity and stability are needed. 
    Another hurdle in using proteases for therapy is their short half-lives in the body. Most 
protease display half-lives on the order of minutes to hours in vivo due to rapid inhibition 
compared to antibodies, which are active in the bloodstream for weeks. The therapeutic 
protease tissue plasminogen activator (tPA), approved for the breakdown of blood clots in 
patients who have recently suffered from heart attack or stroke, displays a biological half-
life of 6 minutes due to its rapid inhibition by plasminogen activator inhibitor-1 (PAI-1)
52
. 
Site-directed mutagenesis of residues in tPA responsible for its fast clearance rate, such as 
those involved in the interaction with PAI-1, extended the half-life of tPA 3-fold, reducing 
the dosing frequency
53–55
. However, levels of tPA that are too high can lead to severe 
bleeding and haemorrhage
56
. Therefore caution must be taken in extending the therapeutic 
window since the multiple biological roles of proteases may produce unintended side 
effects. General methods for improving protease specificity are thus critical for reducing 
off-target activity before protease half-lives can be extended. 
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1.4. Methods for engineering protease specificity 
     The ability to engineer proteases with novel substrate specificities and activities could 
greatly expand the use of proteases in therapy. However, the evolution of proteases poses 
unique complications compared to other protein classes. Because most proteases are 
capable of cleaving multiple substrates, expression of a protease within a cell often causes 
toxicity due to cleavage of essential host cell proteins
57,58
. Variants with improved intrinsic 
activity or expression display even greater levels of toxicity to the cells. This creates a 
major hurdle since protease expression is necessary for characterizing the properties of 
protease variants. Additionally, proteases have the capability of cleaving and inactivating 
themselves, which could lead to low stability during characterization. Despite these 
challenges, researchers have made significant progress in engineering proteases of 
bacterial, viral, and human origin with improved activity, specificity, stability, and 
expression. 
     Protease engineering is a relatively new field with the majority of the high-throughput 
screens for protease evolution being developed in the past decade. Although these methods 
vary substantially, the main steps for protease engineering remain the same. These steps 
include selecting a parent protease, generating diversity through random or targeted 
mutagenesis, screening or selecting for the desired activity, and characterizing the 
properties of isolated variants (Figure 1.2). Often this process is repeated several times as 
mutations are incrementally introduced and screened for enhanced properties of the 
protease. In addition, choosing an optimal protease mutagenesis and screening strategy 
depends heavily on the engineering objective, information available and critical features of 
the parent protease. For example, if the protease contains post-translational modifications 
13 
that are required for protease activity, library screening would need to be accomplished in 
eukaryotic cells, which are capable of performing such modifications. 
 
 
Figure 1.2. Schematic overview of protease engineering.  
 
After selecting a protease design goal and parent protease, the protease is mutated either 
through targeted mutagenesis or the creation of large libraries. Variants are then screened 
for a desired property and positive clones are isolated for further characterization. This 
process can be repeated multiple times before obtaining a variant that satisfies the design 
criteria. 
 
1.4.1. Structure-guided studies 
     Early efforts in engineering proteases have generally centered on structure-guided 
mutagenesis of surface-exposed amino acids lining the active site using low throughput 
assays. Computational analysis of substrate-protease docking models and comparing 
homology between closely related proteases with known structure and function can 
additionally aid in determining sites of interest and predicting favorable substitutions
59
. 
Using this approach, the secondary structural elements or specific point substitutions can 
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be incorporated into a protease based on the structure of another protease. For example, 
trypsin and chymotrypsin have similar tertiary structures, but differ in their specificity. 
Trypsin cleaves after basic residues, arginine and lysine, whereas chymotrypsin prefers 
cleavage after large hydrophobic amino acids. By analyzing the structure and active site of 
both proteases, researchers converted trypsin to have chymotrypsin-like specificity by 
incorporating four amino acid substitutions and two surface loops found in chymotrypsin 
for the analogous sites in trypsin
60
. 
     Studies evolving the specificity of thrombin highlight the clinical utility of redesigning 
protease specificity. Thrombin has opposing functions in hemostasis, since it can convert 
fibrinogen to fibrin monomers that form a stable blood clot and can also elicit 
anticoagulant effects when in complex with thrombomodulin by activating protein C
1
. The 
wild-type protease displays >100 fold higher kcat/KM for cleavage of fibrinogen over 
protein C in the presence of thrombomodulin. Alanine scanning mutagenesis of 97 residues 
covering the solvent accessible surface of thrombin, identified the tryptophan (W) at 
position 215 as an important determinant of specificity
61
. Site-saturation mutagenesis 
revealed that the substitution W215E led to a 1000-fold switch in selectivity favoring 
cleavage of protein C over fibrinogen. The enhancement in anticoagulant properties of 
variant W215E could be efficacious in the breakdown of blood clots after heart attack or 
stroke.  
     Another recent study used structure-guided mutagenesis of residues within the active 
site of neprilysin to engineer its specificity for the amyloid beta peptide. A panel of 
variants was generated and screened in microtiter plates for activity toward Aβ40 and 
multiple non-target physiological substrates using fluorescence polarization to detect 
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activity
62
. A neprilysin variant with two substitutions (G399V/G714K) displayed 20-fold 
improved activity and up to 3200-fold improved selectivity on Aβ40 through reductions in 
cleavage of wild-type substrates. While structure-guided mutagenesis has shown some 
success in redesigning protease specificity, the ability to predict which residues are 
responsible for specificity based on the crystal structure is still a very challenging task. 
Additionally, often multiple substitutions are needed to generate large specificity switches 
and these substitutions may be located far from the active site
63
. Nevertheless, site-directed 
mutagenesis of amino acids in and around the active site of the protease can be used to 
identify residues that are important for activity and specificity providing guidance toward 
directed evolution approaches. 
 
1.4.2. Directed evolution 
     The ability to screen large protease libraries can dramatically improve the probability of 
isolating rare variants with novel activities and selectivities, since typically a combination 
of amino acid substitutions is required to alter specificity while maintaining high levels of 
catalytic activity
64
. Current screening and selection methods are equipped to handle 10
4
 to 
10
13
 variants. Protease libraries can be constructed using a variety of mutagenesis methods, 
such as error-prone polymerase chain reaction (epPCR), site-specific saturation 
mutagenesis, or genetic recombination. Recent advances in the development of high 
throughput assays for protease engineering have utilized bacteria and yeast cells for the 
redesign of bacterial and viral proteases. The advantages and drawbacks of recent screens 
and selection methods are discussed as well as their potential to be applied toward 
additional protease targets. 
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     A cell-based assay was developed in bacteria to exploit the toxicity associated with 
non-specific protease activity. A protease library is expressed in bacteria and non-specific 
variants leading to toxicity are removed, while surviving variants are screened for cleavage 
of a co-expressed reporter substrate
57
. Within the screen, a target peptide from the TNFα 
protein was inserted into a surface accessible loop of the reporter protein β-galactosidase 
(β-gal), such that cleavage of the substrate leads to a decrease in β-gal activity. Human 
immune-deficiency virus type I protease (HIV-Pr) was randomly mutated using epPCR 
and expressed in bacteria to remove toxic, non-specific variants. Surviving variants were 
then assayed for a decrease in β-gal activity. An HIV-Pr variant with two substitutions 
(P9S, I50L) displayed 2-fold increased selectivity for the TNFα peptide over a wild-type 
preferred sequence coupled with non-toxic expression in bacteria. This screen is amenable 
to proteases of bacterial and viral origin, which can be expressed in an active form in the 
cytoplasm of E .coli. 
     Another potential strategy in protease engineering is localizing a transcriptional 
activator at a site separate from the nucleus by fusing it to an anchoring membrane protein 
with a target substrate linking the two proteins. Cleavage of the target substrate causes 
translocation of the transcriptional activator to the nucleus where it turns on expression of 
a reporter protein. This screening design was incorporated into yeast through localization 
of the transcriptional activator LexA-b42 to the cytoplasmic face of the plasma membrane 
by attaching it to an integral membrane protein via a cleavable linker
65
. Four residues 
within the S2 pocket of the hepatitis A virus 3C protease (HAV 3CP) were subjected to 
saturation mutagenesis. Variants were screened for activity toward a substrate containing a 
non-preferred glutamine (Q) at the P2 position and a resulting variant displayed a 160-fold 
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switch in selectivity for Q over T at P2. This method was further used to identify variants 
of HAV 3CP that can cleave glutamine stretches found in the mutant huntingtin protein 
that aggregates in Huntington’s disease66. 
    To increase the throughput of analyzing large libraries, a screen was developed for the 
display of protease variants on the surface of E. coli followed by fluorescence activated 
cell sorting (FACS). Cells displaying the protease library are incubated with substrates that 
upon proteolytic cleavage produce a positively charged fluorescent product that is captured 
on the negatively charged cell surface. The fluorescent signal measured by flow cytometry 
is directly proportional to the catalytic activity of the protease and variants with the desired 
activity can be isolated. Using this screen with a single selection substrate, the E. coli outer 
membrane protein T (OmpT) was engineered to exhibit a 60-fold increase in activity 
against a non-preferred substrate Arg-Val
67
. However, the engineered enzyme displayed 
relaxed overall specificity and also cleaved peptide substrates at Ala-Arg sequences with 
higher efficiency than the wild-type OmpT. This increase in substrate promiscuity has been 
commonly observed when engineering proteases toward unnatural substrates
68,69
.   
     To improve on this method, a counter-selection substrate was added to the cell-based 
assay and OmpT variants were screened for cleavage of the non-preferred Ala-Arg peptide 
bond while counter-selecting for variants that did not cleave the Arg-Arg bond preferred 
by wild-type OmpT (Figure 1.3)
70
. This counter-selection strategy allowed isolation of an 
OmpT variant that cleaved the Ala-Arg bond with three million-fold selectivity over the 
wild-type Arg-Arg preferred cleavage. The isolated variant also had a catalytic efficiency 
for the Ala-Arg sequence similar to wild-type for the preferred substrate. By screening 
libraries with this selection-counter-selection substrate method, an OmpT variant with 
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activity toward Glu-Arg bonds was discovered, a specificity that has not been observed 
among natural proteases
71
. Additionally, OmpT variants were isolated that could 
selectively recognize sulfotyrosine and 3-nitrotyrosine, while discriminating against 
peptides containing unmodified tyrosine
72,73
. Although this method has been successful for 
engineering OmpT to selectively recognize new substrates, it is limited by the display of 
protease libraries on the surface of bacteria, which may not be feasible for more complex 
secreted eukaryotic proteases. 
 
 
Figure 1.3. Schematic for protease engineering using bacterial display.  
 
As a model for protease specificity engineering, OmpT libraries are displayed on the outer 
membrane of E. coli and cells are incubated with a target substrate capable of FRET and a 
fluorescent non-target substrate. Cleavage of the target or non-target substrates by an 
OmpT variant leads to capture of the corresponding fluorescent moeity on the cell surface. 
Cells which express variants displaying activity solely for the target substrate are isolated 
by FACS
70
.  
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     A potential cell-based selection for protease engineering is the coupling of proteolytic 
cleavage of a target substrate to antibiotic resistance permitting cell growth. This concept 
was utilized in a bacterial-based screen where cleavage of a positive selection substrate 
allows β-lactamase translocation from the cytoplasm to the periplasm where it is active and 
can confer antibiotic resistance to carbenicillin
74
. However, proteolytic cleavage of a 
counter-selection substrate causes retention of β-lactamase in the cytoplasm reducing cell 
growth on carbenicillin. Utilizing this selection and counter-selection strategy, a focused 
three member saturation mutagenesis library of the S6 pocket (N171, N176, Y178) of 
Tobacco Etch Virus (TEV) protease was analyzed for increased selectivity for T and P at 
P6 over the wild-type preferred residue E. Growth selection on carbenicillin yielded the 
importance of a single substitution N171D which conferred nearly 12-fold greater in vitro 
selectivity for P over E at P6. While this method employs a counter-selection substrate to 
increase the probability of isolating selective protease variants, it is restricted to proteases 
which can fold in the cytoplasm of E. coli and are non-toxic to the host. In addition, 
selection based methods offer less control over the dynamic range between cells containing 
active or inactive protease variants compared to screens which give a fluorescence or 
colorimetric output.  
     The compartmentalization and secretion pathway of yeast were utilized in a general and 
robust screen for protease engineering by sequestering the protease and substrates within 
the endoplasmic reticulum (ER) after which cleaved substrates are displayed on the outer 
surface of the cell
75
. Fusion of the yeast ER retention signal (FEHDEL) to the substrate or 
protease increases their residence time in the ER improving the opportunity for proteolysis 
to occur. Cleavage of the selection or counter-selection substrates can be quantified by the 
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addition of fluorescent tags specific for epitopes downstream of the cleavage site. Loss of 
fluorescence indicates cleavage of the substrate or counter-selection substrate directly 
upstream, and cells with desired fluorescence profiles are isolated using FACS. The 
FACS-based approach offers the advantages of screening protease libraries with greater 
than 10
7
 members and the ability to fine tune the conditions for sorting to isolate rare 
clones with altered selectivities.  
     The YESS method was used to screen a four member saturation mutagenesis library of 
the S1 pocket (T146, D148, H167, and S170) of TEV against a library of substrates with 
the sequence ENLYFX↓S, where X is any amino acid. The wild-type preferred sequence 
ENLYFQ↓S was used as a counter-selection substrate to increase selectivity of TEV for 
new P1 residues. Variants characterized from this screen were subjected to random 
mutagenesis and additional screening to improve catalytic activity on the desired 
substrates. Two highly active variants isolated from screening displayed 5,000-fold and 
1,100-fold switches in selectivity for E or H at P1, respectively, over the wild-type 
preferred residue Q. In addition, by removing the ER retention signals from the protease 
and substrate, the YESS system recovered a TEV variant with 4-fold improved activity on 
its native substrate ENLYFQS. This screen also displayed sufficient dynamic range for the 
screening of other viral proteases, as well as the human protease granzyme K, which 
contains multiple disulfide bonds. 
     To enable the rapid identification of substitutions that lead to inhibitor resistance in 
proteases, the phage assisted continuous evolution (PACE) system
76
 was modified to link 
protease activity on a target substrate to phage survival and propagation
77
. Within protease 
PACE, phage carry an evolving protease of interest. Protease variants with activity on the 
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selection substrate trigger activation of T7 RNA polymerase, which is responsible for the 
production of an essential protein in phage propagation. Phage that produce inactive 
protease variants are unable to infect E. coli and are diluted out of the pool. Throughout the 
experiment, mutagenesis of the protease is triggered by an inducible, low fidelity DNA 
polymerase, which increases the speed of continuous evolution with minimal researcher 
intervention. This system was used to evolve the hepatitis C virus (HCV) protease in the 
presence of two inhibitors, danoprevir and asunaprevir, for retention of wild-type activity. 
Growth and selection revealed that substitutions D168E and D168Y to HCV protease 
resulted in up to 30-fold resistance to inhibition in vitro by danoprevir and asunaprevir. 
This method requires that the protease of interest be produced in a folded and functional 
form within bacteria and therefore protease PACE would likely not be suitable for human 
proteases. 
     Although, the high-throughput screens developed have enabled the rapid identification 
of protease variants with improved activity, selectivity, and stability, they have only been 
applied to bacterial and viral proteases, which lack therapeutic potential. Bacterial and viral 
proteases are easy to express, since they lack post-translational modifications and often 
display narrow specificities, which limits their toxicity. However, these proteases would 
elicit an immune response if introduced into humans and would not be candidates for 
therapy. Many of the current and potential protease therapeutics are human secreted 
proteases, which contain multiple disulfide bonds. Therefore, this dissertation outlines the 
development of a screen to evolve the specificity of human secreted proteases toward 
target substrates which aggregate in disease, such as the amyloid beta peptide in 
Alzheimer’s disease. By minimizing off-target proteolytic cleavage, protease variants 
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should display lower levels of side effects and increased efficacy for neutralization of the 
target.    
 
1.5. Alzheimer’s disease and Aβ proteolysis 
1.5.1. Amyloid hypothesis 
     Though there is still much debate on the causes of Alzheimer’s disease (AD), the 
amyloid hypothesis proposes that accumulation and aggregation of amyloid beta (Aβ) in 
the brain causes a series of events that leads to cognitive decline in patients with AD
78
. The 
Aβ peptide is produced after sequential cleavage of the amyloid precursor protein (APP), 
an integral membrane protein, by β-secretase and γ-secretase (Figure 1.4)79,80. The Aβ 
monomer is 40 or 42 amino acids in length, with Aβ42 displaying a higher hydrophobicity, 
toxicity, and propensity to form fibrils
81. An important feature of the Aβ peptide is a 
central hydrophobic core of amino acids (KLVFFAED) that is both necessary and 
sufficient for Aβ fibril formation82,83. When Aβ42 accumulates, these monomeric species 
begin to aggregate due to their hydrophobic nature into toxic oligomeric species and 
fibrils, which are the main components of amyloid plaques
84
. Aβ plaques interfere with 
communication between neurons and promote neuronal death
5
.   
     Clearance of amyloid beta is achieved through proteolytic processing by enzymes 
within the brain and also removed by crossing the blood brain barrier into the peripheral 
vasculature
85,86
. However, most AD patients display increased accumulation of Aβ in the 
central nervous systems due to impaired clearance mechanisms
87
. Therefore, a therapeutic 
agent that decreases the amount of Aβ species could be efficacious in the treatment of AD. 
Clinical trials of therapeutics for AD have focused on inhibitors of β-secretase and γ-
secretase to reduce production of the Aβ monomer as well as monoclonal antibodies 
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toward Aβ to reduce its aggregation88–90. However, β- and γ-secretase inhibitors have 
failed to show cognitive improvement in patients with AD and have also led to unwanted 
side-effects due to shutting down the other biological functions of β- and γ-secretase91,92. 
Additionally, the clinical efficacy of therapeutic antibodies has only been observed at high 
dosage concentrations, which have led to side-effects such as vasogenic edema
93,94
. 
Alternatively, another therapeutic strategy is the enhanced proteolytic clearance of Aβ, 
which could irreversibly inactivate the toxic peptide reducing its aggregation in AD
85,95
. 
 
 
 
Figure 1.4. Amyloid metabolism within the human brain.  
 
The amyloid precursor protein (APP) is sequentially cleaved by the proteases β-secretase 
and γ-secretase, respectively, to produce the amyloid beta monomer, which can be 40 or 42 
amino acids in length. The physiological role of Aβ is still uncertain and the monomer is 
cleared from the brain via proteolytic processing or removal via perivascular pathways to 
prevent its accumulation. Deficiencies in the clearance pathway of Aβ lead to build up of 
monomers in the brain which aggregate due to their hydrophobicity. The presence of Aβ 
plaques in the brain has been shown to impair neuronal communication and function 
resulting in cognitive decline. 
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1.5.2. Aβ degrading proteases 
     Multiple proteases have been identified with in vitro activity toward the Aβ peptide and 
many of these proteases have been confirmed to remove Aβ in vivo. Knockout mice for the 
proteases neprilysin (NEP)
96
, endothelin-converting enzyme (ECE)
97
, and insulin 
degrading enzyme (IDE)
98
 display an accumulation of endogenous Aβ confirming Aβ 
regulation by these proteases. The cellular or extracellular localization of Aβ-degrading 
proteases is strongly correlated with their ability to cleave monomeric, oligomeric, and 
fibrillar Aβ. For example, IDE is localized to the cytosol of neurons and microglia and 
cleaves only soluble monomeric Aβ that becomes internalized99. The membrane-bound 
protease NEP cleaves soluble and oligomeric Aβ100,101, whereas secreted proteases, such as 
plasmin and human kallikrein 7 (hK7), have been shown to degrade Aβ monomers and 
fibrils
102,103
. It is likely that the fibrillar forms of Aβ cause certain cleavage sites of the 
monomer to become inaccessible leading to the accumulation of Aβ plaques104. Aβ-
degrading proteases cleave at different sites within the monomer producing a wide array of 
fragments that each display differing levels of reduced aggregation. While much work still 
remains in elucidating the aggregation potential of Aβ degradation products, overall the 
majority of Aβ fragments are less likely to aggregate, less neurotoxic, and more easily 
cleared than full-length Aβ105,106.  
     Enhancement of Aβ clearance through proteolytic cleavage into non-aggregating 
peptides represents a distinct potential alternative to antibody-mediated clearance for the 
treatment of amyloid diseases including AD. Systemically administered monoclonal 
antibodies specific for Aβ have exhibited efficacy in mild AD94. However, antibodies 
toward Aβ monomers and aggregates have resulted in side effects including brain 
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inflammation and vasogenic edema or amyloid-related imaging abnormalities (ARIA)
93,107
. 
These safety concerns have resulted in lowering the antibody dosage during clinical trials 
which may reduce the desired clinical effect
108
. Therapeutic proteases present an 
alternative approach and could be used at much lower doses, providing sustained clearance 
at lower rates. Toward this goal, catalytic antibodies with α-secretase activity toward Aβ 
have been explored
109
. However, known catalytic antibodies suffer from low specificity 
and ~100-fold reduced activity toward Aβ compared to proteases such as neprilysin and 
insulin degrading enzyme (IDE). Upregulation of neprilysin or IDE activity has exhibited 
efficacy in mouse models of AD
110,111
. However due to their large structures and complex 
substrate recognition mechanisms
112
, specificity engineering to reduce neprilysin and IDE 
activity on other physiological substrates has remained challenging
62
. Therefore, the 
identification of Aβ-degrading protease candidates that have smaller structures and open 
active sites suitable for protein engineering could expand the potential of using protease 
replacement therapy in AD. 
     Recent work discovered that the protease human kallikrein 7 (hK7) is capable of 
cleaving Aβ in vitro within the central hydrophobic core (KLVF↓F↓AED) reducing its 
propensity to aggregate
103
. hK7 cleaves the peptide Aβ8 (KLVFFAED) with high activity 
(kcat/KM = 0.24 ± 0.05 μM
-1
·min
-1
), is 4-fold smaller than IDE and NEP, and has an open 
active site which makes it amenable to use in high-throughput protein engineering screens. 
Additionally, hK7 is capable of degrading preformed Aβ fibrils, which has not been 
demonstrated for IDE and NEP
103
. Because multiple studies have characterized both hK7’s 
structural features, mechanism of action, and specificity, we chose this protease as a model 
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enzyme to develop a cell-based method for engineering secreted human proteases toward 
therapeutic targets such as the Aβ peptide103,113,114. 
 
1.6. Human tissue kallikreins 
     The human tissue kallikrein family comprises fifteen serine proteases forming the 
largest contiguous cluster of enzyme-encoding genes within the human genome
115
. The 
physiological roles of many of the kallikrein proteases remain unknown, however they are 
all localized to one or more human tissues, often being co-expressed with other kallikreins, 
suggesting important biological functions
116
. A few kallikrein cascades have been 
described including kallikreins 2, 3, and 5 in seminal plasma
117
 and kallikreins 5, 7, and 14 
in skin
118,119
. Of the fifteen proteases, human kallikrein 3 (hK3) and human kallikrein 7 
(hK7) display chymotrypsin-like specificity and favor cleavage after large hydrophobic 
residues. All other thirteen proteases show trypsin-like specificity for hydrolysis of basic 
amino acids at P1
113
. While the precise physiological targets are difficult to determine, 
upregulation and overexpression of the majority of the tissue kallikreins has been linked to 
multiple cancers
120
. Elevated levels of hK3, also known as prostate specific antigen (PSA), 
have been linked to the presence of prostate cancer and is used as a biomarker for 
screening and diagnosis
121
.  
 
1.6.1. Human kallikrein 7 (hK7) 
     hK7 is a small 27 kDa secreted serine protease initially named stratum corneum 
chymotryptic enzyme after being discovered in the skin. hK7 is translated as a pre-
proenzyme with a 22 residue signal sequence that becomes processed after secretion of the 
protease from the cell. Post-translational modifications to hK7 include six disulfide bonds 
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required for proper folding and one N-linked glycosylation site at N246 (UniProt 
numbering used). After secretion, the protease remains inactive due to a 7 amino acid 
propeptide that prevents correct conformation of the active site. This propeptide is 
processed by cleavage within the sequence EEAQGDK↓I by a protease with trypsin-like 
specificity. hK5 is the only kallikrein capable of processing the hK7 zymogen in vitro and 
also co-localizes with hK7 in the skin suggesting its role in physiological hK7 
activation
122
.  
     After activation, the new N-terminal isoleucine inserts itself into the hK7 structure 
forming an internal salt bridge with D204, which produces a functional active site
114
. The 
S1 pocket of hK7 differs from the other trypsin-like kallikreins in that at the bottom of the 
pocket the negatively charged D199 is replaced with N199 in hK7, which reduces 
interactions with positively charged P1 residues (UniProt numbering used). In addition, the 
pocket is more hydrophobic, accommodating bulky aromatic amino acids such as tyrosine, 
phenylalanine, and leucine. Multiple studies have demonstrated hK7’s strong preference 
for cleavage after tyrosine, likely due to the favorable hydrogen-bonding between N199 
and the hydroxyl group of tyrosine
103,113,123
. In addition, the extended substrate specificity 
of hK7 displays a strong preference for arginine at the P4 or P5 position, and small amino 
acids such as alanine, glycine and serine at the P1’ position103. Two positively charged 
surface patches on hK7 may increase specificity for negatively charged substrates or aid in 
attachment to the cell surface (Figure 1.5)
114
. 
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Figure 1.5. Docking model of human kallikrein 7 with Aβ8.  
 
hK7 has an open active site for the docking of substrates such as the Aβ8 peptide (shown 
in green). Two positive charged surface patches are found on hK7 which may play a role in 
the protease’s specificity by binding negatively charged regions in substrates. Additionally, 
the positively charged surface of the protease may bind to the negatively charged cell 
membrane after secretion. The image above was created with the Chimera software 
package using PDB:2QXI. 
 
     hK7 is most highly expressed in the skin, esophagus, and kidney and at lower levels in 
the brain and other tissues
116
. The physiologically preferred substrates of hK7 include 
intercellular cell adhesion proteins in the cadherin family including desmocollin-1, 
desmoglein-1, and E-cadherin
122,124
. hK7 expressed in the skin plays an important role in 
the shedding of the stratum corneum for continuous regeneration of the skin
119
. However, 
elevated levels of hK7 activity in the epidermis have been linked to inflammation in severe 
skin diseases such as psoriasis, atopic dermatitis, and Netherton syndrome
125,126
. Netherton 
syndrome has been genetically linked to a defect in the SPINK5 gene, which encodes the 
multidomain protein LEKTI, an inhibitor of hK7
127,128
. Furthermore, upregulation of hK7 
activity has been implicated in metastatic tumor growth, especially in ovarian cancer. 
Increasing hK7 expression has been shown to correlate with ovarian cancer stage and a 
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high level of hK7 mRNA is associated with poor prognosis
129,130
. It has been proposed that 
hK7 enhances metastasis by degrading the extracellular matrix which allows tumor cells to 
migrate from the primary tumor.   
    For hK7 to serve as a potential therapeutic in AD, it would be necessary to reduce its 
activity toward its physiological substrates and increase specificity for Aβ. Though hK7 
can cleave after the phenylalanines in Aβ, hK7 has higher selectivity and activity for 
tyrosine at the P1 position. Because many candidate substrates exhibit tyrosine adjacent to 
the scissile bond, we hypothesized that a protease variant that does not recognize substrates 
with tyrosine will be less toxic and more potent. Further, we hypothesized that amino acid 
substitutions in and around the active site of hK7 can generate a structure that favors 
phenylalanine and excludes tyrosine.  
 
1.7. Techniques 
1.7.1. Fluorescent protein FRET 
     Förster resonance energy transfer (FRET) is the transfer of energy from an excited 
donor fluorophore to an acceptor fluorophore when there is significant overlap between the 
emission spectrum of the donor and absorption spectrum of the acceptor. FRET is strongly 
dependent on distance, orientation, and spectrum properties of the donor and acceptor 
fluorophores. The efficiency of energy transfer is proportional to the inverse sixth power of 
the distance between the centers of the two dipoles. Therefore, the donor and acceptor 
molecules must be within a distance of 1-10 nm of each other for efficient energy transfer.  
     Another requirement for FRET is that there must be sufficient separation between the 
excitation spectra of the donor and acceptor to selectively excite the donor. Also the 
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emission spectra of the donor and acceptor should be separated so that each fluorophore 
can be measured independently
131
. When these requirements are met, transfer of energy 
from the excited donor to the acceptor fluorophore results in emission of the acceptor 
molecule leading to the FRET-On state. When the fluorophores are separated, excitation of 
the donor fluorophore results in normal donor emission, termed the FRET-Off state. 
     FRET-based approaches have allowed the detection of protease activity and protein-
protein interactions but are limited by the dynamic range between the FRET-On and 
FRET-Off states and sensitivity of the donor-acceptor pair. To address this problem, a 
CFP-YFP donor-acceptor pair was evolved for enhanced brightness and an improved 
dynamic range. Multiple rounds of mutagenesis and screening with fluorescence activated 
cell sorting (FACS) resulted in a CyPet-YPet pair with a 20-fold ratiometric FRET signal 
change
132
. Using this optimized FRET pair, events such as proteolytic cleavage within a 
substrate flanked by the CyPet and YPet molecules and protein-protein interactions can be 
easily monitored by flow cytometry or fluorescence microscopy (Figure 1.6)
133
.  
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Figure 1.6. FRET probes link proteolytic activity with fluorescence.  
 
A protease susceptible substrate is flanked by the cyan fluorescent protein CyPet and 
yellow fluorescent protein YPet. Excitation with violet light at 408 nm excites CyPet 
which can transfer energy to YPet if it is within a distance of 1-10 nm leading to yellow 
emission (FRET On). Cleavage of the substrate by a protease separates the two 
fluorophores so that violet light excitation leads to cyan emission (FRET Off). 
 
     Fluorescent protein FRET provides a unique tool for flow cytometry-based protease 
library screens for redesigning protease specificity or turnover rate. Aside from enabling 
the detection of protease activity, fluorescent protein sensors are relatively non-toxic to 
host cells and therefore could be co-expressed with a protease library for protease directed 
evolution. In order to use this screening strategy, the protease of interest must be have an 
open active site compatible with a dumbbell-like substrate that is flanked by donor and 
acceptor FRET proteins. Also, it is necessary for the protease to be expressed in active 
form inside the host cell without killing the cell. Non-specific proteases, such as HIV 
protease, recognize essential proteins in E. coli, yeast, and mammalian cells and are 
cytotoxic
57,134
. 
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1.7.2. Fluorescence activated cell sorting (FACS) 
     The use of FRET reporters is appealing for the discovery of proteases with novel 
activities and specificities. However, screening variants by fluorescence spectroscopy or 
microscopy is time and labor intensive and would limit the size of variant libraries. 
Fluorescence activated cell sorting (FACS) is unique among protein library screening 
methods in that millions of single cells can be analyzed rapidly in a high-throughput 
manner while measuring subtle changes in cellular fluorescence intensity
135
.  
     Through flow cytometry, a suspension of cells is hydrodynamically focused into a 
single file line, where each cell can be individually excited by one or more laser beams. 
Most cytometers are equipped with lasers that excite at wavelengths of 407 nm, 488 nm, 
and 633 nm. Photomultiplier tube (PMT) detectors allow simultaneous detection of 
fluorescence from various dyes. The scattered light and fluorescence emissions from each 
laser are collected by detectors and optical signals are converted into digital signals. Using 
a computer attached to the cytometer, size and fluorescence of cell populations can be 
monitored in real time. Light scattered in the forward (FSC) direction gives a measurement 
of particle size, where larger particles will scatter more light. Side-scattered (SSC) light is 
collected at ninety degrees to the laser beam and is proportional to cell granularity or 
roughness. Gates are drawn on plots of FSC versus SSC and SSC height versus SSC width 
to focus the analysis on only individual healthy cells and avoid cell aggregates.  
     If the cytometer is equipped with a cell sorting device, individual cells with desired 
properties, such as size, shape, or fluorescence can be isolated. A gate is drawn around 
cells having the fluorescence profile of interest and eliminating low fluorescent cells based 
on the background fluorescence of a negative control. The stream containing the cell 
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sample is broken into droplets, with each droplet enclosing a single cell. Target cells can 
be separated from negative cells by first charging the droplet that encapsulates the target 
cell. Charged droplets are deflected into a collection chamber after passing between two 
high voltage deflection plates (Figure 1.7). The uncharged droplets are kept in the waste 
stream. With this technology, a subpopulation of interest can be separated from negative 
cells with high purity at speeds greater than ten thousand cells per second
136
. 
 
 
Figure 1.7. Cell based libraries screened using fluorescence activated cell sorting.  
 
Cells are interrogated by a laser and the scattered light is separated into forward scatter 
(FSC), side scatter (SSC), and fluorescence (FL). Single cells are encapsulated by a droplet 
and droplets containing cells of interest are charged and collected after passing between 
two high voltage deflection plates. 
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1.7.3. Strategies for library diversification 
     The ability to screen large protein libraries can dramatically improve the probability of 
isolating rare variants which display a novel function of interest. In nature, proteins display 
slow rates of evolution due to the low rate of DNA mutagenesis found in most organisms. 
This slow rate of mutagenesis is important for long-term survival, since high mutation 
rates have been linked to conditions such as cancer
137
. However, through the use of 
directed evolution, an individual protein of interest can be isolated and randomly or 
selectively mutated to generate a library of diverse variants. Although it is impossible to 
cover the entire mutational space of a protein, gene diversification methods perform an 
optimal sampling of the vast sequence space
138
. This library can then be screened or 
selected for beneficial properties within the course of weeks. Directed evolution has been 
extremely effective in evolving hundreds of proteins for functions such as improved 
catalytic activity, specificity, fluorescence profiles, and stability
139–142
. 
     The success of a directed evolution experiment is directly linked to the quality of the 
library generated and the development of a robust screening methodology for the activity 
of interest. Mutations can be introduced to a gene of interest using a variety of methods 
including chemicals
143
, mutator strains
76
, error-prone polymerase chain reaction 
(epPCR)
144
, site-directed saturation mutagenesis
145
, and genetic recombination
146,147
. 
Chemical agents such as ethyl methanesulfonate (EMS) and ultraviolet irradiation are non-
specific and can randomly mutate DNA. Mutator strains which contain low-fidelity 
polymerases and deactivated proofreading and repair enzymes cause the introduction of 
random mutations at low frequencies within the evolving gene and host genome
148
. 
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Therefore, the ability of the host cell to tolerate random mutations to its genome places an 
upper bound on the in vivo mutagenesis rate. 
     Error-prone PCR is a conservative method for randomly introducing substitutions of 
single bases along the length of the gene of interest. This can be achieved through the use 
of a low-fidelity polymerase such as Taq and the addition of manganese ions to the PCR 
reaction
149
. Magnesium ions are important for polymerase activity and the introduction of 
the larger manganese ions into the reaction causes deformation of the polymerase structure 
resulting in higher rates of base pair mismatches. In addition, unequal concentrations of 
dNTP monomers are used to reduce the natural bias of the polymerase for certain 
mutations promoting a more even representation of substitutions to each of the 20 amino 
acids. With epPCR, 0.15-3% of nucleotides within a gene can be targeted for mutagenesis 
by adjusting the concentrations of manganese and magnesium ions within the reaction
149
.  
     Because mutations are randomly scattered using epPCR, different sites of the protein 
can be sampled for their importance to a given function. Additionally, beneficial 
substitutions can be introduced at sites that would be impossible to predict. This method is 
highly favorable when computational modeling is unable to determine beneficial 
substitutions as in the case of engineering proteins with unsolved structures. A 
disadvantage of epPCR with Taq polymerase is that transitions of A to G and C to T are 
more commonly seen during mutagenesis than transversions, which causes bias in the 
amino acid substitutions
149
. Additionally, because the genetic code contains 64 codons 
encoding 20 amino acids, mutations at the wobble position, or the third position within a 
codon, often result in silent mutations where the amino acid is unchanged. A final 
consideration with epPCR is that because mutations are random, it is very rare for adjacent 
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bases to be mutated. This biases substitution of amino acids to residues which can be 
encoded by a single base pair substitution. These substitutions tend to be similar in 
property to the original amino acid, therefore dramatic changes in side chain structure or 
charge are less common. 
     For proteins with solved structures, computational methods can be used to predict 
residues in a protein that are important for functions such as binding to a target or substrate 
recognition. For example, molecular modeling of proteases often involves docking a 
protease with a substrate and determining which residues in the active site make 
intermolecular contacts with the substrate. Site-directed mutagenesis and kinetic 
characterization can aid in further identifying the function of different residues
150
. 
Important residues can then be targeted for site-directed saturation mutagenesis by using 
primers that enable mutagenesis to all 20 amino acids with little bias. To encode for all 20 
amino acids, the codon NNS is introduced into the primer at a specific position, where N is 
A/C/G/T and S is C/G. Common overlap PCR techniques such as splice overlap 
extension
151
 and gene assembly mutagenesis
152
 can be used to target multiple sites for 
saturation mutagenesis.  
     Site-directed saturation mutagenesis allows for the discovery of the optimal substitution 
at a given position of interest. By focusing saturation mutagenesis on a few residues, 
libraries are made at reasonable sizes for screening and retain some of the benefits of 
random mutagenesis since all residues are explored at a given position. However, 
determining which residues to mutate is still a very challenging task since often 
substitutions to one site can disrupt the structure of neighboring residues that are important 
for binding and catalysis
153
. Because residues involved in the protein’s function are 
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targeted, site-saturation mutagenesis often results in a high portion of the library being 
non-functional. Additionally, this method would miss residues distant from the active site 
that may operate synergistically with active site residues, but would be impossible to 
predict from the crystal structure.  
     Mutations from distinct clones with improved properties discovered from epPCR and 
site-saturation mutagenesis experiments can be combined in later rounds using genetic 
recombination. Recombination methods are most effective on a diverse population of 
functional variants. Additionally, the wild-type DNA sequence can be introduced during 
recombination to eliminate deleterious mutations. To access beneficial combinations of 
mutations, variants are fragmented with DNase and the fragments are reassembled into 
full-length genes by repeated cycles of overlap extension reaction
146
. Another homologous 
recombination technique which does not require treatment with DNase, is staggered 
extension process (StEP)
154
. StEP is a modified PCR method that uses a shortened 
annealing and extension time to promote crossover events along the full length of the 
template sequences. During both these methods, additional point mutations may be 
introduced if the DNA polymerase used has low-fidelity.   
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2. Development of a cell-based screen for protease engineering 
     Proteases have a unique ability to catalytically activate or inactivate proteins or peptides 
and present potential applications for use in therapy. However, most proteases are capable 
of cleaving multiple substrates and therefore would cause unwanted and toxic side-effects 
if introduced into the body. A handful of proteases have been approved for replacement 
therapy with naturally narrow substrate specificities, which limits their toxicity. However, 
the application of therapeutic proteases need not be limited to their native biological 
functions. The emergence of tools to engineer proteases with narrow specificities toward 
substrates involved in disease pathology could greatly expand their potential in therapy. As 
a model system, we have chosen to develop a cell-based method for engineering the human 
secreted protease kallikrein 7 (hK7) toward peptide targets such as the amyloid beta 
peptide that aggregate in disease. To develop a screening method for protease engineering, 
suitable expression hosts for hK7 were evaluated. hK7 formed insoluble aggregates when 
expressed in bacteria likely due to the mispairing of cysteines that form six disulfide bonds 
within hK7. Therefore yeast, which is equipped with enzymes that can aid in the formation 
of multiple disulfide bonds within the oxidizing compartment of the endoplasmic reticulum 
(ER), was assessed for its ability to fold mature, active hK7. hK7 was active and properly 
folded after expression in the ER of yeast. Therefore, a high-throughput screen for protease 
engineering was developed in yeast involving co-expression of a protease library and a 
peptide substrate exhibiting Förster resonance energy transfer (FRET) within the ER. After 
optimizing the co-expression conditions of the protease and FRET reporter substrate, 
significant in vivo activity of hK7 was measured by flow cytometry above background. 
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The dynamic range of the assay could enable screening large protease libraries using 
fluorescence activated cell sorting for the activity of interest. 
 
2.1. Introduction 
     Human proteases represent a potential source of therapeutics capable of clearing toxic 
proteins from the body in a catalytic fashion. Because human proteases are naturally made 
in the body, they would likely cause little immune response when introduced in therapy 
providing a significant advantage over using proteases from bacterial or viral sources. 
Some of the most attractive proteases for engineering into therapeutics are the secreted 
human proteases, which often contain multiple disulfide bonds that can stabilize the 
tertiary structure of these molecules in the extracellular environment. For example, the 
approved protease therapeutics tissue plasminogen activator, coagulation factors VII, VIII 
and IX, and thrombin belong to the family of human secreted proteases and require 
multiple disulfide bonds for proper folding and activity
155
. While engineering screens have 
been developed for membrane bound and intracellular proteases
65,70,74,75
, general methods 
for engineering human secreted proteases are lacking. 
     Human kallikrein 7 (hK7) is a secreted serine protease that is highly expressed in skin 
tissue and plays an important role in cleaving cell adhesion proteins for the shedding of the 
skin
116,122
. hK7 has a total of 12 cysteines within its mature protein sequence that form six 
disulfide bonds within the folded protease (Figure 2.1). Because hK7 has the unique ability 
to cleave both Aβ monomers and fibrils, but prefers cleavage after substrates containing 
tyrosine
103
, we chose this protease as a model enzyme for developing a cell-based screen to 
engineer human secreted protease specificity. A major hurdle in engineering secreted 
proteases, such as hK7, is finding a suitable expression host capable of forming the correct 
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disulfide bonds required for conformational stability and biological activity. hK7 has 
previously been expressed as inclusion bodies in the cytoplasm of bacteria which required 
refolding
113
. Because protein refolding is labor and time intensive
156
, this method of hK7 
production would be inefficient for screening variants. To analyze the activity of multiple 
variants in a high-throughput fashion, hK7 would need to be expressed in an active form 
intracellularly. Ideally, the expression host would be microbial, since mammalian cells 
suffer from slow grow rates and low transformation efficiency which would limit the 
ability to screen large protease libraries for the activity of interest. 
 
Figure 2.1. hK7 ribbon model with disulfide connectivities.  
 
hK7 has six disulfide bonds that are required to form for proper folding and activity 
(shown in red). Additionally, after the propeptide sequence of hK7 is processed the N-
terminus (teal) inserts itself into the hK7 structure causing a conformational change that 
produces a functional active site. The image above was created with the Chimera software 
package using PDB:2QXI. 
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     While the cytoplasm of bacteria is naturally kept in a reduced state that disfavors 
disulfide bond formation, the periplasmic compartment is oxidizing and equipped with 
enzymes that efficiently form disulfide bonds within secreted proteins. Proteins become 
secreted to the periplasm through the secretory pathway which recognizes N-terminal 
signal sequences on proteins that direct their transport
157,158
. Within the periplasm of E. 
coli, the enzyme DsbA catalyzes disulfide bond formation by transferring its one disulfide 
bond to substrate proteins causing DsbA to become reduced in the process
159,160
. The 
integral membrane protein DsbB then reoxidizes the resulting reduced cysteines of DsbA 
to regenerate active DsbA
161
. Because incorrect disulfide bonds formed by DsbA may trap 
the protein in a non-native conformation, enzymes DsbC and DsbG act as proofreading 
chaperones and can break incorrect disulfide bond pairs to form the native disulfide 
bonds
162,163
. Overexpression of DsbA and DsbC has been used to improve the formation of 
native disulfide bonds in eukaryotic proteins produced in bacteria
164–167
. However, often 
eukaryotic proteins contain multiple disulfide bonds with complex bonding patterns that 
overwhelm the E. coli machinery causing improper disulfide linkages. Therefore, although 
the proteins become oxidized, they are often locked in non-native states that may generate 
inclusion bodies
168
.  
     An alternative microbial system for the production of recombinant proteins with 
multiple disulfide bonds is yeast. Yeast, like bacteria, have faster growth rates and higher 
transformation efficiencies than mammalian cells making them suitable for the 
development of protein engineering screens. However, yeast are better equipped than 
bacteria in forming the complex disulfide bonding patterns found in eukaryotic proteins. 
Within the yeast secretory pathway, disulfide bond formation occurs in the endoplasmic 
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reticulum (ER). The enzyme protein disulfide isomerase (PDI) resides in the ER and 
catalyzes both the formation and rearrangement of disulfide bonds until the protein folds 
into its native conformation
169
. PDI achieves both these functions depending on if it is in 
an oxidized or reduced form. When PDI is in the oxidized state, it is capable of forming a 
disulfide bridge in a secreted protein by transferring its own disulfide bond. However, 
reduced PDI acts as an isomerase to break mispaired cysteines in proteins and aid in the 
formation of the correct disulfide bond
170
. Additionally, the chaperone activity of PDI 
allows it to stabilize the misfolded structures of proteins and fold them into their native 
state. Another important protein in disulfide bond formation in yeast is the ER resident 
protein ER oxidoreductin (Ero1). Ero1 introduces oxidizing equivalents into the ER that 
promote reoxidation of reduced PDI
171
. 
     Within yeast, control mechanisms such as endoplasmic reticulum associated 
degradation (ERAD) are in place to prevent the buildup of misfolded proteins in the cell 
which can aggregate and cause cell stress. Misfolded proteins can be recognized by 
chaperones in the ER that bind the proteins and aid in their translocation to the cytosol
172
. 
Once in the cytosol, misfolded proteins are tagged with multiple ubiquitin molecules which 
target them for degradation by the proteasome
173
. However, if misfolded proteins 
accumulate in the ER and overwhelm ERAD clearance mechanisms, the unfolded protein 
response (UPR) is activated. During UPR, translation in the ER is greatly reduced and the 
expression of molecular chaperones that assist in protein folding is increased
174
. If normal 
cellular function is unable to be restored through these mechanisms, the UPR triggers cell 
death
175
. Here, we have evaluated bacteria and yeast for their ability to correct fold the 
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secreted human protease hK7 for the development of a cell-based screen for protease 
engineering. 
 
2.2. Results 
2.2.1. Bacteria as an expression host for secreted proteases 
     Bacteria was first chosen as an expression host for hK7 due to its increased growth rate 
and transformation efficiency compared to eukaryotic cells and because a previous study 
had reported successful production of active hK7 in the periplasmic space of E. coli
176
. 
Since bacteria lack many of the tRNAs necessary for efficient translation of human genes, 
the wild-type hK7 gene was codon-optimized for expression in bacteria. An OmpA signal 
sequence was fused to the N-terminus of hK7 to direct protein secretion to the oxidizing 
environment of the periplasm for formation of the six disulfide bonds within hK7. hK7 
expression was placed under the lactose promoter and different concentrations of the 
synthetic lactose analogue isopropyl β-D-1 thiogalactopyranoside (IPTG) were tested for 
their ability to produce soluble, active hK7 in bacteria. Since IPTG is a membrane 
permeable, small molecule and does not need a transporter, a lower concentration of IPTG 
will correlate to a lower protein induction level. Using a lower concentration of IPTG for 
induction of another disulfide-containing protease was shown to increase cell viability after 
protein expression and increase the formation of correctly folded, active protease
177,178
. 
Therefore, slowing the rate of protein synthesis to provide more time for proper folding 
and formation of disulfide bonds should favor the production of soluble protein. 
     To characterize the effect of inducer concentration on hK7 production, hK7 was 
expressed at a range of IPTG concentrations. Cell pellets with hK7 production and 
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negative control pellets containing a vector without the hK7 gene were ran on a Western 
blot after denaturing and reducing the samples. All samples expressing hK7 displayed two 
bands at ~27 and 29 kDa representing hK7 (Figure 2.2). The higher band likely represents 
unprocessed hK7, which has not been secreted and therefore retains the signal sequence, 
while the lower band may represent processed hK7. The OmpA signal sequence directing 
hK7 to the periplasm is ~2 kDa which would account for the molecular weight difference 
between these two bands. Cells induced with a final concentration of 5 µM IPTG displayed 
a higher ratio of processed hK7 to unprocessed material compared to cells induced with 1 
mM IPTG (Figure 2.2). A higher concentration of inducer may increase protein synthesis 
to a level where the secretion system becomes jammed causing a higher portion of the 
expressed hK7 to stay in the cytoplasm unfolded. 
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Figure 2.2. Lowering the IPTG inducer concentration increases the ratio of processed to 
unprocessed hK7. 
 
hK7 expression in bacteria was placed under the lactose promoter which is inducible by the 
addition of IPTG, a synthetic lactose analogue, to the media. The presence of hK7 
expression was visualized using a Western blot with an anti-C-terminal histidine tag 
antibody. Cells with hK7 expression showed two bands at the correct molecular weights of 
processed (27 kDa) and unprocessed hK7 (29 kDa), which represent hK7 without and with 
the periplasmic signal sequence, respectively. Reducing the IPTG inducer concentration 
increased the ratio of processed to unprocessed hK7 likely due to slowing the secretion rate 
through the periplasm. 
 
 
     To determine if hK7 produced in bacteria with a low concentration of IPTG was 
correctly folded and active, lysis buffer was added to cells expressing hK7 to isolate the 
soluble protein fraction. The presence of hK7 in both the cell pellet and soluble fraction 
was determined by Western blot after the samples were reduced. hK7 was present in the 
cell pellet after 1 hour of expression as a single band at ~27 kDa (Figure 2.3). After 4 hours 
of expression, a band above the original hK7 band was seen representing the accumulation 
of unprocessed hK7 over time (Figure 2.3). Soluble cell lysate samples showed an absence 
of the hK7 bands indicating that hK7 expressed in bacteria was not soluble and may be 
aggregating after expression. Aggregation could likely be attributed to the formation of 
non-specific intramolecular and intermolecular disulfide bonds due to cysteines within 
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hK7 mispairing. Additionally, misfolded protein intermediates often expose hydrophobic 
patches of amino acids, that would otherwise be buried in the core of the protein, that can 
increase self-association
179
. Because the samples are reduced before loading the Western 
blot, higher order aggregates are broken apart and could not be visualized.  
 
 
Figure 2.3. hK7 expressed in bacteria is insoluble. 
 
Bacterial samples expressing hK7 for 1 or 4 hours were collected and a portion of the 
sample was lysed to isolate the soluble lysate fraction. Cell pellets and lysates from 
negative controls and cell expressing hK7 were run on a Western blot with an anti-C-
terminal histidine tag antibody to visualize the presence of hK7. After 1 hour of 
expression, hK7 was present in the cell pellet as a single band at 27 kDa. A second band 
representing unprocessed hK7 was present after 4 hours expression representing the 
accumulation of unprocessed hK7 with its signal sequence. hK7 was not present in the 
soluble cell lysates indicating that hK7 is misfolded and likely aggregating after it is 
produced. 
 
     To improve the formation of the correct disulfide bonds within hK7, 5 mM reduced 
glutathione was added to the media during hK7 induction. Reduced glutathione can help to 
reshuffle disulfide bonds by reducing mispaired disulfide bonds in hK7 and allowing the 
bacterial disulfide isomerase DsbC to form the correct linkages. Additionally, a low 
expression temperature of 15°C was used to slow the rate of protein synthesis and secretion 
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which may give more time for proper folding. Low temperature expression of secreted 
proteases was shown to increase solubility and production of the correctly folded protease 
leading to increased activity
176,177
. However, reduced glutathione and lowering the 
expression temperature had no effect on hK7 solubility for bacterial expression. To 
engineer hK7 activity and specificity, it is essential that hK7 be produced in a soluble and 
active form inside the cell, which would allow screening large libraries in a high-
throughput fashion. Therefore, hK7 expression was tested in yeast, which is eukaryotic and 
better equipped with the machinery to fold complicated human proteins.   
 
2.2.2. Detection of hK7 activity in yeast using the GAL1 promoter  
   Yeast represents an attractive alternative to E. coli for the production of proteins with 
complicated folds and multiple disulfide bonds due to the presence of the endoplasmic 
reticulum (ER) compartment. Within the oxidizing environment of the yeast ER, the 
enzyme protein disulfide isomerase (PDI) catalyzes the formation and shuffling of 
disulfide bonds
169
. Additionally, the ER contains quality control mechanisms that dispose 
of misfolded proteins, reducing the possibility of aggregates building up within the cell
174
. 
The wild-type hK7 gene was isolated from a human brain cDNA library and cloned into a 
yeast centromeric plasmid with a GAL1 promoter for galactose inducible expression. To 
ensure proper translation and folding within the ER, an invertase secretion signal sequence 
was fused to the N-terminus of hK7
180
. 
     Yeast cells were transformed with the hK7 plasmid and protein expression was induced 
for 6 hours at 22°C by addition of galactose to the media. To determine if hK7 expressed in 
yeast was soluble, cells producing hK7 were lysed and the cell lysate was ran on a Western 
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blot to probe for the presence of hK7. As a negative control for activity, an inactive variant 
of hK7 was created with the catalytic serine at position 205 substituted with alanine 
(UniProt numbering used). The hK7 S205A variant should not retain any catalytic activity 
due to the absence of the serine nucleophile within the S1 pocket. A Western blot using a 
polyclonal antibody specific to hK7 showed a single band for both the inactive hK7 and 
wild-type hK7 at the correct molecular weight in the lysate of induced cells (Figure 2.4). 
Interestingly, a positive control sample of active hK7 produced from a mouse myeloma 
cell line showed a band at a slightly higher molecular weight (Figure 2.4). This may be due 
to the addition of an N-linked glycan at the known glycosylation site (N246) in the 
mammalian produced version, which remains unglycosylated in yeast. This initial data 
suggested that hK7 was efficiently produced in a soluble form in yeast and that activity 
should be detectable inside the cell lysate. 
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Figure 2.4. hK7 is present in the soluble cell lysate after expression.  
 
Soluble lysate from cells expressing active hK7 and inactive hK7 was run on a Western 
blot and probed with a polyclonal anti-hK7 antibody. A single band at the correct 
molecular weight of 27 kDa was present in both samples. As a positive control, hK7 
produced from a mouse myeloma cell line was also detected by Western blot. This band 
appeared slightly higher than the yeast derived hK7, indicating an increase in molecular 
weight. This increase is likely due to glycosylation of N246, which is the known N-linked 
glycan site in hK7. 
 
 
     To verify that hK7 was properly folded and active in yeast, hK7 activity in cell lysate 
was measured by adding peptide substrates flanked by fluorescent proteins capable of 
FRET and analyzing the change in FRET over time. Lysate of yeast producing active hK7 
showed high conversion of the peptide substrates PRVMFFT and PRVMYYT that was 
comparable to a 10 nM preparation of commercial hK7 expressed in mammalian cells 
(Figure 2.5). Additionally, the selectivity for cleavage after tyrosine (Y) over 
phenylalanine (F) was maintained for hK7 produced in yeast cells further confirming 
formation of the correctly folded structure and S1 pocket for catalysis. Yeast cells 
expressing the inactive hK7 variant S205A displayed no background activity in crude cell 
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lysate toward the two probes, verifying that no endogenous yeast proteases are responsible 
for the activity seen in active hK7 samples (Figure 2.5). Because yeast can fold hK7 in the 
same manner as mammalian cells, but grow much faster and are easier to transform with 
DNA, they provide an exceptional host to build our cell-based screen for protease 
engineering.  
 
 
Figure 2.5. hK7 expressed in yeast is correctly folded and active. 
 
Cells expressing active hK7 or inactive hK7 were lysed and FRET reporter substrates were 
added to the lysate to determine if hK7 produced in yeast was active. Lysate of cells 
producing active hK7 showed conversion of the two substrates PRVMFFT and 
PRVMYYT that was comparable to a 10 nM commercial preparation of hK7 produced in 
mammalian cells. To confirm that activity was specific to hK7, lysate of cells producing 
the inactive hK7 variant displayed no background activity on the two probes (N=3). Data 
represented as mean ± SD. 
 
     To determine if protease expression was toxic to the yeast cells, cell growth was 
measured over time for cells producing active hK7 or inactive hK7 at 30°C and 22°C. 
Yeast grow best at 30°C, however at this expression temperature, cells producing active 
hK7 showed a dramatic reduction in growth rate compared to cells expressing inactive hK7 
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(Figure 2.6). The reduction in cell growth can likely be attributed to the non-specific 
activity of hK7 which may cut essential yeast proteins compromising the cell’s ability to 
grow and divide. Because protease activity is directly correlated with temperature, the 
expression temperature was lowered to 22°C to reduce toxicity associated with protease 
expression. At this lower expression temperature, cell producing active hK7 or inactive 
hK7 displayed smaller differences in their growth rates over time. Reducing host toxicity is 
critical in the development of protein engineering methods since cell death during 
expression would prevent the isolation of variants during screening.  
 
Figure 2.6. hK7 expression is toxic to yeast.  
 
Growth curves of cells expressing active hK7 at 30°C (red circles) and 22°C (blue squares) 
and cells expressing the inactive hK7 variant S205A at 30°C (red open triangles) and 22°C 
(blue open diamonds) (N = 3). Expression of active hK7 was toxic to yeast and reduced 
cell growth rate compared to cells expressing inactive hK7. Reducing the expression 
temperature from 30°C to 22°C reduced protease activity and toxicity to the cell. Data 
represented as mean ± SD. 
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“Adapted with permission from Guerrero, J. L., O’Malley, M. A., and Daugherty, P. S. 
(2016) Intracellular FRET-based screen for redesigning the specificity of secreted 
proteases. ACS Chem. Biol. 11, 961–970. Copyright 2016 American Chemical Society.” 
2.2.3. Development of the PrECISE cell-based screen for protease engineering 
     To identify Aβ selective hK7 variants, a screening method termed protease evolution 
via cleavage of an intracellular substrate (PrECISE) was developed using co-expression of 
a peptide substrate reporter and candidate protease variant within the endoplasmic 
reticulum (ER) of yeast (Figure 2.7). Because hK7 is secreted with six disulfide bonds, it is 
not amenable to expression in or display on E. coli, nor to cytosolic expression in yeast or 
animal cells. To increase substrate accumulation within the ER and probability of cleavage 
by hK7, a C-terminal yeast ER retention sequence (HDEL) was added to the substrate
181
. 
To reduce toxicity of the co-expressed protease (hK7), the protease was targeted for 
secretion without ER retention. Both protease and reporter substrate are simultaneously 
expressed from the GAL1 promoter (Figure 2.7). The target substrate was flanked by 
fluorescent proteins, CyPet and YPet, optimized for intracellular FRET with violet light 
excitation
132
. Thus substrate cleavage abolishes FRET and increases cyan fluorescence, 
enabling separation of cells with cleaved substrates using fluorescence activated cell 
sorting (FACS) (Figure 2.7).   
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Figure 2.7. Protease evolution via cleavage of an intracellular substrate (PrECISE).  
 
A gene encoding the Aβ8 substrate flanked by fluorescent proteins CyPet and YPet was 
integrated into the yeast genome and hK7 was expressed from a galactose inducible 
plasmid. Both proteins are translated into the ER while only the FRET reporter substrate 
contains an ER retention signal (HDEL). Cleavage of the target substrate by a protease 
variant disrupts FRET and leads to an increase in cyan fluorescence enabling isolation of 
cells with cleaved substrates using FACS. 
 
 
     Substrate specificity was selected for by utilizing the toxicity associated with 
intracellular expression of non-specific, heterologous proteases
57
. Thus, we reasoned that 
variants with narrowed substrate specificity but wild-type activity would effectively 
outcompete variants with broad specificity. Indeed, hK7 expression with ER retention was 
toxic, evidenced by rapid arrest of cell growth. For comparison, when expressed at 22°C 
and secreted without ER retention, hK7 exhibited mild toxicity with a slight reduction in 
growth rate relative to cells expressing inactive hK7 (S205A) (Figure 2.6). Additionally, to 
avoid false positives resulting from YPet cleavage, YPet expression was measured by 
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direct excitation at 488 nm and only cells with high blue-excited yellow fluorescence and 
increased violet-excited cyan fluorescence were recovered. 
     Library screening conditions were optimized by analyzing the separation between cells 
expressing active or inactive hK7 on flow cytometry. The Aβ8 substrate encoding gene 
was integrated into the yeast genome and hK7 was expressed from a galactose inducible 
plasmid to simplify library generation and clone analysis. Cells co-expressing hK7, or 
inactive hK7 S205A, and the Aβ8 substrate were analyzed using flow cytometry after 
expression at 22°C, 30°C, and 37°C at various time points. Substrate cleavage was 
interrogated by measuring the ratio of cyan to yellow fluorescence. Cells expressing active 
hK7 and the Aβ8 FRET reporter at 30°C and 37°C, showed a significant reduction in cell 
density compared to cells expressing the inactive hK7 S205A variant. The expression 
temperature was therefore reduced to 22°C to reduce non-specific protease activity and 
improve cell viability. After 6 hours of expression, significant differences in conversion of 
the FRET reporter were observed by flow cytometry between the samples expressing 
active or inactive hK7 (Figures 2.8a,b). The maximum separation between positive and 
negative cells was observed after 16 hours of expression (Figure 2.8c,d). However at this 
longer co-expression time, cells expressing active hK7 displayed significant growth rate 
reduction compared to cell expressing the inactive hK7. 
 
55 
 
Figure 2.8. Detection of hK7 activity in vivo using PrECISE methodology.  
 
Flow cytometry analysis of cell populations co-expressing inactive hK7 variant S205A 
(a,c) or wild-type hK7 (b,d) with the Aβ8 FRET reporter substrate after 6 hours (a,b) and 
16 hours (c,d) at 22°C. The dynamic range between the positive and negative cell 
populations increased with co-expression time.   
 
 
     To verify that the increase in cyan/yellow fluorescence observed for active hK7 co-
expression was due to hK7 activity within the substrate linking region of the FRET 
reporter, intracellular conversion of a negative hK7 substrate (GGSGSGGS) was 
measured. Co-expression of active hK7 with the GGSGSGGS FRET reporter substrate at 
22°C for 16 hours caused no change in the ratio of cyan fluorescence to yellow 
fluorescence as measured by flow cytometry (Figure 2.9). This result further confirmed 
that hK7 does not cut outside of the substrate linking region to produce a false positive 
signal. Furthermore, intracellular conversion of an optimal hK7 substrate (PRVMYYT) 
was much higher compared to the Aβ8 (KLVFFAED) FRET substrate indicating that 
subtle differences in hK7 cleavage kinetics for various substrates can be effectively 
measured using the PrECISE screen. 
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Figure 2.9. PrECISE methodology allows effective discrimination between different hK7 
substrates in vivo. 
 
Active hK7 or inactive hK7 were co-expressed at 22°C for 16 hours with three different 
FRET reporters containing either a negative hK7 substrate (GGSGSGGS), the Aβ8 peptide 
(KLVFFAED), or an optimal hK7 substrate (PRVMYYT). Intracellular conversion of the 
FRET reporters was analyzed by flow cytometry by measuring the ratio of cyan to yellow 
fluorescence. No significant conversion of the GGSGSGGS reporter by active hK7 was 
measured. Active hK7 co-expression reduced FRET and caused an increase in cyan 
fluorescence for the Aβ8 and PRVMYYT probes, indicating cleavage within the substrates 
(N = 3). Data represented as mean ± SD. 
 
 
     To determine the optimal expression conditions for screening an hK7 library using the 
PrECISE methodology, enrichment of active hK7 cells from a background of inactive hK7 
cells was determined for various co-expression parameters such as time and temperature. 
We hypothesized that at shorter co-expression times with an expression temperature of 
22°C there would be less cellular toxicity associated with wild-type hK7 expression and 
cells expressing the inactive variant would be less likely to outgrow active hK7 cells 
during screening. Though the separation between positive and negative cells is much 
smaller at shorter co-expression times, oversampling the number of cells sorted with high 
cyan/yellow fluorescence ratio should lead to active hK7 enrichment. Cells expressing 
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active hK7/Aβ8 and cells expressing inactive hK7 S205A/Aβ8 were mixed at a ratio of 
1:10 based on optical density measurements after expression at 22°C for 6 hours. Yeast 
cells with high cyan/yellow fluorescence were sorted over two rounds and plated after each 
round of sorting (Figure 2.10). We sequenced ten random clones after each round of 
sorting and determined that 7/10 sequences were active hK7 after the second sort. An 
enrichment factor of ~2.7 for wild-type hK7 was calculated for each round of sorting. In 
contrast, when the same enrichment experiment was performed after co-expression at 22°C 
for 16 hours, no enrichment of active hK7 was measured. This indicated that cells 
expressing the inactive variant had outcompeted cells with active protease likely due to 
their faster growth rate during long co-expression times. To improve enrichment of active 
hK7 variants during library screening, cells co-expressing the hK7 library and CyPet-Aβ8-
YPet were induced at 22°C for 6 hours. 
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Figure 2.10. Workflow for enrichment of active hK7 from a background of cells expressing 
inactive variants to determine optimal co-expression conditions for library screening. 
 
Cells expressing active hK7 with the Aβ8 FRET reporter were mixed with an excess of 
cells expressing inactive hK7 and the Aβ8 FRET reporter at various ratios (1:10, 1:100). 
Enrichment of active hK7 cells from the background of inactive variants was determined 
for various expression parameters by sorting cells with high cyan/yellow fluorescence 
using FACS. Random colonies from the enriched population were sequenced to identify 
the percentage of cells containing active protease after one and two rounds of sorting. 
 
2.3. Discussion 
     To develop a cell-based method for engineering the specificity of secreted proteases, 
both bacteria and yeast were evaluated for their ability to express active hK7 which 
requires six disulfide bonds for proper folding. Human secreted proteases are attractive 
targets for use in therapy due to their enhanced stability imparted by their intermolecular 
disulfide bonds and because they would cause less immunogenicity if introduced into the 
body compared to a bacterial or viral protease. However, the expression of correctly folded 
eukaryotic proteins with multiple disulfide bonds remains a challenging feat to accomplish 
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in microbial systems. Because of this, no general methods have been developed and 
applied to engineering secreted proteases in a high-throughput fashion. The lack of 
methods for engineering secreted proteases greatly limits their potential to be redesigned to 
cleave new targets which are relevant in disease with high specificity.   
     Bacteria was first evaluated for its ability to produce active hK7 because of its fast 
growth rate and high transformation efficiency. hK7 expression was directed to the 
periplasm of bacteria to promote disulfide bond formation. However, hK7 accumulated 
within E. coli as misfolded aggregates. For short expression times and low inducer 
concentrations, the majority of misfolded protein was localized to the periplasm. Whereas, 
longer expression times resulted in the accumulation of aggregated protein in the 
cytoplasm. This change in localization is likely due to the secretion system becoming 
overcrowded causing the majority of the expressed hK7 to stay in the cytoplasm unfolded. 
While multiple parameters were tested to enhance the formation of disulfide bonds in hK7, 
no improvements were seen in hK7 solubility or activity upon expression in bacteria. 
Because many of the native disulfide bonded proteins produced in the periplasm of 
bacteria contain two or fewer disulfides, mispairings are less likely to occur
163
. However, 
in a eukaryotic protein such as hK7, which contains six disulfide bonds, mismatches have a 
higher probability of occurring and likely overwhelmed the E. coli machinery, which is 
less equipped to recognize eukaryotic protein folding patterns. 
     While yeast do not glycosylate proteins in the same manner as mammalian cells, they 
have been shown to form the correct disulfide bonds in eukaryotic proteins with 
complicated folds
182,183
. hK7 secretion to the endoplasmic reticulum of yeast resulted in 
correctly-folded, active protease indicating formation of the six disulfide bonds within 
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hK7. hK7 produced in yeast had the same substrate selectivity as mammalian cell 
produced hK7 confirming that the active site and S1 pocket were equivalent. However, 
active hK7 expression in yeast mediated excessive toxicity to the cell, which was not 
observed for expression of an inactive hK7 variant. Therefore, non-specific protease 
activity rather than merely hK7 expression led to reduced cell growth. It is very hard to 
determine which yeast proteins become cleaved non-specifically due to hK7 activity since 
multiple yeast proteins contain tyrosine and phenylalanine residues that could be favored 
as sites of cleavage by hK7. However, by reducing the expression temperature, we were 
able to reduce non-specific activity of hK7 and also toxicity to the cell comparable to the 
inactive hK7 variant. 
     hK7 intracellular activity in yeast was coupled to the fluorescence output of a co-
expressed FRET reporter substrate to enable the screening of large protease libraries by 
fluorescence activated cell sorting (FACS). The protease and FRET reporter are co-
expressed in the endoplasmic reticulum to promote disulfide bond formation in hK7 and 
also increase the probability of substrate cleavage occurring. Using the PrECISE 
methodology, protease libraries created through random mutagenesis or site-saturation 
mutagenesis can be screened for activity toward a peptide sequence of interest. Because the 
FACS-based approach is a quantitative method, changes to the co-expression parameters 
such as time and temperature can be easily assessed and optimized in order to favor 
variants with improved activity. Here, we have optimized screening conditions for hK7 
intracellular activity toward the hydrophobic core of the Aβ peptide. Reducing the co-
expression time and temperature were both found to be critical in the enrichment of cells 
with the active protease from a background of cells expressing an inactive variant. 
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2.4. Materials and methods 
2.4.1. hK7 bacterial vector construction and expression 
     The active wild-type hK7 gene consisting of 226 amino acids was codon-optimized for 
expression in E. coli (DNA 2.0) and cloned between the EcoRI and HindIII sites in the 
vector pLAC22
184
, which contains a lactose promoter. Expression of genes under the 
lactose promoter can be turned on by the addition of lactose or a lactose derivative such as 
the small molecule isopropyl β-D-1 thiogalactopyranoside (IPTG) to the media. An OmpA 
signal sequence (MKKTAIAIAVALAGFATVAQA) was placed upstream of the hK7 gene 
to direct its export to the periplasm for the formation of disulfide bonds. Additionally, a 
histidine tag (GHHHHHH) was fused to the C-terminus of hK7 to simplify downstream 
purification of the protease. The E. coli strain MC1061 was transformed with the pLAC22 
plasmid containing the hK7 gene and transformed colonies were selected for on plates 
containing ampicillin (100 μg/mL). As a negative control, MC1061 cells were transformed 
with an empty pLAC22 vector. 
     To test for hK7 expression in bacteria, overnight cultures containing either the empty 
vector or the hK7 vector were grown in 5 mL Luria broth (LB) media with ampicillin (100 
μg/mL). In the morning, cells were subcultured 1:50 into 40 mL LB with ampicillin and 
grown for 2 hours until cell growth reached an optical density of 0.6. Cells were then 
induced with IPTG for hK7 expression. Protease expression was tested under various 
induction conditions such as IPTG concentration (5 µM - 1 mM), temperature (15°C and 
25°C), time for expression (1 – 16 hours), and addition of reduced glutathione (5 mM) to 
the media. After expression, a small sample of 8 x 10
8
 cells was spun down at 3000g for 5 
minutes for analysis of the cell pellet fraction by Western blot. The rest of the 40 mL 
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culture was spun down at 3000g for 10 minutes at 4°C to remove the media. Cell samples 
were then frozen at -80°C for 2 hours to improve cell lysis and soluble lysate extraction. 
Cell pellets from 40 mL cultures were lysed by adding 3 mL B-PER II reagent (Thermo 
Scientific) and pipetting until the mixture was homogenous. Cell samples were then gently 
shook at room temperature for 30 minutes. Soluble cell lysate was isolated by 
centrifugation at 20,000g for 25 minutes. 
 
2.4.2. hK7 yeast vector construction and expression  
     The gene encoding the proform of human kallikrein 7 (hK7) was amplified from a 
human brain cDNA library (BD Biosciences) with primers designed on the basis of the 
known hK7 coding sequence. The mature form of hK7 was then amplified to contain the 
invertase secretion signal (MLLQAFLFLLAGFAAKISA) at the N-terminus and a 6x 
histidine (GHHHHHH) purification tag at the C-terminus. Inactive hK7 variant S205A was 
created using PCR-driven overlap extension
151
 with forward primer 5’ GCCTGCAATGG 
TGACGCAGGGGGACCGTTGG and reverse primer 5’ CCAACGGTCCCCCTGC 
GTCACCA TTGCAGGC. The resulting fragments were cloned between the HindIII and 
PmeI sites in the pYC2/NT plasmid (Invitrogen), which contains a GAL1 promoter for 
galactose-inducible expression (Figure 2.11). Electrocompetent DH5α E. coli were 
transformed by electroporation with the ligated vector and cells were plated on media 
supplemented with ampicillin (100 μg/mL). Plasmid DNA was isolated using a Zyppy 
plasmid miniprep kit (Zymo Research) and the yeast strain JYL69 (MATa ura3-1 ADE2+ 
his3-11,15 leu2-3,112 trp1-1 can1-100; isogenic to W303) was transformed with 1 µg of 
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the hK7 plasmid using the high efficiency PEG/lithium acetate method
185
 and plated on 
minimal SD-Ura media.   
 
 
Figure 2.11. Plasmid map of pYC2/NT for hK7 expression and secretion in yeast.  
 
The pYC2 vector has a GAL1 promoter for protein expression in yeast. The vector is 
centromeric and contains a CEN6/ARSH4 sequence that maintains the plasmid at 1-2 
copies per cell. Additionally, ampicillin and URA3 selection markers allow for selection 
and maintenance of the plasmid in bacteria and yeast, respectively. The hK7 gene insert 
contains an N-terminal secretion signal to direct protein translation to the ER and a C-
terminal histidine tag for downstream purification and characterization. 
 
 
     To determine if hK7 was correctly folded and active in yeast, cells were cultured 
overnight in 10 mL SD-Ura media with 2% raffinose to an OD600 of 4. Cells were then 
subcultured to an OD600 of 0.75 in 40 mL fresh SD-Ura media with 2% raffinose and 2% 
galactose for induction at a specific temperature and length of time. Expression parameters 
were varied to assess the effect of temperature (22°C, 30°C, and 37°C) and expression time 
(0 – 16 hours) on hK7 activity. After expression, cell pellets were isolated from the media 
by centrifugation at 5000g for 10 minutes. Cells were lysed by adding 3 mL Y-PER 
reagent (Thermo Scientific) and gently shaking the homogenous mixture at room 
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temperature for 30 minutes. Soluble lysate fractions were recovered by spinning the 
solution at 15,000g for 5 minutes. 
 
2.4.3. Construction of FRET reporter yeast strains  
     The yeast strain JYL69 (MATa ura3-1 ADE2+ his3-11,15 leu2-3,112 trp1-1 can1-100; 
isogenic to W303) was constructed to express FRET reporter substrates flanked by 
optimized cyan and yellow fluorescent proteins, CyPet and YPet
132
. Individual yeast 
strains were constructed for expression of FRET reporter substrates containing the 
sequences KLVFFAED (Aβ8), GGSGSGGS, or PRVMYYT. FRET substrates were 
amplified to contain the N-terminal invertase secretion signal 
(MLLQAFLFLLAGFAAKISA) to direct protein translation to the ER and a C-terminal 
yeast ER retention signal sequence, HDEL
181
. The resulting fragments were cloned 
between the HindIII and PmeI sites in the pYES3/CT plasmid (Invitrogen), which contains 
a GAL1 promoter for galactose-inducible expression (Figure 2.12). Electrocompetent 
DH5α E. coli were transformed by electroporation with the ligated vector with the 2-μm 
origin removed and cells were plated on media supplemented with ampicillin (100 μg/mL). 
Plasmid DNA was isolated using a Zyppy plasmid miniprep kit (Zymo Research) and the 
resulting plasmid containing the FRET reporter substrate was digested with Bsu361, which 
cuts once within the TRP1 locus. The linearized plasmid was integrated into the yeast 
genome using the high efficiency PEG/lithium acetate method
185
 and plated on minimal 
SD-Trp media.   
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Figure 2.12. Plasmid map of pYES3/CT for FRET reporter expression in yeast.  
 
The pYES3 vector has a GAL1 promoter for protein expression in yeast. The 2μ origin was 
deleted from the vector and genomic integration into yeast is achieved by cutting once 
within the TRP1 locus. Integration occurs at 1-2 copies per cell. Additionally, ampicillin 
and TRP1 selection markers allow for selection and maintenance of the plasmid in bacteria 
and yeast, respectively. The FRET reporter gene contains an N-terminal secretion signal to 
direct protein translation to the ER and a C-terminal sequence HDEL for ER retention in 
yeast. 
 
     To identify a highly fluorescent Aβ8 substrate expressing cell line for subsequent 
library transformations, individual clones expressing the Aβ8 FRET reporter were assessed 
via flow cytometry for yellow fluorescence due to FRET. Cells were cultured overnight in 
SD-Trp media with 2% raffinose to an OD600 of 4. Cells were then subcultured to an OD600 
of 0.75 in fresh SD-Trp media with 2% raffinose and 2% galactose for induction at a 
specific temperature and length of time. After expression, the cells were pelleted by 
centrifugation at 5,000g for 5 minutes and resuspended in 1x PBS for analysis on a 
FACSAria flow cytometer (BD Biosciences) with violet light excitation. Cells were 
pregated for high blue-excited yellow fluorescence to ensure that all cells analyzed had 
produced full-length FRET reporters. After analysis of 15 individual clones, a clone with 
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high violet-excited yellow fluorescence was chosen for co-transformations with the 
protease vector. 
 
2.4.4. Western blots for hK7 expression 
     Cell lysate samples (32 µL) or cell pellet fraction diluted with 32 µL ddH20 were 
incubated with 8 µL of 5x SDS-reducing loading buffer (Thermo) for 5 minutes at 95°C. 
Reduced samples (30 µL) were then loaded onto a 4-20% Tris-Glycine gel (NuSep) and 5 
µL of Novex Sharp Prestained Protein Standard (Life Technologies) was loaded for a 
molecular weight ladder. As a positive control, 20 ng of recombinant hK7 (R&D Systems) 
produced from a mouse myeloma cell line was used. Protein samples were separated in 1x 
Tris-Glycine running buffer using an XCell SureLock Mini-Cell electrophoresis system 
(Thermo Fisher) and applying a voltage of 150 V for 1 hour. 
     Protein samples separated by SDS-PAGE were transferred to a PVDF membrane using 
a Mini-PROTEAN tetra cell and mini trans blot module (Bio-Rad) for 1 hour at 100 V. 
PVDF membranes were activated with 100% methanol for 30 seconds then rinsed with 
ddH20 prior to transfer. After protein transfer, the membrane was rinsed briefly in 1x Tris-
buffered saline (TBS) and then incubated with 8 mL Blocking Buffer for Fluorescent 
Western blots (Rockland) for 1 hour at room temperature in a closed container. The 
membrane was then incubated with polyclonal goat anti-hK7 (R&D Systems) diluted 
1:400 in 8 mL blocking buffer for 16 hours at 4°C in the dark. To reduce non-specific 
binding of the primary antibody, membranes were washed three times with 0.05% Tween 
in TBS. Membranes were then incubated with the Alexa Fluor680 donkey anti-goat 
secondary antibody (Thermo Fisher) diluted 1:2500 in blocking buffer for 1 hour at room 
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temperature in the dark. Membranes were washed briefly in 0.05% Tween in TBS before 
imaging using a ChemiDoc MP Imager (Bio-Rad).  
     For colorimetric detection of histidine-tagged proteins by Western blot, membranes 
were incubated with a mouse anti-C-terminal histidine-tag primary antibody (Thermo 
Fisher) and a goat anti-mouse secondary antibody conjugated to alkaline phosphatase 
(Thermo Fisher). Blots were developed by the addition of 1-Step NBT/BCIP (Thermo 
Fisher) for 5-15 minutes until the desired color developed. Developed membranes were 
then washed with distilled water.  
 
2.4.5. Detecting hK7 activity in vivo 
     Using flow cytometry, expression conditions were optimized to detect hK7 activity in 
yeast with the co-expressed intracellular Aβ8 FRET reporter. hK7 and FRET reporter 
expression were both under control of the GAL1 promoter, which is inducible by the 
addition of galactose to the media. Triplicate samples of cells expressing wild-type hK7 
and the Aβ8 FRET reporter were analyzed after expression at 22°C, 30°C, and 37°C for 
various time points (0 – 16 hours) and compared to cells co-expressing the inactive hK7 
variant S205A and the Aβ8 FRET substrate to determine the optimal dynamic range of the 
assay. Cells were cultured overnight in SD-Trp-Ura media with 2% raffinose to an OD600 
of 4. Cells were then subcultured to an OD600 of 0.75 in fresh SD-Trp-Ura media with 2% 
raffinose and 2% galactose for induction. After expression, the cells were pelleted by 
centrifugation at 5,000g for 5 minutes and resuspended in 1x PBS for analysis on a 
FACSAria flow cytometer (BD Biosciences) with violet excitation.   
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3. Design of a human protease targeting amyloid beta peptides 
     Proteases are attractive as therapeutics given their ability to catalytically activate or 
inactivate their targets. However, therapeutic use of proteases is limited by insufficient 
substrate specificity, since off-target activity can induce undesired side-effects. In addition, 
few methods exist to enhance the activity and specificity of human proteases, analogous to 
methods for antibody engineering. Given this need, a general methodology termed protease 
evolution via cleavage of an intracellular substrate (PrECISE) was developed to enable 
engineering of human protease activity and specificity toward an arbitrary peptide target 
(Chapter 2). PrECISE relies on co-expression of a protease and a peptide substrate 
exhibiting Förster resonance energy transfer (FRET) within the endoplasmic reticulum of 
yeast (Chapter 2). Use of the FRET reporter substrate enabled screening large protease 
libraries using fluorescence activated cell sorting for the activity of interest. To evolve a 
human protease that selectively cleaves within the central hydrophobic core 
(KLVF↓F↓AED) of the amyloid beta (Aβ) peptide, PrECISE was applied to human 
kallikrein 7, a protease with Aβ cleavage activity but broad selectivity, with a strong 
preference for tyrosine (Y) at P1. Screening randomly mutated hK7 libraries for activity on 
Aβ8 yielded a protease variant which displayed up to 30-fold improvements in Aβ 
selectivity mediated by a reduction in activity toward substrates containing tyrosine. 
Additionally, the increased selectivity of the variant led to reduced toxicity toward PC12 
neuronal-like cells and 16-1000-fold improved resistance to wild-type inhibitors. PrECISE 
thus provides a powerful high-throughput capability to redesign human proteases for 
therapeutic use.  
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“Adapted with permission from Guerrero, J. L., O’Malley, M. A., and Daugherty, P. S. 
(2016) Intracellular FRET-based screen for redesigning the specificity of secreted 
proteases. ACS Chem. Biol. 11, 961–970. Copyright 2016 American Chemical Society.” 
3.1. Introduction 
     Deficiencies or abnormalities in protease activity are common to many diseases, 
therefore proteases present attractive targets for use in therapy
4
. Due to their catalytic 
nature, protease therapeutics could potentially be used at lower doses reducing the cost of 
treatment. However, most proteases are thought to have as many as 10-100 physiological 
substrates and therefore their expression, localization and activity are tightly regulated to 
prevent unwanted proteolysis. Insufficient target substrate specificity has limited 
therapeutic uses of proteases since cleavage of non-target substrates can lead to side-
effects. Among FDA approved therapeutic proteases, most recognize only a few 
physiological substrates thereby limiting their toxicity. 
     Prior efforts to redesign protease specificity have focused upon the use of structure-
guided mutagenesis within the active site and surface loops
60,61,186
. However, rational 
design of specificity has proven difficult since substitutions far from the active site can 
alter active site geometry and specificity
140
. Furthermore, substitutions within the active 
site can disrupt the structure of neighboring residues that are important for binding and 
catalysis. The identification of rare protease variants with increased target specificity has 
typically required screening large variant libraries
64
. Library screening has been 
successfully applied to a handful of model proteases including E. coli outer membrane 
protease OmpT, human immunodeficiency virus type 1 (HIV) protease, hepatitis A virus 
3C protease, and tobacco etch virus protease (Chapter 1)
57,65,70,71,75,77
. While these methods 
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have enabled engineering of membrane bound and intracellular proteases; methods for 
specificity redesign of human secreted proteases - candidates for therapeutic use - are 
needed. 
     We have developed a cell-based assay to enable design and engineering of human 
proteases by screening protease libraries for variants that cleave a peptide substrate 
exhibiting FRET (Chapter 2). This method was applied to human kallikrein 7 (hK7), a 
member of the trypsin-like serine protease superfamily, to identify variants that selectively 
cleave the central hydrophobic core (KLVFFAED) of the Aβ peptide involved in the 
pathology of Alzheimer’s disease (AD)187. Alzheimer’s disease is characterized by 
increased accumulation of Aβ within the central nervous system due in part to impaired 
clearance mechanisms
87
. hK7 cleaves Aβ in vitro within the central hydrophobic core 
KLVF↓F↓AED (Aβ8) thereby preventing aggregation103. Given that hK7 exhibits modest 
activity toward Aβ, but prefers tyrosine (Y) over phenylalanine (F) at P1, we sought to 
improve activity and narrow hK7 specificity toward Aβ. Our results demonstrate that 
screening randomly mutated hK7 libraries using PrECISE yielded a protease variant with 
improved selectivity for the Aβ hydrophobic core, reduced in vitro toxicity to mammalian 
cells, and increased resistance to inhibitors. Further, PrECISE provides a general method to 
evolve human proteases for specific degradation of proteins implicated in a disease state. 
 
3.2. Results 
3.2.1. Screening randomly mutated hK7 libraries for Aβ8 specificity 
     To identify variants with increased Aβ8 specificity, yeast cells harboring the Aβ8 FRET 
substrate were transformed with a library of 3 x 10
7
 hK7 variants (~2 base pair 
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substitutions per gene). Cells expressing hK7 variants mediating Aβ8 cleavage after co-
expression at 22°C for 6 hours were enriched in 6 sorting cycles from 0.8% of gated cells 
to 10% - a value representing wild-type like activity (Figure 3.1). Enrichment was due to 
sorting, since repeated regrowth and induction of the library did not yield detectable 
enrichment. Cells from the enriched library were plated to isolate individual clones for 
flow cytometry analysis.  
 
Figure 3.1. Sorting a first generation hK7 random mutagenesis library for Aβ8 cleavage.  
 
A first generation hK7 error-prone library was created using the gene encoding wild-type 
hK7 as a template and transformed into cells harboring the Aβ8 FRET reporter. The hK7 
library was co-expressed with the Aβ8 substrate and cells were sorted as stated in Methods. 
FACS plots of the initial first generation library (a) and after the first (b), second (c), third 
(d), fourth (e), fifth (f), and sixth (g) rounds of enrichment. After the second round of 
enrichment, gates were adjusted to collect the top 1% of cells in the cyan fluorescence 
gate. 
 
     The Aβ8 cleavage activity of isolated variants was ranked using the cell-based assay 
and ten unique protease variants were identified by DNA sequencing (Table 3.1). To 
validate the clonal ranking obtained using the cell-based assay, protease activity in cell 
72 
lysates was measured using freshly added Aβ8 FRET reporter. To simplify initial 
evaluation of library variants, relative second order rate constants (kcat·[E]/KM) were 
determined which do not take into account differences in expression. Confirming the 
effectiveness of the cell-based screening assay, in vitro measured Aβ8 cleavage activities 
linearly correlated with FRET signals from the whole cell assay (Spearman correlation = 
0.88) (Figure 3.2). Three variants displayed lower lysate activity than would be predicted 
from intracellular cyan fluorescence. But importantly, none of the clones had both low 
cyan fluorescence and high in vitro activity indicating that rare variants with improved 
activity are unlikely to be excluded during sorting.  
 
Table 3.1. Substitutions identified for first generation hK7 variants.   
 
hK7 variant substitutions frequency 
1.1 R132M, K198I 1/30 
1.2 N230I 1/30 
1.3 L53P 4/30 
1.4 N119D, K129R, F241S 1/30 
1.5 D83G 1/30 
1.6 D156G, N246S 2/30 
1.7 K251E 4/30 
1.8 N186T, K250E 2/30 
1.9 R100C, R123M 3/30 
1.10 K181R, K240Q 2/30 
Nine of the sequenced clones were the wild-type hK7 gene  
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Figure 3.2. Intracellular cyan fluorescence correlates linearly to Aβ8 activity in cell lysates.  
 
To validate the cell-based assay, individual variants from the final round of sorting the first 
and second generation libraries were analyzed by flow cytometry for cyan fluorescence 
after co-expression with the Aβ8 FRET substrate. Relative second order rate constants 
(kcat·[E]/KM) toward Aβ8 in vitro linearly correlated with the percentage of cells having 
cyan fluorescence above background. Spearman correlation coefficients were 0.88 (first 
generation variants) and 0.82 (second generation variants) giving a combined correlation of 
0.77 (all variants). 
 
    Four variants obtained from screening the initial library exhibited increased activity 
toward Aβ8 and KLVYYAED (Figure 3.3). However, none of these variants exhibited 
improved selectivity for Aβ8 over KLVYYAED using the cell lysate assay. Variant hK7-
1.10 showed a 1.7-fold improvement in activity toward Aβ8 compared to wt-hK7. Variants 
with improved activity in vitro possessed substitutions that reduced positive surface 
charge. hK7 has been reported to have an isoelectric point of ~9 and contains two 
positively charged surface patches that have been proposed to bind to negatively charged 
substrates or aid in attachment to the cell surface
114,188
. To determine whether variants with 
improved Aβ8 lysate activity were produced at higher levels per cell compared to wild-
type, differences in expression were evaluated using Western blot. Each of the variants 
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with reduced positive surface charge were expressed at higher levels on a per cell basis 
(Figure 3.4). 
 
 
Figure 3.3. First generation hK7 variants display improved intracellular activity for Aβ8.  
 
In vitro activity of unique variants acquired from sorting the first generation library was 
assessed toward the target Aβ8 and non-target KLVYYAED substrates to determine 
changes in P1 selectivity. Equal numbers of cells expressing each variant were lysed to 
determine a relative second order rate constant kcat·[E]/KM which does not take into 
account differences in protease expression levels per cell (N = 3). Inactive hK7 variant 
S205A was used as a control to determine background activity by yeast proteases toward 
these two substrates. Four variants hK7-1.7, hK7-1.8, hK7-1.9, and hK7-1.10 exhibited 
increased activity toward both Aβ8 and KLVYYAED. Variant hK7-1.10 showed a 1.7-fold 
improvement in lysate activity toward Aβ8 compared to wild-type hK7. Data represented 
as mean ± SD. 
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Figure 3.4. hK7 variants with improved in vitro activity show improved expression levels. 
 
(a) Equal numbers of cells expressing wt-hK7 or the hK7 variants were lysed and hK7 
expression levels were assessed using a Western blot with a poly-clonal anti-hK7 antibody. 
hK7 expected molecular weight is ~27 kDa. Arrows indicate increased expression of 
variants hK7-1.7, hK7-1.8, hK7-1.9, and hK7-1.10 per cell normalized to wt-hK7 
expression. (b) Model of hK7 docked with Aβ8 (KLVFFAED) substrate (green) indicating 
the location of positively charged surface residues that are substituted in variants with 
improved expression.  
 
     Collectively, our results indicated that the population of variants enriched by sorting the 
first generation library was diverse and spanned a range of apparent activities influenced 
by intrinsic activity and expression level. Improvements in expression had the benefit of 
improving the assay dynamic range. Given this, we further diversified this pool using error 
prone PCR, to create a second generation library of 1 x 10
7
 variants with ~5 base pair 
substitutions per gene. Library members with high cyan fluorescence were enriched using 
6 cycles of FACS after co-expression at 22°C for 6 hours, from 0.8% to 15% gated cells in 
the final round (Figure 3.5). Individual isolated clones (n = 10) exhibiting high Aβ8 
substrate conversion were then assayed for activity toward Aβ8 and KLVYYAED in vitro 
(Figure 3.6). Variant hK7-2.10 exhibited 2-fold increased activity toward Aβ8 compared to 
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wt-hK7 and possessed three substitutions of solvent exposed arginines (Table 3.2). 
Importantly, variant hK7-2.7 exhibited improved Aβ8 selectivity, conferred by reduced 
activity toward KLVYYAED. This Aβ8 selective variant possessed seven substitutions, 
including Q52R, N119S, K129G, V157G, L189Q, Q228R, and G233V (UniProt 
numbering used). 
 
 
Figure 3.5. Sorting a second generation hK7 random mutagenesis library for Aβ8 cleavage.  
 
hK7 second generation error-prone library was created using the final pool of first 
generation variants as a template and transformed into cells harboring the Aβ8 FRET 
reporter. The hK7 library was co-expressed with the Aβ8 substrate and cells were sorted as 
stated in Methods. FACS plots of the initial second generation library (a) and after the first 
(b), second (c), third (d), fourth (e), fifth (f), and sixth (g) rounds of enrichment. After the 
second round of enrichment, gates were adjusted to collect the top 1% of cells in the cyan 
fluorescence gate. 
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Figure 3.6. Second generation hK7 variant displays improved Aβ8 selectivity.  
 
In vitro activity of unique variants acquired from sorting the second generation library was 
assessed toward the target Aβ8 and non-target KLVYYAED substrates to determine 
changes in P1 selectivity. Equal numbers of cells expressing each variant were lysed to 
determine a relative second order rate constant kcat·[E]/KM (N = 3). Variant hK7-2.10 
displayed 2-fold increased activity on Aβ8 compared to wt-hK7 while variant hK7-2.7 
displayed a substantial reduction in activity toward the non-target KLVYYAED and 
maintained activity on Aβ8 comparable to wild-type. Data represented as mean ± SD. 
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Table 3.2. Substitutions identified for second generation hK7 variants.   
 
hK7 variant substitutions Frequency 
2.1 V166G, K181E, K251E 1/20 
2.2 R100C, R123M, D162V 1/20 
2.3 K198E, K250T 2/20 
2.4 R63H, M73I, T106A, K117M, 
V157A, I171V 
3/20 
2.5 K169R, T223A, K250E 2/20 
2.6 K130N, R136C, M164T 2/20 
2.7 Q52R, N119S, K129G, 
V157G, L189Q, Q228R, 
G233V 
2/20 
2.8 N119D, K129R, F241S, 
K250E 
3/20 
2.9 Q174L, N186T, R212S, 
V238A, K250E 
1/20 
2.10 R100C, R123M, R212S 3/20 
 
 
3.2.2. Characterization of variant hK7-2.7 selectivity switch 
     To probe the apparent selectivity improvement of hK7-2.7 toward Aβ8, activities 
toward Aβ8 and a panel of non-target substrates were measured after purification. 
Substrates were designed to probe specificity at multiple sub-sites. This panel consisted of 
reported hK7 substrates, including a matrix metalloproteinase-9 activation site 
(RHLY↓GPRP) and an activation sequence in prochemerin (GQFAF↓SKA)189,190. Given 
hK7’s role in skin desquamation116, candidate sites within cell adhesion proteins 
fibronectin (RYRVTYSS), corneodesmosin (SQVSYSSG), desmoglein-1 (RITKYSTV), 
desmocollin-1 (RVTIFTVP), and E-cadherin (RTAYFSLD, KVFYSITG) were 
included
122,124,191
. hK7 cleaved Aβ8 (kcat/KM = 0.61 ± 0.02 μM
-1
·min
-1
) and exhibited the 
highest activity toward fibronectin sequence RYRVTYSS (kcat/KM= 92.5 ± 3.5 μM
-1
·min
-1
) 
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(Figure 3.7a). The substrate RYRVTYSS is to our knowledge the fastest cleaved substrate 
reported for hK7 and contains two potential cleavage sites in agreement with hK7’s 
reported preference for Y at the P1 position and R or S at the P1’ position123. Analysis of 
the rates of cleavage for panel substrates supported previous findings that hK7 prefers 
tyrosine (Y) at the P1 position over phenylalanine (F)
113,123
 and prefers arginine (R) at 
P4/P5
103
 (Schechter and Berger nomenclature
12
). 
     In contrast, the Aβ8 selective variant hK7-2.7 retained activity on Aβ8 (kcat/KM = 0.47 ± 
0.01 μM-1·min-1) and other phenylalanine containing substrates, while exhibiting decreased 
activity toward non-target substrates containing tyrosine (Figure 3.7b). For example, hK7-
2.7 retained only 3% of wild-type hK7 activity on substrate RHLYGPRP, 4.5% on 
RYRVTYSS, 5% on SQVSYSSG, and 8.7% wild-type activity on RITKYSTV resulting in 
10- to 30-fold selectivity increases (Figure 3.8). Furthermore, hK7-2.7 exhibited 4-fold 
improved selectivity toward Aβ8 (KLVFFAED) over KLVYYAED, and selectivity toward 
PRVMFFT over PRVMYYT was increased by 4-fold. Modest selectivity enhancements 
were observed on substrates containing both phenylalanine and tyrosine (e.g. RTAYFSLD, 
KVFYSITG). hK7-2.7 displayed activity comparable to wt-hK7 on GQFAFSKA and 
RVTIFTVP, which both lack tyrosine. Selectivity was also improved outside of the P1 
pocket since hK7-2.7 exhibited increased selectivity for KLVFFAED over the Aβ8 variant 
KLVFFAAD. Thus, in vitro studies confirmed that library screening yielded an hK7 
variant with improved selectivity for Aβ8, mediated by exclusion of tyrosine containing 
substrates.  
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Figure 3.7. Analysis of wt-hK7 and variant hK7-2.7 activity on a panel of substrates.  
 
(a) Wild-type hK7 was purified from yeast cell lysate and activity toward the Aβ8 
substrate and a panel of non-target substrates was measured in vitro. (b) Similarly, kcat/KM 
values were determined for variant hK7-2.7 on the same panel of substrates (kcat/KM = 0.05 
± 0.01 μM-1·min-1 for *RHLYGPRP). 
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Figure 3.8. hK7-2.7 exhibits enhanced selectivity for Aβ8 due to decreased activity on 
tyrosine.  
 
Variant hK7-2.7 was more selective for Aβ8 (KLVFFAED) due to a reduction in activity 
on substrates containing tyrosine (black bars) and substrates containing tyrosine and 
phenylalanine (dark gray bars). Importantly, hK7-2.7 retained wild-type activity on Aβ8 
and other substrates containing phenylalanine (light gray bars). Values are the average 
activity measurements of quadruplicate experiments each performed in duplicate wells and 
the error is their standard deviation. 
 
 
     To assess whether the improved selectivity of hK7-2.7 could reduce cytotoxicity due to 
decreased off-target substrate cleavage, toxicity toward differentiated PC12 neuronal-like 
cells was compared to that of wt-hK7. The Aβ8 selective variant hK7-2.7 exhibited 
significantly reduced toxicity (p = 0.03) when compared to wt-hK7 (Figure 3.9). 
Furthermore, it was anticipated that improved selectivity would reduce yeast cytotoxicity 
during screening and improve growth. Therefore, growth rates of hK7-2.7 and wt-hK7 
were determined for the expression conditions used during library screening. Cells 
expressing hK7-2.7 displayed a 30% increased growth rate during expression (0.13 ± .01 
hr
-1
) compared to cells expressing wt-hK7 (0.10 ± .01 hr
-1
) (Figure 3.10).   
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Figure 3.9. hK7-2.7 displays reduced toxicity to PC12 neuronal-like cells.  
 
Cell viability was measured 24 hours after addition of purified wild-type hK7, hK7-2.7, or 
elution buffer to differentiated PC12 cells. Treatment of PC12 cells with wild-type hK7 (1 
nM) reduced cell viability to 38% (p = 0.004). Cell viability increased by 47% when cells 
were incubated with hK7-2.7 (p = 0.03). The mean is the result of three experiments each 
performed in N=5 wells. p-values represent an unpaired t-test.  
 
 
Figure 3.10. Variant hK7-2.7 confers improved yeast growth during expression.  
 
Growth rates of cells expressing wild-type hK7 or variant hK7-2.7 were measured for the 
expression conditions used during library sorting (T = 22°C). Variant hK7-2.7 displayed an 
improved growth rate of 0.13 ± .01 hr
-1
 during expression compared to the wild-type 
growth rate of 0.10 ± .01 hr
-1
 and the divergence of the slopes was clearly seen for the 6 
hour expression time used for library sorting (N = 3). Data represented as mean ± SD. 
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     We next investigated whether selectivity enhancing substitutions within hK7-2.7 had 
altered its susceptibility to wild-type inhibitors. Inhibitor IC50 values for bovine pancreatic 
trypsin inhibitor (BPTI), soybean trypsin inhibitor (SBTI), α-antichymotrypsin, and 
lympho-epithelial Kazal-type-related inhibitor (LEKTI) fragment consisting of domains 
10-15 were measured for wt-hK7 and hK7-2.7 in assays containing 5 nM protease and 200 
nM substrate. Although BPTI and SBTI are not endogenous to humans, they have been 
reported to be effective in vitro inhibitors of wild-type hK7
192
. BPTI inhibited wt-hK7 with 
an IC50 value of 47 nM, but did not inhibit hK7-2.7 at the highest concentration tested (30 
µM), giving a >640-fold increased resistance to BPTI (Figure 3.11a). Similarly, SBTI 
inhibited wt-hK7 with an IC50 value of 17 nM but weakly inhibited hK7-2.7 at 50 µM 
SBTI (Figure 3.11b). Human α-antichymotrypsin, a serpin inhibitor, potently inhibited wt-
hK7 (IC50 = 2.5 nM), but was 16-fold less potent toward hK7-2.7 (IC50 = 40 nM) (Figure 
3.11c). Additionally, we tested inhibition by the physiologically relevant inhibitor LEKTI 
which has been shown to be a tight binding inhibitor of hK7
193
 and co-localizes with hK7 
in the skin
194
. LEKTI (domains 10-15) inhibited wt-hK7 with an IC50 of 55 nM and 
displayed no inhibition toward hK7-2.7 at the highest concentration tested (130 nM) 
(Figure 3.11d). The reduced sensitivity of hK7-2.7 to inhibitors further confirms changes 
in the active site binding selectivity.   
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Figure 3.11. hK7-2.7 exhibits reduced sensitivity to wild-type inhibitors.  
 
Aβ8 cleavage activity was measured in assays using 5 nM protease and 200 nM substrate 
in the presence of a range of concentrations of four wild-type inhibitors. (a) hK7 tight-
binding inhibitor bovine pancreatic trypsin inhibitor (BPTI) inhibited wild-type hK7 with 
an IC50 value of 47 nM but did not inhibit hK7-2.7. (b) Wild-type hK7 was inhibited by 
soybean trypsin inhibitor (SBTI) with an IC50 value of 17 nM, while hK7-2.7 was partially 
inhibited in the micromolar range. (c) α-antichymotrypsin potently inhibited hK7 with an 
IC50 of 2.5 nM but showed reduced inhibition on hK7-2.7 with an IC50 of 40 nM. (d) The 
physiologically relevant inhibitor LEKTI (domains 10-15) inhibited wt-hK7 with an IC50 
of 55 nM while hK7-2.7 activity was not affected. Values are the average activity 
measurements of three replicate experiments each performed in duplicate wells and the 
error is their standard deviation. 
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     To investigate the mechanism by which substitutions in hK7-2.7 improved selectivity, a 
model of hK7 docked with Aβ8 was analyzed103. Strikingly, hK7-2.7 substitution G233V 
was located deep within the S1 pocket and contacted the P1 phenylalanine in Aβ8 (Figure 
3.12a). Thus, G233V partially fills the S1 pocket to exclude the hydroxyl group of tyrosine 
while retaining favorable hydrophobic interactions with phenylalanine (Figure 3.12b). 
Indeed, substitution G233V was responsible for roughly 50% of the selectivity increase, 
with 2-fold reduced activity on KLVYYAED (Figure 3.13a). Nevertheless, G233V 
exhibited only partial selectivity improvement for Aβ8 over the panel of non-targets 
(Figure 3.13b). Thus, substitutions aside from G233V contribute to selectivity 
improvements. For example, substitution Q52R could enhance selectivity by forming salt 
bridges with the substrate prime side residues glutamic acid and aspartic acid. 
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Figure 3.12. Improved Aβ8 selectivity is mediated by a S1 pocket substitution that 
excludes tyrosine (Y).  
 
(a) Seven substitutions in hK7-2.7 shown on the hK7 structure docked with Aβ8 substrate 
KLVFFAED. Substitution G233V (red) occurs within the S1 pocket of hK7 which contacts 
the P1 phenylalanine (F) in Aβ8 (blue residue). Additionally, Q52R (purple) can interact 
with negatively charged prime side residues within Aβ8. (b) The single substitution G233V 
conferred a 2-fold switch in selectivity for phenylalanine (F4) over tyrosine (Y4). Valine 
may increase steric hindrance with the hydroxyl group of tyrosine. The images shown were 
created using PDB:2QXI with the UCSF Chimera Software package. 
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Figure 3.13. Substitution G233V is partially responsible for Aβ8 selectivity improvement 
in hK7-2.7.  
 
(a) The single substitution variant G233V displayed reduced activity on the non-target 
KLVYYAED but showed only a 2-fold selectivity improvement for Aβ8 over 
KLVYYAED. (b) Activity of variant G233V was assessed with a larger panel of non-target 
wild-type preferred substrates. Though the single substitution variant G233V exhibited 
reductions in activity toward a majority of the non-targets, it is not solely responsible for 
the switch in selectivity of variant hK7-2.7. Values are the average activity measurements 
of quadruplicate experiments each performed in duplicate wells and the error is their 
standard deviation.   
 
3.3. Discussion 
    Wider application of proteases as therapeutics for human disease is hindered by the lack 
of effective methods to optimize their activity, selectivity, stability, and expression. 
Although several high-throughput methods have been developed, their use has been 
limited to model proteases unlikely to find use in therapy
57,65,70,71,75,77
. Furthermore, the 
majority of these methods are limited to proteases that can be expressed in the reducing 
environment of the cytosol or on the outer membrane of E. coli. Given these limitations, 
we developed a general strategy to redesign the specificity of the largest class of human 
proteases toward therapeutic targets. As a target protease, we selected a member of the 
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largest family (kallikreins) in the largest superfamily (trypsin-like serine proteases) of 
human proteases.     
     Discovery of the Aβ selective variant hK7-2.7 would have been unlikely without 
PrECISE to screen large protease libraries, since multiple substitutions contributed to 
increased selectivity. PrECISE relies on co-expression of the protease and substrate within 
the ER of yeast which provides an oxidizing environment for the formation of multiple 
disulfide bonds common to human secreted proteases. Using this method, randomly 
mutated libraries or rationally designed libraries for proteases with solved structures can be 
screened for substrate cleavage without exogenous reagents or labeling steps. Additionally, 
the FACS-based approach provides a quantitative assessment of library enrichment after 
each round of sorting and the ability to optimize screening conditions to favor desired 
variants. Here we used sequential rounds of low error rate random mutagenesis to 
incrementally introduce and screen for beneficial substitutions in hK7 leading to improved 
Aβ8 activity and selectivity due to reduced host cell toxicity. After only two rounds of 
library generation and screening, variant hK7-2.7 displayed up to 30-fold improvements in 
Aβ8 selectivity over substrates containing tyrosine and exhibited reduced toxicity toward 
yeast cells and PC12 neuronal-like cells compared to wt-hK7. Among the seven 
substitutions in hK7-2.7, G233V directly contacted the P1 phenylalanine of Aβ but was 
only partially responsible for the selectivity switch of hK7-2.7.   
     Endogenous protease inhibitors limit the serum half-lives of therapeutic proteases, 
therefore bypassing inhibition is of significant importance when translating the in vitro 
properties of proteases to therapeutic settings
195,196
. Prior efforts to reduce protease 
inhibition have relied on structural analysis to identify residues recognized by inhibitors 
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but that are not responsible for substrate recognition, a strategy which has proven 
challenging
53,197
. Current high-throughput methods for evolving proteases with reduced 
sensitivity to inhibitors have generated variants with up to 30-fold resistance to 
inhibition
77
. Here, the redesigned active site of hK7-2.7 was significantly less sensitive to 
inhibitors. hK7-2.7 displayed a 16-fold reduction in inhibition by the serpin α-
antichymotrypsin and greater than a 2-fold reduction in inhibition by LEKTI (domains 10-
15). Additionally, hK7-2.7 exhibited greater than 600-fold reduced susceptibility to the 
known tight binding, but non-endogenous inhibitors SBTI and BPTI. Though we did not 
directly screen for inhibitor resistance, this trait was acquired along with the increase in 
substrate specificity.   
     Although improvements in selectivity can be achieved by counter-selecting for a non-
target substrate while simultaneously selecting for target cleavage
70,71,75
, it can be 
challenging to identify the most relevant non-target substrate(s). Here, we circumvented 
this problem by screening for retention of target activity, while reducing host toxicity. 
Even so, adaptation of PrECISE to enable simultaneous consideration of multiple non-
target substrates would likely increase the range of applications. Currently, proteases 
approved for therapy have been engineered primarily for serum half-life and stability using 
rational design
54
. The ability to engineer human proteases with narrowed substrate 
specificities could greatly expand the use of proteases for therapy by reducing toxic side-
effects while maintaining efficacy.   
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3.4. Materials and methods 
3.4.1. hK7 random mutagenesis library construction 
     The wild-type hK7 gene was randomized using error-prone PCR to create a library with 
an average of 2 mutations per gene. For low error-rate mutagenesis, 0.5 mM MnCl2 was 
added to the PCR mixture with Taq polymerase, 1.5 mM MgCl2 and unbalanced dNTPs 
(dATP = dGTP = 0.2 mM and dCTP = dTTP = 1mM) as described
144
. Error-prone PCR 
was performed using an Eppendorf Mastercycler thermocycler as follows: 1 cycle, 3 min at 
95°C; 30 cycles, 30 sec at 95°C, 30 sec at 58°C, 5 min at 68°C; 1 cycle, 8 min at 68°C. The 
amplified PCR product was concentrated using a Thermo GeneJet PCR purification kit 
(Thermo Scientific). The insert was then digested with HindIII and PmeI and gel purified 
using a Zymo gel extraction kit (Zymo Research). The purified DNA (5.5 μg) was ligated 
with 10 μg of HindIII/PmeI digested pYC2/NT (Invitrogen). Ligation products were 
concentrated using a Zymo Clean and Concentrator kit (Zymo Research) and desalted on 
0.025 μm VSWP membrane filters (Millipore) using ddH2O for 2 hours. DH5α E. coli 
were transformed by electroporation with library plasmid DNA. Transformed aliquots 
were each incubated in SOC media for 1 hour at 37°C with shaking. The transformations 
were pooled and serial dilutions were plated onto LB plates supplemented with 100 μg/mL 
ampicillin to determine the library size. The transformed cells were added to 500 mL LB 
supplemented with ampicillin (100 μg/mL) and 0.2% glucose and cultured for 9 hours. 
Library plasmid DNA was extracted from the transformed cells using a Zyppy Plasmid 
Maxiprep kit (Zymo Research). Twenty randomly picked colonies were sequenced to 
estimate the error rate (Genewiz).   
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     Yeast cells containing the integrated Aβ8 FRET reporter gene were transformed with 
library plasmid DNA using the high efficiency PEG/lithium acetate method
185
 and plated 
on SD media lacking tryptophan and uracil to determine library size. The transformed cells 
were added to 500 mL SD-Trp-Ura media supplemented with 2% glucose and penicillin-
streptomycin (pen-strep) at a final concentration of 100 units/mL and 100 μg/mL 
(Invitrogen) and allowed to recover for 24 hours. To create the second generation hK7 
library, first generation variant plasmid from the sixth round of sorting was recovered from 
yeast using a Zymoprep yeast plasmid miniprep II kit (Zymo Research) and 
electrocompetent DH5α cells were transformed with the recovered plasmid. The 
transformed sample was recovered from bacteria and used as a template for a second round 
of random mutagenesis using error-prone PCR as described above. Yeast cells containing 
the integrated Aβ8 FRET reporter gene were transformed with the second generation 
library for screening.  
     The single substitution variant G233V was created using PCR-driven overlap extension 
with forward primer 5’ CAACCCAATGACCCAGTAGTCTACACTCAAGTG and 
reverse primer 5’ CACTTGAGTGTAGACTACTGGGTCATTGGGTTG151. This insert 
was cloned into the pYC2 vector as previously described (Chapter 2). 
 
3.4.2. Library screening and FACS analysis  
     Cells transfected with the protease-encoding plasmid library and Aβ8 FRET reporter 
were grown overnight in 50 mL SD-Trp-Ura media with 2% raffinose and penicillin-
streptomycin (pen-strep) at a final concentration of 100 units/mL and 100 μg/mL 
(Invitrogen). Overnight cells were subcultured to a final OD600 of 0.75 and approximately 
5 x 10
8
 cells were induced with 2% galactose in fresh SD-Trp-Ura media containing 2% 
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raffinose. After induction, cells were grown at 22°C for 6 hours with shaking. A total of 5 
x 10
7
 cells, around 2-fold larger than library sizes, were spun down and resuspended in 1x 
PBS buffer for screening using a FACSAria flow cytometer (BD Biosciences) to isolate 
clones exhibiting an increase in cyan fluorescence. Cells not producing a full-length FRET 
reporter were excluded from the FRET analysis by pregating cells with high yellow 
emission (530/30 nm) with blue excitation (488 nm). The cyan (450/40 nm) and yellow 
(530/30 nm) fluorescence intensities with violet excitation (407 nm) were collected. Cells 
displaying a high cyan to yellow fluorescence ratio were sorted into SD-Trp-Ura media 
with pen-strep and 2% glucose to repress further expression. After 24 hours, cells were 
subcultured into fresh SD-Trp-Ura media containing 2% raffinose and pen-strep and 
allowed to grow for 16 hours before the next round of sorting. After each round of sorting, 
the population of cells was plated on selective SD-Trp-Ura media. Sixty individual clones 
from the sixth round of sorting were analyzed on flow cytometry after 6 hours co-
expression to compare intracellular Aβ8 FRET reporter conversion to wild-type hK7. The 
top thirty clones with the highest intracellular Aβ8 activity were amplified using yeast 
colony PCR and sent for sequencing (Genewiz) to determine which mutations had 
occurred.   
 
3.4.3. Construction of non-target FRET reporter substrates  
     To determine changes in specificity for the hK7 variants isolated from the cell-based 
screen, a panel of non-target FRET reporters was constructed. The non-target panel 
included a cleavage site within matrix metalloproteinase-9 that leads to activation 
(RHLY↓GPRP) and a C-terminal sequence that activates prochemerin (GQFAF↓SKA) 
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which are confirmed in vitro substrates of wild-type hK7, as well as potential cleavage 
sites within confirmed in vitro hK7 substrates such as fibronectin (RYRVTYSS), 
corneodesmosin (SQVSYSSG), desmoglein-1 (RITKYSTV), desmocollin-1 (RVTIFTVP), 
and E-cadherin (RTAYFSLD, KVFYSITG)
122,124,189–191
. To determine the potential 
cleavage sites, the substrate specificity profile previously described
103
 was aligned with the 
full protein sequence of confirmed in vitro substrates and 8-amino acid regions with high 
similarity were cloned into FRET reporters to assess wild-type hK7 activity. Non-target 
FRET reporters were constructed, expressed in E. coli, and purified as previously 
described
198
. Confirmed in vitro substrates PRVMYYT, PRVMFFT, KLVYYAED, 
KLVFFAAD, and KLVFFAED were previously constructed as FRET reporters
103
.   
 
3.4.4. Characterizing activity and specificity of hK7 variants  
     Activity of isolated variants toward the target substrate Aβ8 and non-target substrate 
KLVYYAED was initially measured in yeast lysate. Cultures of variants and wild-type 
hK7 were grown overnight and subcultured to an OD600 of 1 in 30 mL SD-Trp-Ura media 
with 2% raffinose and 2% galactose and expressed for 6 hours at 22°C. Equal numbers of 
cells expressing each variant were harvested by centrifugation at 5,000g for 10 minutes and 
cell pellets were lysed with 500 μL Y-PER (Thermo Scientific). Protease activity was 
measured in lysates using the FRET reporter assay described below to determine a relative 
second order rate constant kcat·[E]/KM. For large scale expression and purification of hK7 
variants and wild-type hK7, 150 mL starter cultures were grown overnight in SD-Trp-Ura 
media with 2% raffinose to an OD600 of 3. Cells were then subcultured to an OD600 of 1 in 
360 mL fresh SD-Trp-Ura media with 2% raffinose and 2% galactose and expressed for 6 
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hours at 22°C. Cells were harvested by centrifugation at 5,000g for 10 minutes and froze 
overnight. Cell pellets were lysed with 6 mL of Y-PER for 30 minutes at room temperature 
and then centrifuged for 10 minutes at 5,000g to clarify the lysate. Lysate was incubated 
with 1 mL Ni-NTA resin (Qiagen) for 1 hour at 4°C. Supernatant was flowed through a 
gravity flow column and resin was washed twice with 6 mL wash buffer (50 mM 
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH = 8.0). Histidine-tagged hK7 protease 
was eluted into 1 mL of elution buffer (50 mM NaH2PO4, 300mM NaCl, 250 mM 
imidazole, pH = 8.0) and determined to be >90% pure as determined by SDS-PAGE with 
Western blot staining using a polyclonal anti-hK7 antibody (R&D Systems) (Figure 3.14). 
The concentration of active wild-type hK7 was determined by active site titration with the 
hK7 tight inhibitor α-antichymotrypsin (Sigma-Aldrich). Due to the reduced sensitivity of 
variant hK7-2.7 to wild-type inhibitors, no suitable inhibitor for active site titration was 
found. The fraction of active variant hK7-2.7 after purification was assumed to be the same 
as wild-type. 
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Figure 3.14. Western blot analysis of hK7 concentration before and after purification. 
 
Wild-type hK7 and variant hK7-2.7 were purified from yeast cell lysate using affinity 
chromatography with nickel beads. Cell lysate samples and purified samples were run on a 
Western blot with an anti-hK7 polyclonal antibody. The expected molecular weight of hK7 
is 27 kDa. The concentration of protease dramatically increased after one purification step 
from the lysate to the purified fraction. The concentration of active protease within the 
purified fraction was determined by active site titration using a tight-binding hK7 inhibitor. 
 
     Purified protease (5 nM) was incubated with FRET reporter substrate (200 nM) and 
conversion of the substrate was monitored by measuring the fluorescence emissions at 475 
nm and 527 nm every 5 min upon excitation at 433 nm for 4 hours at 37°C using a Tecan 
Infinite 200 PRO spectrophotometer (Tecan). The in vitro conversion of the FRET reporter 
was calculated by measuring the change in the FRET ratio (yellow fluorescence/ cyan 
fluorescence) over time and is given by the equation: 
minmax
timemax
FRFR
FRFR
Conversion


  
 
where FRmax is the maximum FRET ratio (527/475 nm), FRtime is the ratio at a given time 
within the assay, and FRmin is the minimum FRET ratio achievable with 100% cleavage. 
Second order rate constants (kcat/KM) were determined for hK7 variants and wild-type hK7 
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toward the Aβ8 FRET reporter and non-target FRET substrates using the simplified 
Michaelis-Menten equation
20
: 





 
 tE
K
k
Conversion
M
cat ][exp1  
where [E] is the protease concentration and t is time. Reported values are the average 
kcat/KM and standard deviation of quadruplicate experiments each performed in duplicate 
wells.   
     Four different wild-type hK7 inhibitors were tested for their ability to inhibit purified 
wild-type hK7 and purified variant hK7-2.7. The above FRET assay was used to determine 
the rate of Aβ8 FRET reporter cleavage (200 nM) with a protease concentration of 5 nM 
and inhibitor concentrations in the range of 0.5 nM to 50 μM. The hK7 tight-inhibitors 
bovine pancreatic trypsin inhibitor (Sigma-Aldrich), soybean trypsin inhibitor (Sigma-
Aldrich), α-antichymotrypsin (Sigma-Aldrich) and, LEKTI fragment domains 10-15 (R&D 
Systems) were dissolved to 300 μM, 500 μM, 15 μM, and 1.3 μM stock solutions in water, 
respectively. Inhibitors were diluted to the appropriate concentration and were incubated 
with purified protease samples for 10 minutes at 37°C prior to the addition of the Aβ8 
FRET reporter. IC50 values were determined for the assay conditions above and generated 
by plotting the activity as a fraction of the uninhibited control against log10[inhibitor] and 
GraphPad Prism (GraphPad Software, San Diego, CA) was used to fit the data. 
 
3.4.5. PC12 toxicity assay  
     Rat pheochromocytoma PC12 cells were plated at high density on poly-L-lysine coated 
white, clear bottom 96 well culture dishes (1 x 10
4
 cells/well) in Dulbecco modified Eagle 
medium (DMEM) with 44 mM NaHCO3, 5% horse serum, 5% calf serum, and 1x 
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antibiotic-antimycotic (Life Technologies) and grown at 37°C in a CO2 incubator. 16 hours 
after plating, media was replaced with fresh media supplemented with dibutyryl-cAMP 
(dbcAMP-Sigma) at a final concentration of 0.5 mM to initiate differentiation. 24 hours 
post dbcAMP addition, media was replaced with fresh media supplemented with nerve 
growth factor (NGF-Sigma) at a final concentration of 20 ng/mL. Media changes 
supplemented with NGF were performed every 2 days for a total of 6 days. To assess the 
ability of variant hK7-2.7 to reduce protease-mediated toxicity to cells compared to wild-
type hK7, variant hK7-2.7 was diluted 1/4 into media (50 μL) in the presence of PC12 
cells. Similarly wild-type hK7 (5 nM) was diluted 1/5 into media (50 μL) so that the rate of 
Aβ8 cleavage was equal for the two samples. Cells were incubated with protease for a total 
of 24 hours at 37°C in a CO2 incubator. As a negative control, cells were also incubated 
with elution buffer diluted 1/4 into media. PC12 viability was measured using the CellTiter 
Glo assay (Promega) which quantifies the ATP content of live cells. Luminescent values 
were normalized between untreated control cells (100% viable) and background 
luminescence measured in media without the presence of cells (0% viable). The mean is 
the result of three experiments each performed in N=5 wells. Statistical analysis was 
performed using an unpaired t-test using GraphPad Prism. 
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4. Determinants of S1 pocket specificity within hK7 
     The PrECISE methodology was developed to enable engineering the activity and 
specificity of human secreted proteases toward peptide targets relevant in disease. This 
screening system allows detection of intracellular protease activity by flow cytometry 
through use of a co-expressed peptide substrate exhibiting FRET (Chapter 2). We 
previously described the application of this cell-based assay for FACS screening of large 
randomly mutated libraries of the secreted protease hK7 for improved activity and 
selectivity toward the Aβ8 peptide (Chapter 3). Here we applied PrECISE to screen a 
focused site-saturation library of the hK7 S1 pocket (N199, A200, G222, G227, G233) for 
activity on the substrate PRVMFFT to gain a deeper understanding of the molecular 
mechanisms by which proteases achieve a high level of substrate selectivity. Monomeric 
variants of CyPet and YPet were constructed to eliminate the weak heterodimer interaction 
and improve enrichment of active clones during sorting. hK7 favors cleavage of tyrosine 
(Y) over phenylalanine (F) at P1 and we hypothesized that substitutions within the S1 
pocket could lead to a variant with greater selectivity for F over Y. However, screening the 
S1 pocket focused library of hK7 revealed that substitutions within this subsite were not 
well tolerated and led to reduced catalytic efficiency of the protease. Sequencing analysis 
of isolated clones from the post sort 5 population suggested that the original wild-type 
residues at the five mutated positions within the S1 subsite were optimal for hK7 activity 
on PRVMFFT.  
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4.1. Introduction 
     The development of high-throughput methods for redesigning protease specificity is not 
only useful for therapeutic applications but also in elucidating the molecular mechanism 
proteases employ to recognize their substrate
199,200
. If the crystal structure of a protease has 
been solved, focused libraries of residues within the active site that make side chain 
contacts with the substrate can be targeted for mutagenesis
201,202
. This approach often leads 
to the discovery of epistatic combinations of substitutions within the active site that are 
required for dramatic changes in activity or selectivity
69,71
. The identification of multiple 
synergistic substitutions within a protease active site using random mutagenesis would be 
rare given the low probability of introduced mutations to be grouped to a particular 
location on the protease
203
. Because mutations to the active site can often lead to protease 
unfolding and inactivity, amino acids targeted for mutagenesis can be partially saturated 
with specific sets of residues that may reduce the fraction of non-functional variants in the 
library
204
. Site-saturation library screening has been successfully applied in numerous 
cases to generate large switches in protease selectivity for non-optimal substrates
70,71,75
. 
     Analysis of the hK7 crystal structure has elucidated potential mechanisms for its strong 
preference for cleavage after bulky aromatic amino acids at the P1 position. The S1 subsite 
of hK7 is large and hydrophobic which promotes favorable interactions with the 
hydrophobic side chains of P1 residues such as tyrosine (Y), phenylalanine (F) and leucine 
(L)
114
. Further, the presence of asparagine N199 at the bottom of the S1 pocket can create a 
hydrogen bond with the polar hydroxyl group of tyrosine leading to the high favorability of 
hK7 cleavage after tyrosine compared to all other amino acids
103,113,123
. We hypothesized 
that partial saturation mutagenesis of residues within the S1 pocket could generate a 
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structure with a higher preference for F over Y at P1. Here, we have generated a focused 
library of the hK7 S1 subsite (N199, A200, G222, G227, G233) which was screened using 
the PrECISE cell-based assay for improved activity toward the PRVMFFT substrate. 
 
4.2. Results 
4.2.1. Improving the dynamic range of the PrECISE method 
     CFP and YFP are weak heterodimers with an estimated KD of 100 µM
205
. Within the 
PrECISE method, the high concentration of FRET reporter in the yeast ER could lead to a 
false negative signal after proteolysis of the substrate due to non-specific interactions 
between CyPet and YPet. Therefore we tested if reducing the interaction between CyPet 
and YPet could improve the dynamic range of the assay allowing enhanced isolation of 
cells with active proteases toward the target substrate. Previous work discovered that 
hydrophobic residues at the crystallographic interface of CFP and YFP were responsible 
for the dimerization of these two proteins
205
. Substitution of the hydrophobic residue A206 
with the positively charged lysine (K) in both CFP and YFP led to monomeric proteins 
incapable of dimerizing while maintaining sufficient FRET
141,205
. Therefore this 
substitution was introduced into the CyPet and YPet of the PRVMYYT FRET reporter and 
the construct was integrated into the yeast genome. Transformants were analyzed by flow 
cytometry after expression at 22°C for 6 hours to select a clone expressing high levels of 
the substrate. Interestingly, addition of the A206K substitutions to the FRET reporter 
slightly reduced yellow fluorescence due to FRET of the intact reporter likely due to the 
decrease in CyPet and YPet interaction (Figure 4.1). However, CyPet and YPet brightness 
were unchanged.  
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Figure 4.1. A206K substitutions to CyPet and YPet decrease FRET efficiency. 
 
(a) Flow cytometry analysis of cells carrying the PRVMYYT FRET reporter gene that have 
not been induced with galactose. (b) Fluorescent profile of cells expressing the PRVMYYT 
FRET reporter for 6 hours at 22°C. (c) Fluorescent profile of cells expressing the 
engineered PRVMYYT FRET reporter, which contains the substitution A206K to CyPet 
and YPet, for 6 hours at 22°C. The engineered FRET reporter displayed a decrease in 
yellow fluorescence due to FRET causing a slight shift in the population to higher cyan 
fluorescence.  
 
 
     To determine if the variant FRET reporter could improve the dynamic range of the 
PrECISE screen, cells carrying the engineered PRVMYYT FRET reporter were co-
expressed with active or inactive hK7 and compared to co-expressions in the original 
FRET strain. Co-transformants were analyzed by flow cytometry after co-expression at 
22°C for 6 hours. Cells co-expressing the inactive hK7 protease with the engineered FRET 
reporter displayed reduced yellow fluorescence due to FRET compared to inactive hK7 co-
expression in the original strain (Figure 4.2). Co-expression of the engineered PRVMYYT 
FRET with the wild-type protease led to a higher increase in cyan fluorescence/yellow 
fluorescence for three unique co-transformants compared to the change in fluorescence 
with the original FRET reporter (Figure 4.2). This modest improvement in the dynamic 
range of the assay could enhance the enrichment of cells with active protease and reduce 
the chance of false negatives occurring due to interactions between free CyPet and YPet in 
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the ER of yeast. A PRVMFFT FRET reporter with the A206K substitutions was 
constructed to screen a site-saturation mutagenesis library of the S1 pocket of hK7. 
 
Figure 4.2. PRVMYYT-A206K FRET reporter displays improved dynamic range.  
 
The engineered PRVMYYT FRET reporter, which contains the addition of the A206K 
substitutions to CyPet and YPet, showed a larger shift in the cyan/yellow fluorescence ratio 
between inactive hK7 and active hK7 co-expression compared to co-expressions in the 
original PRVMYYT FRET strain (N = 3). Data represented as mean ± SD. p-values 
represent an unpaired t-test. 
 
4.2.2. Screening a rationally designed S1 pocket library of hK7 
     Although past studies have determined that hK7 prefers tyrosine (Y) over phenylalanine 
(F) at the P1 position
103,113
, little information is known concerning which residues can be 
cleaved at P1 besides Y and F. To elucidate which amino acids can be tolerated at the P1 
and P1’ positions by hK7, eight FRET reporters were constructed, expressed and purified 
from bacteria containing the substrates: PRVMYYT, PRVMFFT, PRVMLLT, 
PRVMMMT, PRVMWWT, PRVMHHT, PRVMVVT, and PRVMPPT. Cleavage of the 8 
substrates was analyzed by fluorimetry in assays using 10 nM wild-type hK7 and 200 nM 
substrate. hK7 displayed a catalytic efficiency (kcat/KM) that was 2-fold higher for 
PRVMYYT compared to PRVMFFT and 10-fold higher for PRVMYYT over PRVMLLT 
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and PRVMMMT (Figure 4.3). Interestingly, hK7 was also able to accommodate the large 
hydrophobic tryptophan (W) residue in the S1 pocket although activity was reduced 35-
fold compared to PRVMYYT. No activity was detected on PRVMHHT, PRVMVVT, and 
PRVMPPT.  
 
Figure 4.3. hK7 prefers cleavage after tyrosine (Y) at the P1 position. 
 
A panel of FRET reporter substrates was constructed in bacteria to determine which 
residues can be accommodated within the S1 pocket of hK7. Assays with 10 nM wild-type 
hK7 and 200 nM substrate revealed a strong preference for tyrosine (Y) at the P1 position. 
hK7 can also cleave after phenylalanine (F), leucine (L), methionine (M), and tryptophan 
(W) with reduced activity compared to tyrosine (N = 3). Data represented as mean ± SD. 
 
     To target selectivity switches in hK7 toward different P1 residues, we created a 
rationally designed library of hK7. Five residues in the hK7 S1 pocket (N199, A200, 
G222, G227, G233) were targeted for saturation mutagenesis with degenerate codons. 
Residues were chosen based on crystal structural analysis to determine amino acids with 
close proximity to the P1 phenylalanine in the docked substrate (Figure 4.4). Residues 
N199, A200, G222, G227 and G233 are each respectively 5.4Å, 4.3Å, 3.8Å, 7.7Å, and 
5.5Å away from the benzyl ring of phenylalanine and therefore likely play a role in 
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determining the activity and specificity of hK7 toward different P1 residues. Within the 
hK7 S1 pocket library, position N199 was replaced with all possible amino acids while 
position A200 was substituted with residues A, V, I, L, M, T, or P. Positions G222 and 
G227 were replaced with G, A, or V and position G233 was replaced with G, A, V, I, L, 
M, T or P. We chose to limit the substitutions at these positions to reduce the fraction of 
inactive variants due to more dramatic changes in the amino acid side chains
204
. The S1 
pocket library was created using the hK7-2.10 variant as a template, which has higher 
intracellular expression levels (Chapter 3).  
 
Figure 4.4. Structural analysis of the S1 subsite of hK7. 
 
(a) Five residues within the S1 pocket of hK7 (N199, A200, G222, G227, G233) were 
selected for site-saturation mutagenesis to create a targeted hK7 library. (b) hK7 docking 
model with the bound Aβ8 peptide (light blue) indicating the localization of position N199 
(purple), A200 (blue), G222 (green), and G233 (red). Position G227 is located deeper 
within the pocket and therefore not shown. The images shown were created using 
PDB:2QXI with the UCSF Chimera Software package. 
 
     To isolate hK7 variants with improved activity toward P1 phenylalanine (F), yeast 
harboring the engineered PRVMFFT FRET substrate with A206K substitutions were 
transformed with the hK7 S1 pocket library yielding a library size of 3 x 10
7
 members. 
Control populations of cells co-expressing the inactive hK7 variant S205A and the 
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engineered PRVMFFT substrate or the hK7-2.10 variant and the engineered PRVMFFT 
substrate for 6 hours at 22°C were analyzed by flow cytometry to determine the 
appropriate gates for library screening (Figure 4.5). Cells carrying the hK7 S1 pocket 
library were co-expressed with the PRVMFFT substrate at 22°C for 6 hours and cells with 
high cyan/yellow fluorescence ratio were sorted over six rounds from 0.6% to 10% gated 
cells in the final round (Figure 4.6). Cells collected after the fifth and sixth rounds of 
sorting were plated to determine the substitutions within isolated variants. 
 
 
Figure 4.5. Analysis of hK7 activity in vivo against the PRVMFFT substrate. 
 
To determine the proper gates for sorting the hK7 S1 pocket library, control populations 
co-expressing inactive hK7 and the engineered PRVMFFT FRET reporter (a) or variant 
hK7-2.10 and the engineered PRVMFFT FRET reporter (b) for 6 hours at 22°C were 
analyzed by flow cytometry. The sorting gate was drawn based on the cyan/yellow 
fluorescence readout of the negative population allowing for only 1% of negative cells to 
be included in the sorted fraction. 
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Figure 4.6. Sorting an hK7 S1 pocket library for cleavage of PRVMFFT. 
 
An hK7 S1 pocket library consisting of partial mutagenesis to residues N199, A200, G222, 
G227, and G233 was transformed into cells harboring the engineered PRVMFFT FRET 
reporter. The library was co-expressed with the PRVMFFT substrate and cells were sorted 
as stated in Methods. FACS plots of the initial library population (a) and after the first (b), 
second (c), third (d), fourth (e), fifth (f), and sixth (g) rounds of enrichment.  
 
 
     Forty individual clones from the fifth and sixth rounds of sorting were sequenced using 
yeast colony PCR to determine the diversity of unique variants. Analysis of the 
substitutions occurring at the five mutated positions within the naïve library and after the 
fifth round of sorting revealed certain preferences for substitutions that may be important 
for hK7 activity toward F at P1. For example, within the naïve library, position N199 was 
mutated to all amino acids but by the fifth round of sorting there was a strong preference 
for the wild-type residue asparagine (N) and also a tolerance for cysteine (C) at this 
position (Figure 4.7). Position A200 displayed a strong preference for the small amino acid 
proline (P) and also a tolerance for threonine (T) and valine (V) in variants isolated from 
the fifth round of sorting (Figure 4.8). Interestingly, position G222 did not seem to 
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accommodate any other amino acids and over 80% of the variants sequenced had the wild-
type glycine at this position by the fifth sort (Figure 4.9). The wild-type glycine was also 
highly favored at position G227 (Figure 4.10), whereas sequenced variants tolerated 
multiple substitutions at position G233 (Figure 4.11). From sequencing analysis, we 
hypothesized that positions N199, A200, and G233 may be more tolerant to substitutions 
whereas mutations to the glycines at positions 222 and 227 may have deleterious effects to 
hK7 folding and activity on PRVMFFT.  
 
 
Figure 4.7. Amino acids C and N are prevalent at position 199 after post sort 5. 
 
Substitutions within twenty sequenced clones of the naïve library and forty sequenced 
clones in the post sort 5 population were analyzed to determine amino acid prevalence at 
position 199 in the naïve library (a) and after post sort 5 (b). Within the naïve library, N199 
was mutated to all amino acids. However, after five rounds of sorting for cleavage of 
PRVMFFT, the majority of variants analyzed showed a strong preference for either the 
wild-type residue asparagine (N) and also a preference toward mutations to cysteine (C). 
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Figure 4.8. Position 200 tolerates small amino acid substitutions. 
 
The frequency of substitutions at position A200 was evaluated in twenty sequenced clones 
of the naïve library (a) and forty sequenced clones in the post sort 5 population (b). A200 
was mutated to residues A, I, L, M, P, T, or V in the focused library. Substitutions to small 
amino acids such as proline (P), threonine (T) and valine (V) were well tolerated at A200. 
However, the larger amino acids isoleucine (I), leucine (L), and methionine (M) displayed 
low substitution frequency at A200 in the post sot 5 clones. 
 
 
 
Figure 4.9. The wild-type residue glycine is strongly preferred at position 222. 
 
Analysis of substitution frequency at position G222 in the naïve library (a) and in the post 
sort 5 population (b) revealed that the wild-type residue glycine is highly preferred at this 
position. G222 was mutated to G, A, or V in the naïve library but by post sort 5, over 80% 
of clones had reverted back to the wild-type residue glycine (G). 
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Figure 4.10. Position 227 displays preference for the wild-type glycine. 
 
The amino acid prevalence at position G227 was evaluated in twenty sequenced clones of 
the naïve library (a) and forty sequenced clones in the post sort 5 population (b). While 
position G227 was mutated to residues G, A, or V in the S1 pocket library, post sort 5 
clones displayed a strong preference for the wild-type residue glycine (G) at this position.  
 
 
 
Figure 4.11. Multiple residues are tolerated at position 233.  
 
The substitution frequency at position G233 was evaluated for twenty sequenced clones in 
the naïve library (a) and forty sequenced clones in the post sort 5 population (b). Although, 
position 233 was targeted for mutagenesis to G, A, I, L, M, P, T or V, the degenerate codon 
used for these substitutions also included potential mutations to serine (S) and arginine (R). 
After five rounds of sorting for PRVMFFT activity, no clear preference was seen at 
position 233 although the wild-type glycine (G) was seen with highest frequency in 
sequenced clones. 
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     Sequencing analysis of the post sort 6 population revealed that a single variant hK7-
S1.9 which contained three substitutions N199C, A200P, G233A had enriched to over 65% 
of the population by the sixth sort (Table 4.1). The wild-type gene was present in 5% of the 
sequenced clones of the post sort 6 population while it was not present in post sort 5 
sequenced clones indicating successful enrichment of active clones during the sixth round 
of sorting (Table 4.1). Interestingly, no variants with substitutions to G222 were sequenced 
from the post sort 6 population confirming the importance of the wild-type glycine at this 
position for activity. Unique variants discovered from sequencing analysis of the post sort 
5 and post sort 6 populations were evaluated in cell lysates for activity toward the target 
PRVMFFT substrate and a non-target PRVMYYT substrate.  
     All variants analyzed displayed decreased activity in cell lysates on the target substrate 
PRVMFFT compared to the parent protease hK7-2.10, which was used as a template to 
construct the library. Ten variants with the highest in vitro activities toward PRVMFFT 
were compared to the activity of variant hK7-2.10 (Figure 4.12). Variants with the highest 
PRVMFFT activity contained substitutions to positions N199, A200, and G233 which 
were predicted to be more tolerant to amino acid changes from sequencing analysis of 
enriched clones. However, the activity of these variants was reduced by 2-fold or greater 
on PRVMFFT when compared to wild-type. Variants with substitutions to G227 all 
displayed more dramatic reductions in activity for the target substrate PRVMFFT. Overall 
substitutions within the S1 pocket of hK7 seemed to be deleterious for hK7 activity on 
PRVMFFT. Variant hK7-S1.10 showed a 1.4-fold improved selectivity on PRVMFFT 
over PRVMYYT however this modest change in specificity came at a cost to the catalytic 
activity (Figure 4.12). Variants with improved activity on PRVMFFT may not have been 
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present in the naïve library because the residues chosen for mutagenesis were critical for 
activity as seen by the majority of sequenced clones containing the wild-type residues by 
post sort 5. Or variants with improved activity in the naïve library were present at too low 
of a frequency for the screen to isolate them from the background of inactive variants. 
 
 
Table 4.1. Substitutions identified for hK7 variants with highest PRVMFFT activity. 
 
hK7 variant substitutions post sort 5 
frequency 
post sort 6 
frequency 
S1.1 A200V, G227A, G233V 0/40 1/40 
S1.2 N199S, A200T, G227A 1/40 0/40 
S1.3 N199S, G227A 0/40 2/40 
S1.4 N199Q, A200P, G233P 0/40 1/40 
S1.5 N199Q 1/40 0/40 
S1.6 G227A 1/40 0/40 
S1.7 N199Q, A200P 0/40 1/40 
S1.8 N199T, G233V 0/40 1/40 
S1.9 N199C, A200P, G233A 3/40 27/40 
S1.10 N199A, A200V, G233A 0/40 2/40 
S1.wt none 0/40 2/40 
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Figure 4.12. S1 pocket variants display reduced activity on PRVMFFT.    
 
Unique variants sequenced from the post sort 5 and post sort 6 populations screened for 
intracellular PRVMFFT cleavage were assessed for in vitro activity. Activity in cell lysates 
was measured toward the target PRVMFFT and non-target PRVMYYT substrates to 
determine changes in P1 selectivity. Equal numbers of cells expressing each variant were 
lysed to determine a relative second order rate constant kcat·[E]/KM (N = 3). Here the top 
ten variants with activity toward PRVMFFT are shown. All variants displayed reduced 
activity on the target PRVMFFT, while one variant hK7-S1.10 showed a modest 1.4-fold 
switch in selectivity for PRVMFFT over PRVMYYT. Data represented as mean ± SD. 
 
4.3. Discussion 
     For proteases with solved crystal structures, site-directed mutagenesis of residues 
within the active site engaging in close contacts with the substrate has been successful in 
generating changes in protease selectivity
60–62
. However, at each site chosen for 
mutagenesis, there are 19 other potential amino acids that could be substituted and the 
number of variants to be analyzed grows exponentially if more than one site is chosen for 
mutagenesis. Because it is still difficult to predict which substitutions will be beneficial at 
a particular position, the development of screens for protease activity, such as PrECISE, 
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enables screening multiple combinations of substitutions within the active site 
simultaneously to determine optimal residues at each position. Additionally, by 
distinguishing which substitutions within the active site increase or decrease the activity of 
the protease toward a particular substrate, a deeper understanding of the mechanism by 
which proteases recognize their substrates can be gained. Therefore we applied the 
PrECISE methodology toward a focused library of the hK7 S1 pocket to elucidate which 
residue substitutions in this subsite may improve activity toward phenylalanine (F) over 
tyrosine (Y).  
     The dynamic range of the PrECISE method was increased by reducing the interaction 
between YPet and CyPet after proteolytic cleavage of the FRET reporter substrate to 
enhance isolation of active variants. Addition of the substitution A206K to CyPet and YPet 
led to an increase in the separation between inactive hK7 and active hK7 clones on flow 
cytometry while maintaining sufficient FRET for screening
205
. The engineered FRET 
reporter was used for screening an hK7 S1 pocket library consisting of partial saturation 
mutagenesis of five residues (N199, A200, G222, G227, G233) for improved activity on 
the target substrate PRVMFFT. The five positions in the hK7 S1 subsite were chosen for 
mutagenesis based their proximity to a P1 phenylalanine in a structural docking model. To 
reduce the number of inactive variants in the initial library population, four of the five sites 
(A200, G222, G227, G233) were partially saturated to prevent large changes in amino acid 
side chain chemistry that could cause the protease to unfold. Screening the hK7 S1 pocket 
library for PRVMFFT cleavage led to slow enrichment of clones with improved 
cyan/yellow fluorescence in early rounds indicating that a low fraction of the library was 
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active. However, by the sixth round of sorting, the cell population displayed improved 
cyan/yellow fluorescence that was comparable to the positive control. 
     Sequencing analysis of 40 random clones from the post sort 5 and post sort 6 
populations revealed that substitutions to G222 and G227 were not well tolerated, whereas 
positions N199, A200, and G233 displayed a higher prevalence of amino acid switches in 
enriched clones. However, at all positions, except A200, the wild-type residue showed the 
highest frequency of enrichment. Additionally, the wild-type sequence was present in 5% 
of clones in the post sort 6 population confirming isolation of wild-type-like variants. 
Interestingly, when activity of the unique hK7 S1 pocket variants was evaluated in cell 
lysates, all variants displayed reduced activity on PRVMFFT compared to the parent 
protease hK7-2.10 used to make the library. This result further confirmed that substitutions 
to the hK7 S1 pocket were not well tolerated and led to deleterious effects in activity of 
hK7. 
     There are many potential reasons why enriched clones were not more active for the 
target substrate compared to wild-type. First, the five positions within the S1 pocket 
chosen for mutagenesis may be critical for folding and activity. Therefore the initial library 
contained weaker activity variants and only sub-optimal variants could be enriched. On the 
other hand, we may not have enriched beneficial variants because substitutions to more 
than five positions in the active site were necessary to improve hK7 activity and 
selectivity. Expanding the zone of mutagenesis has previously been shown to improve 
selectivity when small groups of mutations had no effect
71,202
. Additionally, the PrECISE 
screen may not be sensitive enough for the isolation of low frequency variants that have 
enhanced activity due to the overlap between positive and negative populations and the 
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inherent toxicity of hK7 variants with increased activity. Further, the screen does not 
contain a counter-selection substrate which could dramatically improve the probability of 
isolating a variant with improved selectivity and reduce the appearance of wild-type like 
variants in the sorted populations.      
 
4.4. Materials and methods 
4.4.1. Addition of A206K substitutions to the FRET reporter substrates 
     To increase the dynamic range of the PrECISE screen, the substitution A206K was 
added to both CyPet and YPet to reduce dimerization that may occur between the 
monomers after proteolytic cleavage of the FRET reporter substrate. To introduce the 
A206K substitution to CyPet, PCR driven overlap extension
151
 was used with internal 
forward primer 5’ TTGTCTACCCAGTCAAAATTGTCCAAGGACCCA and internal 
reverse primer 5’ TGGGTCCTTGGACAATTTTGACTGGGTAGACAA. Similarly, the 
A206K substitution was added to YPet using internal forward primer 5’ 
TTATCCTATCAATCTAAATTATTCAAAGATCCA and internal reverse primer 5’ 
TGGATCTTTGAATAATTTAGATTG ATAGGATAA. The FRET reporters carrying the 
substrates PRVMYYT and PRVMFFT were used as templates for the addition of the 
A206K substitutions. The resulting full-length FRET reporter fragments were cloned 
between the HindIII and PmeI sites in the pYES3/CT plasmid (Invitrogen) and 
transformed into DH5α E. coli as described in Chapter 2. Plasmid DNA was recovered 
from bacteria and digested with Bsu361 to linearize the plasmid for integration into the 
genome of the yeast strain JYL69 as described in Chapter 2.  
     The fluorescence profiles of individual clones expressing the engineered FRET 
reporters with substrates PRVMFFT or PRVMYYT were assessed via flow cytometry. 
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Cells were cultured overnight in SD-Trp media with 2% raffinose to an OD600 of 4. Cells 
were then subcultured to an OD600 of 0.75 in fresh SD-Trp media with 2% raffinose and 
2% galactose for expression at 22°C for 6 hours. After expression, the cells were pelleted 
by centrifugation at 5,000g for 5 minutes and resuspended in 1x PBS for analysis on a 
FACSAria flow cytometer (BD Biosciences). Cells were analyzed with violet light 
excitation (407 nm) to determine the cyan (450/40 nm) and yellow (530/30 nm) 
fluorescence intensities. Highly fluorescent clones expressing the engineered PRVMFFT 
FRET reporter or the engineered PRVMYYT FRET reporter were selected for co-
transformation with the wild-type hK7 plasmid and inactive hK7 plasmid. 
 
4.4.2. Construction of an S1 pocket library of hK7 
     Five residues within the S1 pocket of hK7 (N199, A2000, G222, G227, G233) were 
partially saturated to create a targeted library of hK7. Splice-overlap extension PCR was 
used to introduce the degenerate codon NNS at position 199 which encodes for all the 
amino acids, codon VYS was introduced at position 200 which encodes for A, V, I, L, M, 
T, and P, codon GBY was introduced at positions 222 and 227 which encodes for G, A, 
and V and codon VBS was introduced at position 233 to encode for G, A, V, I, L, M, T, 
and P (where B, G, N, S, V, Y are standard nucleotide codes). Primers were designed 
based on coding sequence of the hK7-2.10 variant as a template, which contains three 
substitutions R100C, R123M and R212S shown to improve intracellular expression levels 
(Chapter 3) (Table 4.2). Splice overlap extension was performed as described
151
 with the 
high fidelity KOD polymerase using an Eppendorf Mastercycler thermocycler with a 
program as follows: 1 cycle, 3 min at 94°C; 30 cycles, 30 sec at 94°C, 30 sec at 60°C, 1 
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min at 72°C; 1 cycle, 5 min at 72°C. The amplified library PCR product was digested, 
ligated into vector pYC2/CT (Invitrogen), and DH5α E. coli were transformed by 
electroporation with library plasmid DNA as described in Chapter 3. Library transformants 
were picked from LB + ampicillin plates to send for sequencing to determine the library 
quality.  
 
Table 4.2. Primers used in SOEing PCR for hK7 S1 pocket library construction.   
 
Forward external 5’TAGAAAGCTTGGCCACATAGGCCACCATGTTGTTGCAAGC
ATTTTTGTTTTTGTTGGCTGGTTTTGCTGCTAAAATTTCTGCT 
Reverse internal 5’ACACCAGACCTTGCAGGGTACCACTGCACACCAACGGTCC
CCCTGAGTCACCATTGCASRBSNNTTTCTTGGAGTCGGG 
Forward internal 5’TACCCTGCAAGGTCTGGTGTCCTGGGBYACTTTCCCTTGC 
GBYCAACCCAATGACCCAVBSGTCTACACTCAAGTG 
Reverse external 5’ATCTGTTTAAACGGCCGAATTGGCCTTATCAATGATGATG
ATGATGATGACC 
 
 
     Yeast cells containing the engineered PRVMFFT FRET reporter gene were transformed 
with library plasmid DNA using the high efficiency PEG/lithium acetate method
185
 and 
plated on SD media lacking tryptophan and uracil to determine library size. The 
transformed cells were added to 500 mL SD-Trp-Ura media supplemented with 2% 
glucose and penicillin-streptomycin (pen-strep) at a final concentration of 100 units/mL 
and 100 μg/mL (Invitrogen) and allowed to recover for 24 hours.  
 
4.4.3. Library screening and FACS analysis 
     Cells carrying the engineered PRVMFFT FRET reporter and S1 pocket library of hK7 
were grown overnight in 50 mL SD-Trp-Ura media with 2% raffinose and penicillin-
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streptomycin (pen-strep) at a final concentration of 100 units/mL and 100 μg/mL 
(Invitrogen). Overnight cells were subcultured to a final OD600 of 0.75 in fresh SD-Trp-Ura 
media containing 2% raffinose and induced with 2% galactose. The hK7 S1 pocket library 
and the engineered PRVMFFT FRET reporter were co-expressed at 22°C for 6 hours with 
shaking. A total of 2 x 10
7
 cells were spun down and resuspended in 1x PBS buffer for 
screening using a FACSAria flow cytometer (BD Biosciences) to isolate clones displaying 
an improved cyan/yellow fluorescence ratio. Cells were sorted as described in Chapter 3 
and plated on selective SD-Trp-Ura media after each round of sorting. Forty individual 
clones from the fifth and sixth rounds of sorting were amplified using yeast colony PCR 
and sent for sequencing (Genewiz) to determine which mutations had occurred.   
 
4.4.4. Characterization of variant activity in cell lysate 
     To determine the activity of individual variants, cells were cultured overnight in 10 mL 
SD-Trp-Ura media with 2% raffinose to an OD600 of 3. Cells were then subcultured to an 
OD600 of 1 in 30 mL fresh SD-Trp-Ura media with 2% raffinose and 2% galactose for 
expression at 22°C for 6 hours. After expression, cells were centrifuged at 5000g for 5 
minutes and the cell pellets were frozen at -80°C overnight. Cells were lysed by adding 
450 μL Y-PER reagent (Thermo Scientific) and gently shaking the homogenous mixture at 
room temperature for 30 minutes. Cell lysate fractions were recovered by spinning the 
solution at 10,000g for 5 minutes. Protease activity was measured in lysates using the 
FRET reporter assay described in Chapter 3 to determine relative second order rate 
constants kcat·[E]/KM of the variants. 
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5. Incorporation of a non-target substrate within the cell-based screen 
     Most human proteases participate in multiple physiological pathways and have been 
estimated to cut anywhere from 10 to 100 substrates to fulfill their biological functions. 
Therefore their activity, expression, and localization are tightly controlled to prevent 
unwanted proteolysis. This lack of substrate specificity has severely limited the use of 
proteases in therapy since unregulated proteolysis would lead to adverse side-effects. The 
redesign of proteases with narrow selectivities could be greatly enhanced by the 
development of protease engineering screens that not only profile protease activity toward 
a target substrate but also incorporate counterselection substrates to reduce off-target 
activity. To improve upon the PrECISE methodology for the isolation of selective variants, 
we sought to incorporate a non-target counterselection substrate within the cell-based assay 
for simultaneous assessment of protease activity toward a target and non-target substrate. 
Insertion of a non-target substrate within a surface exposed loop of YPet did not lead to 
reduced yellow fluorescence in the presence of hK7. Therefore, we developed a new cell-
based assay using degradation signals attached to fluorescent substrates to determine if 
hK7 co-expression could rescue fluorescent proteins from degradation by the yeast 
proteasome. Although, hK7 co-expression did not lead to higher fluorescence output of 
fluorescent protein substrates with degradation tags, the studies described here provide a 
starting point for future incorporation of a counterselection substrate within the PrECISE 
method. 
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5.1. Introduction 
     The ability to engineer proteases with high activity and selectivity for a target substrate 
could greatly expand their use in therapeutic and biotechnological applications. However, 
laboratory evolution of enzymes to accept novel substrates has generally led to the 
discovery of “promiscuous” variants which retain activity on wild-type substrates in 
addition to cleaving a newly selected target substrate
67–69,206
. In nature, enzymes evolve 
new functions through positive selection pressure for the target substrate and negative 
selection pressure to reduce off-target activity that would lead to adverse side effects. 
Therefore to emulate natural evolution, protease engineering screens have been developed 
with positive and negative selection pressure to isolate variants with activity on a target 
substrate, while removing variants which cut a wild-type preferred sequence. Screens 
which simultaneously profile protease activity on a target substrate and a counterselection 
substrate have generated selectivity switches on the order of 1,000-3,000,000 fold
70,75
. 
However, the incorporation of a counterselection substrate has not yet been applied for 
engineering human protease selectivity. Here, we have tested two routes for the 
incorporation of a non-target substrate within the PrECISE screen for the development of 
highly selective human secreted proteases for their expanded use in therapy. 
     A potential strategy for the incorporation of a counterselection substrate within the 
PrECISE screen would be the insertion of a non-target substrate within an exposed loop of 
YPet such that cleavage of the non-target substrate would lead to a reduction in blue-
excited yellow fluorescence. Insertion of random peptide sequences within exposed loops 
of GFP has in most cases led to deleterious effects for GFP folding and fluorescence
207
. 
However, tyrosine at position 145 of YFP was found to tolerate whole protein insertions in 
121 
addition to peptide insertions without affecting yellow fluorescence
208
. It is hypothesized 
that the two portions of YFP on either side of Y145 have the ability to independently fold 
in the presence of an inserted sequence. Interestingly, the insertion of the calcium binding 
protein calmodulin at position Y145 in YFP led to increased yellow fluorescence in the 
presence of calcium ions indicating that conformational changes in the insert could affect 
fluorescence
208
. However, protease hydrolysis of a peptide substrate inserted at Y145 in 
YFP has not been tested and may provide a route for counterselection if cleavage of the 
peptide destabilizes fluorescence. 
     An additional strategy for the introduction of a counterselection substrate for protease 
engineering would be splitting the FRET reporter into the individual fluorescent proteins 
YPet and CyPet which would carry a target or non-target substrate at the C-terminus, 
respectively, followed by a degradation signal that targets the complex for degradation by 
the yeast proteasome. In this screen, cleavage of the target or non-target substrate would 
release the degron tag and increase fluorescence of the corresponding reporter. A similar 
strategy was employed in bacteria to profile TEV specificity using short-lived fluorescent 
substrates in the cytoplasm of E. coli where protease co-expression caused an increase in 
fluorescence proportional to protease activity on the substrate
209,210
. To apply this 
screening strategy in yeast, C-terminal hydrophobic peptides have been discovered that 
promote degradation of fusion proteins by the yeast proteasome
211,212
. These degron tags 
additionally contain a positively charged residue where attachment of ubiquitin occurs to 
target degradation by the ubiquitin system
213,214
. Here we have tested two routes for 
incorporation of a counterselection substrate within the PrECISE screen to improve 
isolation of selective variants. 
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5.2. Results 
5.2.1. Introducing a counterselection substrate within a YPet exposed loop 
     Addition of a non-target counter-selection substrate within the cell-based assay would 
allow for enrichment of protease variants with a specific selectivity profile and also serve 
to decrease enrichment of wild-type-like variants. We tested whether the yellow 
fluorescent protein (YPet) within the FRET reporter would tolerate insertion of a non-
target substrate such that cleavage of the non-target would unfold YPet and abolish blue-
excited yellow fluorescence as measured by fluorimetry and flow cytometry. Substrates 
were cloned between Y145 and N146 within YPet which has previously been shown to 
tolerate peptide insertion without reducing fluorescence
208
. The four substrates inserted 
into YPet included the well-cleaved hK7 substrate PRVMYYT, a negative control 
GGSGSGGS, and extended substrates GGSGPRVMYYTGGSG, GGSGGGSGSGGS 
GGSG to determine if longer substrates would be more accessible to hK7 proteolysis. 
These constructs were expressed in bacteria with a His-tag and purified using affinity 
chromatography for in vitro analysis of susceptibility to cleavage by wild-type hK7.  
     After purification of the YPet substrates, sample concentrations were measured by 
fluorimetry and YPet substrates were diluted in water to 6 µM. We tested in vitro cleavage 
of YPet with either the PRVMYYT or GGSGSGGS insertion compared to a negative 
control YPet probe without substrate insertion in assays using 240 nM of the substrate and 
5 nM, 16 nM and 80 nM of commercial wild-type hK7. Yellow fluorescence of the 
substrates was measured over 2.5 hours at 37°C to determine if hK7 cleavage could 
significantly reduce yellow fluorescence of YPet with the PRVMYYT substrate insertion. 
As a negative control, the hK7 active site inhibitor SBTI was added at a final concentration 
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of 10 µM to completely shut down hK7 activity and determine the background yellow 
fluorescence. No significant decrease in yellow fluorescence was seen for addition of hK7 
to YPet with the PRVMYYT insertion at the highest protease concentration tested 
compared to the background with inhibitor indicating no cleavage of the inserted peptide 
(Figure 5.1). Cleavage may not have occurred due to the accessibility of the insertion site. 
Additionally, if proteolysis of the substrate did occur, YPet may have been stable after 
cleavage. 
 
Figure 5.1. Substrates inserted into YPet are not susceptible to cleavage in vitro by hK7.    
 
Substrates PRVMYYT and GGSGSGGS were inserted between residues Y145 and N146 
in YPet to determine if addition of wild-type hK7 could reduce yellow fluorescence by 
cleaving the optimized PRVMYYT substrate. As a negative control, YPet without 
substrate insertion was analyzed for non-specific cleavage. The tight binding active site 
inhibitor SBTI (10 µM) was additionally used to determine the background fluorescence of 
each sample. Addition of 80 nM hK7 did not lead to a reduction in yellow fluorescence for 
YPet with the PRVMYYT insert compared to background.  
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5.2.2. Protease profiling using short-lived fluorescent substrates 
     To develop a novel cell-based screen with the incorporation of a counterselection 
substrate, the FRET reporter was split into the individual proteins YPet and CyPet and a C-
terminal yeast degradation signal was added to both fluorescent proteins. The hydrophobic 
amino acid sequence ACKNWFSSLSHFVIHL, which we have termed DegK, has been 
shown to target proteins for degradation by the ubiquitin system in yeast when fused at the 
C-terminus
211
. Within this novel screen, a target substrate can be inserted between YPet 
and DegK and multiple non-targets can be inserted between CyPet and DegK. Cleavage of 
the target substrate will release the degradation tag causing the cell to fluoresce yellow 
(Figure 5.2). Off-target activity on a wild-type preferred non-target substrate would lead to 
an increase in cyan fluorescence. The absence of protease activity on either substrate 
permits attachment of ubiquitin molecules to the degron tag and degradation of the 
fluorescent proteins by the proteasome causing cells to be non-fluorescent. Using this 
screen, cells with high yellow fluorescence and minimal cyan fluorescence are isolated via 
FACS indicating cleavage of only the target substrate (Figure 5.2).  
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Figure 5.2. Cell-based screen for protease engineering using degradation of fluorescently 
tagged substrates.    
 
A protease susceptible substrate is flanked by an N-terminal fluorescent protein and a C-
terminal degradation signal that targets the complex for proteolysis by the proteasome in 
the cytosol. Protease co-expression with the substrate in the ER releases the degradation 
tag allowing the cell to fluoresce the corresponding color of the upstream fluorescent 
protein. Using this assay, a target substrate can be inserted between YPet and the 
degradation signal and multiple non-targets can be inserted between CyPet and the 
degradation signal. Cleavage of the target substrate by a protease variant leads to an 
increase in yellow fluorescence enabling isolation of cells with cleaved target substrates 
using FACS. 
 
     To test the effectiveness of yeast degradation signals to reduce YPet fluorescence, the 
degron tag ACKNWFSSLSHFVIHL (DegK) was fused to C-termius of YPet and yellow 
fluorescence was monitored after expression in yeast. The yellow fluorescence of cells 
expressing YPet-DegK was compared to cells expressing YPet using flow cytometry to 
determine the maximum dynamic range of the system. Cells expressing YPet-DegK at 
22°C or 30°C for expression times between 0 to 6 hours displayed reduced yellow 
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fluorescence compared to cells expressing YPet (Figure 5.3). After 6 hours of expression, 
the separation between positive and negative cells was greater than 2-fold. Four substrates 
were inserted between YPet and DegK to determine if substrate insertion affected 
degradation of the yellow fluorophore. Cells expressing the YPet-substrate-DegK 
constructs at 22°C or 30°C for 6 hours showed a similar 2-fold or greater reduced yellow 
fluorescence compared to YPet expressing cells (Figure 5.4). Insertion of the PRVMYYT 
substrate increased degradation and cells expressing YPet-PRVMYYT-DegK displayed 
greater than 3.3-fold reduced yellow fluorescence compared to YPet expressing cells.  
 
Figure 5.3. Addition of DegK to the C-terminus of YPet leads to reduced yellow 
fluorescence after expression.    
 
Yellow fluorescence intensity was measured for cells expressing YPet-DegK and 
compared to cells expressing YPet using flow cytometry after expression at 22°C (a) or 
30°C (b) for various lengths of time from 0-6 hours. Expression of YPet-DegK led to a 
reduction in YPet fluorescence for all expression times analyzed. After 6 hours of 
expression at 22°C or 30°C, YPet-DegK intracellular yellow fluorescence was reduced 
greater than 2-fold compared to cells expressing YPet (N = 3). Data represented as mean ± 
SD. 
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Figure 5.4. Substrate insertion between YPet and DegK does not affect degradation. 
 
The four hK7 substrates KLVFFAED (Aβ8), KLVYYAED, PRVMYYT, and 
GGSGSGGS were inserted between YPet at the N-terminus and DegK at the C-terminus. 
Expression of the YPet-substrate-DegK constructs at 22°C or 30°C for 6 hours, led to 
greater than 2-fold reduction in intracellular yellow fluorescence compared to cells 
expressing YPet (N = 3). Data represented as mean ± SD. 
 
     To determine if substrate proteolysis could rescue yellow fluorescence of the YPet-
substrate-DegK constructs, active hK7 and inactive hK7 were co-transformed into yeast 
strains carrying the four substrates for co-expression analysis using flow cytometry. 
Because hK7 can potentially cleave the DegK sequence which would give a false positive 
signal, we first tested hK7 activity on the DegK sequence in vitro. hK7 did not effectively 
cleave the DegK signal, likely due to the lack of tyrosine residues, and therefore off-target 
cleavage of the degradation signal would not contribute to any increase in intracellular 
fluorescence. Co-expression of active hK7 with substrates PRVMYYT, KLVYYAED or 
KLVFFAED flanked between YPet and DegK at 30°C for 6 hours did not lead to an 
increase in yellow fluorescence compared to cells co-expressing an inactive hK7 variant 
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with the substrates (Figure 5.5). In contrast, wild-type hK7 co-expression caused a further 
reduction in yellow fluorescence. This result was also seen for active hK7 co-expression at 
22°C for 6 hours. 
 
Figure 5.5. Active hK7 co-expression does not rescue yellow fluorescence of YPet 
substrates fused to DegK.    
 
Cells carrying the YPet-substrate-DegK constructs were co-expressed with either active 
hK7 or inactive hK7 to determine if active hK7 co-expression could cleave the substrates 
releasing the degradation tag causing increased intracellular yellow fluorescence. 
However, active hK7 co-expression led to a reduction in yellow fluorescence of all the 
substrates tested relative to inactive hK7 co-expression (N = 3). Data represented as mean 
± SD. 
 
5.3. Discussion 
     Although the majority of protease engineering screens developed only profile protease 
reactivity with a target selection substrate, the incorporation of a non-target substrate has 
been shown to improve isolation of selective variants by removing variants which retain 
wild-type activity
70,75
. The development of human protease therapeutics that display a high 
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level of specificity for residues flanking the cleavage site is critical since any off target 
activity could lead to adverse side effects. Here we tested two different methods for 
incorporation of a counterselection substrate within the PrECISE screen for engineering 
human protease selectivity toward peptide targets relevant in disease. 
     Non-target peptide substrates were inserted within a surface exposed loop of YPet to 
determine if proteolysis of the substrates could destabilize the protein and lead to a 
reduction in yellow fluorescence. However, the addition of high concentrations of wild-
type hK7 did not cause a decrease in fluorescence in vitro of a YPet construct with an 
optimal hK7 substrate insertion. Potentially the substrate may have not been accessible to 
cleavage or more likely cleavage of the substrate did not reduce stability of the fluorescent 
protein. In support of this hypothesis, non-fluorescent GFP fragments have been found to 
associate strongly resulting in green fluorescence emission
215
. Therefore, further testing 
would be necessary to determine if the YPet substrate insertion was cleaved and the 
fragments generated still led to fluorescence output. 
     An additional strategy for incorporation of a non-target substrate for protease 
engineering was tested using fluorescent substrates attached to degron signals mediating 
degradation by the yeast proteasome. In this screen, co-expression of an active protease 
should release the degron tag and increase fluorescence of the upstream reporter protein 
proportional to the proteolytic activity on the target substrate. Although, cells expressing 
YPet-DegK displayed reduced yellow fluorescence compared to cells expressing YPet, co-
expression of active hK7 with an optimal hK7 substrate inserted between YPet and DegK 
did not rescue yellow fluorescence. In contract, active hK7 co-expression with the YPet-
substrate-DegK constructs led to reduced yellow fluorescence compared to co-expression 
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with an inactive hK7 variant. One explanation for this result is that active hK7 expression 
triggers the unfolded protein response in yeast which may lead to enhanced ubiquitination 
of the degron tag and enhanced proteasome activity
174
. This screening system may 
therefore be more amenable to proteases which are easier to express and do not require 
post-translational modifications such as the tobacco etch virus (TEV) protease.  
 
5.4. Materials and methods 
5.4.1. Construction, expression and purification of YPet substrate insertions  
     Splice overlap extension PCR
151
 was used to clone four substrates (PRVMYYT, 
GGSGPRVMYYTGGSG, GGSGSGGS, and GGSGGGSGSGGSGGSG) between residues 
Y145 and N146 of YPet
132
. PCR products were cloned between the SfiI sites of the vector 
pBAD33
216
, which carries an arabinose promoter for bacterial expression. YPet contains a 
C-terminal histidine tag (HHHHHH) for downstream purification. The E. coli strain 
MC1061 was transformed with the pBAD33 plasmid containing the YPet constructs and 
transformed colonies were selected on plates containing chloramphenicol (30 μg/mL). 
Plasmid sequencing (Genewiz) of transformed colonies verified substrate insertions into 
YPet. 
     To determine if substrates inserted into YPet were susceptible to proteolysis, each of the 
four constructs was expressed in bacteria and purified for fluorimetry analysis after 
protease addition. Cells carrying the sequenced plasmids were grown for 20 hours at 37°C 
in 5 mL Luria broth (LB) media with choramphenicol (30 μg/mL). Cells were subcultured 
1:100 into 80 mL LB with chloramphenicol and grown for 2 hours at 37°C until cell 
growth reached an optical density of 0.6. Cells were then induced with a final 
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concentration of 0.02% arabinose and expression was carried out for 16 hours at room 
temperature. After expression, cells were spun down at 10,000g for 10 minutes and media 
was decanted. Samples were then frozen at  -80°C for 2 hours to improve cell lysis and 
soluble lysate extraction. Cell pellets were lysed by adding 5 mL B-PER II reagent 
(Thermo Scientific) and pipetting until the mixture was homogenous. Lysis mixtures were 
gently shook at room temperature for 30 minutes. Soluble lysate was isolated by 
centrifugation at 20,000g for 25 minutes.  
    To isolate purified YPet substrates, lysate was incubated with 500 μL Ni-NTA resin 
(Qiagen) for 1 hour at 4°C. Supernatant was flowed through a gravity flow column and 
resin was washed twice with 6 mL wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole, pH = 8.0). YPet substrates were eluted into 1 mL of elution buffer (50 mM 
NaH2PO4, 300mM NaCl, 250 mM imidazole, pH = 8.0). Recombinant hK7 (R&D 
Systems) was incubated with the YPet substrates (240 nM) and conversion of the substrate 
was monitored by measuring the yellow fluorescence emission at 527 nm every 5 min 
upon excitation at 488 nm for 2.5 hours at 37°C using a Tecan Infinite 200 PRO 
spectrophotometer (Tecan).  
 
5.4.2. Addition of a degradation tag to yeast expressed YPet 
     To develop a cell based assay with a non-target counterselection step, we tested if a 
yeast degradation signal fused to the C-terminus of YPet would lead to a loss in yellow 
fluorescence. We also placed a protease susceptible substrate between YPet and the 
degradation signal, to determine if co-expression with active hK7 could rescue yellow 
fluorescence visualized by flow cytometry. The degradation signal 
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ACKNWFSSLSHFVIHL (DegK) was fused to the C-terminus of YPet containing an N-
terminal invertase signal sequence (MLLQAFLFLLAGFAAKISA) for expression in the 
ER of yeast. Additionally four constructs were made containing the substrate sequences 
KLVFFAED, KLVYYAED, PRVMYYT, or GGSGSGGS flanked by YPet at the N-
terminus and the degradation signal at the C-terminus. All inserts were created using 
seqeuntial PCR steps using the YPet gene as a template. The resulting full-length YPet 
reporter fragments were cloned between the HindIII and PmeI sites in the pYES3/CT 
plasmid (Invitrogen) and transformed into DH5α E. coli as described in Chapter 2. Plasmid 
DNA was recovered from bacteria and digested with Bsu361 to linearize the plasmid for 
integration into the genome of the yeast strain JYL69 as described in Chapter 2.  
     The fluorescence profiles of individual clones expressing YPet-DegK or YPet-
substrate-DegK were assessed via flow cytometry. Cells were cultured overnight in SD-
Trp media with 2% raffinose to an OD600 of 4. Cells were then subcultured to an OD600 of 
0.75 in fresh SD-Trp media with 2% raffinose and 2% galactose for expression at various 
temperatures (22°C or 30°C) and times (0-6 hours). After expression, the cells were 
pelleted by centrifugation at 5,000g for 5 minutes and resuspended in 1x PBS for analysis 
on a FACSAria flow cytometer (BD Biosciences). Cells were analyzed with blue light 
excitation (488 nm) to determine the yellow (530/30 nm) fluorescence intensity. Clones 
with loss of YPet fluorescence due to degradation by the proteasome were selected for co-
transformation with the wild-type hK7 plasmid and inactive hK7 plasmid. 
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6. Conclusions 
6.1. Perspectives 
6.1.1. Development of a cell-based screen for evolving human proteases 
     The catalytic turnover of proteins by proteases presents unique opportunities to exploit 
in therapy, which could reduce the dosage and cost of treatment compared to antibodies 
which bind stoichiometrically to their targets
4
. However, the lack of protease substrate 
specificity has hindered their therapeutic use since unregulated proteolysis would lead to 
adverse side effects. Additionally, neutralization by inhibitors found in tissues and serum 
limits the activity and stability of proteases in vivo and can reduce their half-life to on the 
order of minutes
52
. Currently no general methods have been developed and applied to 
evolving the specificity and stability of human proteases for their expanded use in the 
clinic. In an effort to fill this need, we developed a high-throughput, general method for 
screening large libraries of human secreted proteases for activity on a fluorogenic substrate 
to redesign their specificity for therapeutic targets. 
     The reasoning for protease template selection is often omitted from reports, however it 
is important to select an optimal parent protease based on its downstream application
217
. 
Additionally, information on the protease crystal structure and the protease substrate 
specificity profile is critical in guiding directed evolution experiments. We chose to focus 
our efforts on engineering human secreted proteases since these proteases would be less 
immunogenic in downstream therapeutic applications compared to bacterial or viral 
proteases. In addition, common to human secreted proteases are post-translational 
modifications such as glycosylation and multiple disulfide bonds which stabilize the active 
form of the molecule in the extracellular environment. As a model system, we chose to 
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engineer the secreted protease human kallikrein 7 (hK7). hK7 was selected because of its 
open active site which made it amenable to screening with larger substrates such as the 
FRET reporter substrate used in these studies
114
. Additionally, hK7 displays basal levels of 
activity toward a therapeutic target of interest- the amyloid beta (Aβ) peptide, which 
provided a significant starting point in improving its activity and stability rather than 
designing a protease de novo
103
.  
     Engineering human secreted proteases poses additional obstacles compared to bacterial 
or viral proteases since multiple post-translational modifications such as disulfide bonds, 
glycosylation, and correct processing of the N-terminal signal peptide are required for 
proper folding and activity. In developing a high-throughput screen, it is crucial that the 
protease be produced in an active form to expedite analysis and characterization. hK7 
expression in bacteria resulted in insoluble aggregates due to the mispairing of cysteines 
that form six disulfide bonds in active hK7. However yeast, which has the machinery to 
form complex disulfide bonds, was found to be a suitable host for active hK7 production. 
In addition, yeast offered the advantages of faster growth rate and higher transformation 
efficiency compared to mammalian cells, making it an ideal cell type to build a screen for 
protease engineering. 
     To screen through large libraries of hK7 variants using FACS, protease activity was 
linked to fluorescence output through the use of FRET reporter substrates
58,132
. Co-
expression of the fluorogenic substrate and protease variant in the ER of yeast was 
essential for the formation of hK7’s six disulfide bonds and to increase the local 
concentration of protease and substrate for catalysis to occur. However, overexpression of 
hK7 activity in yeast led to degradation of essential host cell proteins resulting in toxicity 
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to the yeast. The toxicity associated with active protease expression presented a unique 
challenge in engineering hK7’s specificity and activity compared to other protease targets 
such as the tobacco etch virus (TEV) protease which is relatively non-toxic. It was 
necessary to reduce hK7 toxicity to the cell without eliminating the fluorescence signal 
correlating to intracellular activity. Reducing the time and temperature of co-expression 
alleviated most of the cellular toxicity associated with active protease expression and 
allowed the successful isolation of active variants during screening.  
 
6.1.2. Application of PrECISE to randomly and rationally mutated hK7 libraries 
     The success of any directed evolution experiment not only requires the development of 
a robust screening methodology for the activity of interest, but is also influenced by the 
quality of the protease library generated. Therefore we compared two methods of 
diversification for generating hK7 libraries to determine the advantages and drawbacks of 
random mutagenesis and site-saturation mutagenesis in evolving human proteases using 
PrECISE. Low error-rate mutagenesis was employed to reduce the fraction of inactive 
variants and to incrementally screen for beneficial substitutions within hK7 in an iterative 
process as has been suggested
140
. The first round of random mutagenesis allowed 
enrichment of hK7 variants with improved cell lysate activity, whereas a second round of 
random mutagenesis enabled isolation of an hK7 variant with improved selectivity toward 
Aβ8. This result suggested that multiple rounds of mutagenesis and screening were 
required to isolate variants with changes in selectivity since random single substitutions on 
their own likely did not drastically change protease specificity. The hK7 variant with 
improved selectivity for Aβ8 was found to have seven substitutions, with the majority of 
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these substitutions being distant from the active site. Therefore random mutagenesis 
enabled the acquisition of beneficial substitutions within hK7 at unusual sites. Further, our 
results indicated that these distant substitutions work cooperatively with the active site 
substitution G233V to enable large changes in selectivity of the hK7-2.7 variant for 
phenylalanine (F) at P1 over tyrosine (Y). Interestingly, the switch in selectivity of variant 
hK7-2.7 was accompanied by reduced toxicity toward mammalian cells and improved 
resistance to wild-type inhibitors, which further confirmed rearrangements to the active 
site
58
. 
     While random mutagenesis has the advantage of not requiring crystal structure 
information, it often misses substitutions localized to the active site that operate 
synergistically since the probability that two random substitutions will occur near each 
other is rare. Therefore, we additionally screened a site-saturation library of five residues 
within the S1 pocket of hK7 for improved activity toward F over Y at P1 to determine if 
multiple substitutions within this subsite could cooperate favorably to switch selectivity. 
To reduce the fraction of inactive variants within the naïve library, four of the five sites 
were partially saturated by predicting which residues would be tolerated due to similar side 
chain chemistry to the wild-type residue. However, a high portion of the naive library was 
found to be inactive and multiple rounds of screening for hK7 activity on PRVMFFT were 
required to see enrichment by FACS. Isolated variants from the final rounds of screening 
were found to have reduced activity on the selection substrate compared to wild-type, 
without large changes in selectivity indicating that the majority of substitutions to the hK7 
S1 pocket were deleterious. Overall, low-error rate random mutagenesis and screening was 
more effective in introducing beneficial substitutions since biasing mutations to the active 
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site of hK7 dramatically reduced activity. Additionally, variants with improved activity in 
the rationally designed library were likely at too low of a frequency to become enriched 
with the PrECISE screen. 
 
6.1.3. Incorporation of a non-target substrate within the PrECISE screen 
     Although the PrECISE screen only profiles protease cleavage on a selection substrate, 
the toxicity associated with non-specific intracellular hK7 activity was exploited to enrich 
variants with improved growth rates as a result of narrowed specificity. This strategy 
enabled isolation of an hK7 variant with improved selectivity and growth. However, the 
addition of a counter-selection substrate to the PrECISE method could greatly improve the 
probability of isolating selective variants by removing proteases which retain activity on a 
preferred wild-type substrate. Screening randomly mutated and rationally designed 
libraries of hK7 often gave back the wild-type parent protease, which could have been 
eliminated using negative selection on a wild-type substrate. 
     However, addition of a counterselection substrate to PrECISE was a non-trivial task 
since the availability of fluorescent reporters which do not overlap with the FRET reporter 
used in these studies is limited. Therefore, we chose to test incorporation of a non-target 
substrate within a surface exposed loop of YPet. While position Y145 within YPet 
tolerated peptide insertions, addition of hK7 to the YPet substrate in vitro did not reduce 
yellow fluorescence indicating that the inserted substrate was not accessible to proteolysis 
or cleavage did not destabilize the protein. Another tested strategy for non-target substrate 
incorporation was attachment of degradation signals to the fluorescent protein substrates. 
While, the degradation signal chosen for this assay was effective in degrading an N-
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terminal YPet-substrate fusion partner after expression, hK7 co-expression with the short-
lived fluorescent substrate did not rescue fluorescence. Future work in adding a non-target 
substrate to the screen could test tethering a yeast transcription factor to a ER integral 
membrane protein where cleavage of a non-target substrate linker releases the transcription 
factor to turn on expression of a reporter gene. 
 
6.2. Future directions 
     While proteases present a unique opportunity to exploit their catalytic properties in 
therapeutic and biotechnological applications, the toxicity commonly associated with 
protease expression is a major barrier to evolving proteases with novel specificities and 
activities
57,58
. Cell death cause by non-specific intracellular protease activity prohibits 
proper isolation of active variants during screening and additionally hinders downstream 
characterization of the properties of protease variants. For this reason, tobacco etch virus 
protease (TEVp) has been used as a model for the vast majority of protease engineering 
screens due to its high level of characterization, ease of expression in different host 
platforms, and naturally narrow substrate specificity, which greatly minimizes toxic 
expression effects
74,75,218
. However, TEVp lacks potential for use in therapy since it is of 
non-human origin. Therefore, future efforts in developing screens for protease engineering 
should focus on the more challenging problem of evolving proteases of human origin.  
     Most proteases of human origin have complicated folds and multiple post-translational 
modifications such as glycosylation and disulfide bonds required for proper activity. 
Therefore, production of active protease would require expression in the secretory pathway 
of eukaryotic hosts. Additionally, many human proteases are non-selective; often they 
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cleave essential host cell proteins and are toxic when expressed. Therefore it would be 
critical to determine assay conditions that allow sufficient protease activity for screening, 
while minimizing host cell toxicity. Current methods developed for TEVp would need to 
be optimized to become extendable for human proteases. Alternatively, recent 
developments in the screening of free enzymes using emulsions could circumvent toxicity 
issues associated with intracellular protease expression and may provide an advantageous 
route for protease evolution
219
. 
     Protease engineering methods that solely incorporate positive selection on a target 
substrate have shown success in narrowing protease selectivity by constantly challenging 
the protease to form stronger interactions with the selection substrate
57,58,65
. However, 
incorporation of a counterselection substrate within the PrECISE methodology would be 
highly beneficial in isolating variants with selectivity changes directed at specific residues 
within the substrate. This precise control over selectivity switches is critical in the 
development of human protease therapeutics that display a high level of specificity for 
residues flanking the cleavage site. The development of screens where protease activity 
can be interrogated on multiple non-target substrates simultaneously will further increase 
the rate at which variants with narrow specificities can be identified. Additionally, among 
current high-throughput methods for protease engineering, only linear peptide targets have 
been used as selection substrates rather than fully folded target proteins. Because substrate 
conformation and accessibility plays an important role in determining the level of protease 
activity, the incorporation of fully folded target proteins within screens will aid in the 
development of effective protease therapies. 
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6.3. Overall conclusions 
     Most naturally occurring proteases lack the specificity and stability to be directly 
translated for therapeutic use. A key contribution of this work was the development of a 
novel cell-based screen for evolving human protease specificity toward therapeutic targets. 
To the best of our knowledge, this is the first application of using random mutagenesis and 
high-throughput screening to redesign human protease specificity. Screening 
methodologies for the directed evolution of protease activity and specificity hold strong 
promise over traditional methods of structure-guided rational design, since variants with 
novel activities may require multiple substitutions that would be impossible to predict a 
priori. Random mutagenesis provided an unbiased diversification approach to 
incrementally introduce a small number of substitutions throughout the hK7 structure. 
Multiple round of screening using PrECISE allowed isolation of beneficial substitutions in 
hK7, leading to improved activity and selectivity for Aβ8. Within our studies, we found 
that multiple substitutions were required to alter hK7’s specificity for Aβ. These 
substitutions were scattered throughout the protease, with the majority being distant from 
the active site and therefore impossible to predict. Analysis of the crystal structure of an 
improved variant assisted in hypothesizing a potential mechanism within hK7 that was 
responsible for changes in selectivity, which was confirmed using site-directed 
mutagenesis. The PrECISE screening methodology and techniques for characterizing 
isolated variants developed here can be generalized for the directed evolution of other 
human secreted proteases that require post-translational modifications and are toxic to the 
host during expression. In summary, harnessing the catalytic properties of human proteases 
provides an attractive alternative to antibodies for the irreversible clearance of toxic 
141 
proteins and peptides implicated in disease. Future advances in the development and 
optimization of screens for evolving the activity, selectivity, and stability of human 
proteases will undoubtedly bolster their application as therapeutics.  
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7. Appendix 
7.1. Appendix A: Expression of hK7 from the CUP1 yeast promoter 
7.1.1. Introduction 
     To decouple expression of the protease and substrate from the GAL1 promoter within 
the PrECISE screen, the gene encoding hK7 was cloned into a yeast centromeric vector 
containing the weaker CUP1 promoter. Placing expression of the protease under a separate 
regulated promoter could facilitate optimizing the concentration of protease and substrate 
in the ER of yeast for proteolysis by individually tuning their expression. The CUP1 
promoter is one of the few regulated promoters in yeast and is inducible by addition of 
copper ions in the form of CuSO4 to the media. Since low micromolar amounts of Cu
2+
 can 
inhibit the enzymatic activity of hK7, a copper resistant variant, hK7 H99F, was cloned 
into the CUP1 vector
114
. From studies of the hK7 crystal structure, the histidine at position 
99 was determined to be the structural basis for Cu
2+
 inhibition of hK7
114
.   
 
7.1.2. Results and Discussion 
     To determine if the H99F substitution impacted activity of hK7, the hK7 H99F variant 
was first cloned under the GAL1 promoter and activity was measured in cell lysates after 
expression. Activity of the hK7 H99F variant was unchanged from wild-type hK7 
indicating that the mutation did not affect hK7 enzymatic activity. We next tested 
expression of the hK7 H99F variant from the CUP1 promoter for various amounts of time 
(1-16 hours) and with different copper induction concentrations (1 µM, 10 µM, 100 µM, 
and 1 mM) at 22°C and 30°C in minimal media supplemented with either raffinose or 
glucose. Protease activity was not detectable for expression of hK7 H99F in minimal 
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media containing raffinose. When the expression media was replaced with minimal media 
supplemented with 2% glucose and hK7 was expressed from the CUP1 promoter for 4 
hours, hK7 activity was detected in cell lysates with the FRET PRVMYYT reporter 
(Figure 7.1). Yeast grow faster in glucose containing media compared to raffinose and 
therefore likely diverted more energy toward hK7 production in glucose media.  
 
Figure 7.1. hK7 expression from the CUP1 promoter is measurable in yeast lysate. 
 
The copper resistant variant hK7 H99F was expressed under the CUP1 promoter for 4 
hours at 22°C in glucose containing media with various concentrations of copper for 
induction. Activity of hK7 H99F was then measured in cell lysate using the PRVMYYT 
FRET reporter by monitoring the change in yellow fluorescence/cyan fluorescence over 
time with fluorimetry. Induction with the highest concentration of copper tested (1 mM) 
gave a weak signal for activity, whereas lower concentrations of copper (1-100 µM) were 
effective in producing higher quantities of active hK7. 
 
     Expression of the protease in glucose media would inhibit simultaneous production of 
the FRET reporter substrate from the GAL1 promoter in the PrECISE screen. Therefore, 
we tested if expression of the FRET reporter substrate prior to hK7 H99F expression could 
allow for intracellular detection of hK7 activity from the CUP1 promoter. Producing the 
FRET reporter prior to induction of hK7 allows more time for the probe to fold prior to 
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protease expression. Also, by halting FRET probe production, the cell can divert more of 
its energy to producing folded hK7. The FRET reporter containing the optimized hK7 
substrate PRVMYYT under the GAL1 promoter was expressed for 6 hours at 22°C in 
minimal media with 2% galactose. After expression of the FRET probe, cells displayed 
high yellow fluorescence with minimal cyan fluorescence (Figure 7.2). Cells were then 
spun down and the media was removed and replaced with minimal media containing 2% 
glucose and 100 µM CuSO4 for hK7 H99F expression. Cells were analyzed using flow 
cytometry after 2 and 4 hours to measure the change in FRET. After 4 hours of protease 
expression, no shift in FRET was detected and the amount of FRET probe was 
dramatically reduced since the addition of glucose inhibited further production of the 
fluorescent substrate (Figure 7.2).   
 
Figure 7.2. hK7 expression in vivo is not detectable with the CUP1 promoter. 
 
Flow cytometry analysis of sequential expression of the PRVMYYT FRET substrate from 
the GAL1 promoter at 22°C for 6 hours in minimal media with galactose prior to induction 
of hK7 H99F from the CUP1 promoter for 2 or 4 hours at 22°C in minimal media with 
glucose and 100 µM CuSO4. Expression of hK7 H99F under the CUP1 promoter did not 
cause a shift in the cyan/yellow fluorescence visualized by FACS indicating minimal 
intracellular cleavage of the FRET reporter. 
 
 
145 
     Because no hK7 H99F activity was detectable in vivo under the CUP1 promoter, but 
hK7 activity had been previously visualized in vivo under the GAL1 promoter, we decided 
to characterize hK7 expression levels from both promoters using a Western blot. hK7 was 
expressed under the GAL1 promoter for 4 hours at 22°C with 2% galactose in minimal 
media. Induction from the CUP1 promoter has been reported to be quite rapid
220,221
. 
Therefore, hK7 H99F was similarly expressed under the CUP1 promoter for 4 hours at 
22°C in minimal media with 2% glucose. Cells were collected and lysed after expression 
and lysates were ran on an SDS-PAGE gel and transferred to a membrane. As a negative 
control, the cell lysate of the parent yeast strain JYL69 was also ran on the gel. Samples 
were incubated with a polyclonal antibody against human kallikrein 7 and a secondary 
antibody conjugated to an Alexa Fluor 680 dye. After imaging for fluorescence, hK7 
expression was detected under the GAL1 promoter in the yeast cell lysate, but no 
expression was seen under the CUP1 promoter (Figure 7.3). The cell lysate of the parent 
strain, JYL69, also did not show a band for hK7 expression as expected (Figure 7.3). Since 
no hK7 expression could be detected in the cell lysate after expression from the CUP1 
promoter, all samples were loaded onto a nickel column to purify and concentrate any His-
tagged hK7 in the lysate. The purified samples were then run on a Western blot to probe 
for hK7 expression. The band for hK7 expressed under the GAL1 promoter became 
stronger and more defined after purification indicating that the protein had been 
successfully concentrated (Figure 7.3). A faint band for hK7 appeared for the purified 
sample expressed under the CUP1 promoter which suggested that hK7 H99F had been 
expressed, but the expression level was much less than that obtained under the GAL1 
promoter (Figure 7.3). 
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Figure 7.3. Comparison of hK7 expression levels under the CUP1 and GAL1 promoters. 
 
Western blot analysis for hK7 expression in yeast cell lysate and after purification after 
expression from the GAL1 promoter in an integrated vector (pYES2) or a centromeric 
vector (pYC2) compared to expression under the CUP1 promoter from a centromeric 
vector (pCUP). As a negative control, untransformed yeast cells (strain JYL69) were 
probed for the presence of hK7 with a polyclonal anti-hK7 antibody. Expression of hK7 
was detectable in cell lysate for expression under the GAL1 promoter but not under the 
CUP1 promoter (top blot). Purification caused an increase in intensity of the hK7 band for 
GAL1 promoter expression and the appearance of a faint band for CUP1 promoter 
expression (bottom blot).  
 
7.1.3. Methods 
     The gene encoding mature human kallikrein 7 (hK7) with an N-terminal invertase 
secretion signal (MLLQAFLFLLAGFAAKISA) and a C-terminal 6x histidine 
(GHHHHHH) tag was amplified for insertion into pCu416CUP1 (pCUP). Copper resistant 
hK7 variant H99F was created using PCR-driven overlap extension
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 with forward primer 
5’ TACTCC ACACAGACCTTTGTTAATGACCTCATG and reverse primer 5’ 
CATGAGGTCATT AACAAAGGTCTGTGTGGAGTA. The resulting fragments were 
cloned between the SmaI and ClaI sites in the pCUP plasmid (Addgene), which contains a 
CUP1 promoter for copper-inducible expression. DH5α E. coli were transformed by 
electroporation with the ligated vector and cells were plated on media supplemented with 
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ampicillin (100 μg/mL). Plasmid DNA was isolated using a Zyppy plasmid miniprep kit 
(Zymo Research) and the yeast strain JYL69 was transformed with 1 µg of the hK7 H99F 
plasmid using the high efficiency PEG/lithium acetate method
185
 as described in Chapter 2. 
     Expression of hK7 H99F from pCUP was analyzed by culturing cells overnight in 10 
mL SD-Ura media with 2% glucose to an OD600 of 4. Cells were then subcultured to an 
OD600 of 0.75 in 40 mL fresh SD-Ura media with 2% glucose with 1 µM – 1 mM CuSO4 
for induction. The expression temperature (22°C, 30°C) and time (1-16 hours) were varied 
to optimize production of active hK7. After expression, cell pellets were isolated by 
centrifugation at 5000g for 10 minutes. Cells were lysed by adding 3 mL Y-PER reagent 
(Thermo Scientific) and gently shaking the homogenous mixture at room temperature for 
30 minutes. Soluble lysate fractions were recovered by spinning the solution at 15,000g for 
5 minutes. Western blot analysis and activity in cell lysate was assessed as described in 
Chapter 2. Co-expression with the PRVMYYT FRET reporter was determined via FACS 
as stated in Chapter 2. 
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